Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2014

Stress management for cancer survivors using a technologically
adapted psychosocial intervention: A randomized trial
determining the effect of expressive writing on
psychoneuroimmunology based outcomes
Utkarsh B. Subnis
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Mental and Social Health Commons, Psychiatry and Psychology Commons, Public Health
Commons, and the Social and Behavioral Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/3596

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Stress management for cancer survivors using a technologically adapted psychosocial
intervention: A randomized trial determining the effect of expressive writing on
psychoneuroimmunology based outcomes

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy (Ph.D.) in Social and Behavioral Health at the School of Medicine,
Virginia Commonwealth University, Medical College of Virginia (MCV) Campus

by
Utkarsh B. Subnis
M.A., Pennsylvania State University, USA, 2011
M.B.B.S., Maharashtra University of Health Sciences, India, 2008

Dissertation Director: Dr. Richard F. Brown, Ph.D.
Assistant Professor, Dept. of Social and Behavioral Health
School of Medicine, Virginia Commonwealth University

Virginia Commonwealth University
Richmond, Virginia
November, 2014

ii

Acknowledgements
This dissertation is dedicated to the millions of cancer survivors the world over who are
bravely facing the tribulations and challenges of survivorship. I want to acknowledge the
participants who chose to be part of this dissertation study. Your will to help with science and
research shows the spirit of kindness that cancer survivors have even within the midst of
infirmity and suffering. I want to acknowledge my grandfather, late Mr. Murlidhar Roplekar who
was the bravest cancer survivor I personally had the honor to know. Ajoba, you were the most
powerful and strong person throughout your life, I pledge to inspire the world with your story. I
also want to honorably mention my friend Sandeep who passed away from metastatic cancer
when I was in medical school. Sandy, it was your courageous and strong spirit that I saw during
cancer treatments that gave me the inspiration to research cancer and it’s psychosocial impacts.
I want to thank my mother, Sandhyarani Subnis, for committing herself towards
completing my PhD dissertation. Mom, it was only because of your support that my dissertation
was possible, despite your backache you slept on the ground, as well cooked for me and kept me
sane during my dissertation, I love you. I want to thank my father, late Dr. B.M. Subnis for his
lifelong love and commitment towards developing compassionate healthcare and medicine. Papa,
I still think you are like Superman and can take care of any disease and any problem; you will
always be with me and our family and you are the inspiration for me to continue my work. I want
to thank my sister Priya Arte, for providing me with healing and motivation. Didi, you are the
most amazing healer and an inspiration for those on the path towards self-realization. I want to
thank my niece, Tanishqua for bringing joy and happiness to me and my family. Manya, you
make life exciting and fun for everyone you come in touch with, love you lots.

iii

My dissertation required the support of several compassionate and highly knowledgeable
researchers and scholars. Most importantly, I want to thank my adviser Dr. Richard Brown for
his support, criticism and intelligent insights as well as continued guidance and encouragement.
Dr. Brown, you were not just my academic advisor, but also a mentor for conducting myself as
responsible researcher and I am here today only because of your commitment towards my
graduate career. What I learned from you, will always be with me forever, and I thank you for
your patience with my ADHD. I also want to thank my graduate program director, Dr. Kellie
Carlyle for her kind support and encouragement throughout the PhD Program. Dr. Kellie, finding
encouragement for my ideas and ambitions was truly an amazing experience for me. I would also
like to thank my committee members Drs. Angela Starkweather, Nancy McCain, Jennifer ElstonLafata, Wendy Kliewer and Maureen Wilson for their support and guidance.
Dr. Angela your compassionate and unconditional commitment is the reason why I could
complete this project; I learned the importance of kindness and research rigor from you. Dr.
McCain your gentle and fun nature motivated me to keep pursuing my goals, you challenged my
ideas and furthered my scholarship. Dr. Jennifer, I learned so many pragmatic issues related to
research from you, and you kept me grounded in my thoughts and ideas. Dr. Maureen, I thank
you for guiding me through the tortuous world of statistics and quantitate analyses, I can call
myself a scientist only because of your intelligent pedagogy. Dr. Kliewer your encouragement
and continued support helped me come back from many low-points in graduate school and
continue my work. It was an huge honor to have worked with every one of my committee
members. Y’all were my true gurus and brought me from darkness (gu) into the light (ru).
Last, but certainly not the least, I am incredibly grateful to my network of colleagues and
friends who provided support throughout my graduate career. I want to thank Danielle Catona

iv

for her unconditional support and counseling; your presence in my life helped me cope with the
many stressors of graduate school. I want to thank Lindsey Saul and Ben Saul for their
commitment towards our friendship; I hope we all grow old together at the Guru resort. I want to
acknowledge Dannielle Kelley for being a wonderful friend and support throughout the tough
times of graduate school. I want to thank my friend Omar, who provided much needed comic
relief and cooked for me several meals, GFU btw. I want to acknowledge Jen and Bill Russell,
you two are great friends and we had good times together. I give my regards to Anthony
Molisani for being such a trustworthy and dependable friend throughout graduate school. Finally,
I thank the omniscient, omnipresent forces of the universe that guide us to the truth; let us all
work towards bringing compassion and healing in healthcare.

v

Table of Contents
List of Tables ………………………………………………………………………... vi
List of Figures ……………………………………………………………………….. viii
List of Abbreviations ………………………………………………………………… ix
Abstract ………………………………………………………………………………. x
Chapter I. Introduction ……………………………………………………………….. 1
Chapter II. Literature review …………………………………………………………. 12
Chapter III. Specific Aims ……………………………………………………………. 41
Chapter IV. Significance and Innovation …………………………………………….. 43
Chapter V. Methods …………………………………………………………………... 46
Chapter VI. Results ………………………………………………………………….... 94
Chapter VII. Discussion ………………………………………………………………. 123
Chapter VIII. Conclusion …………………………………………………………....... 161
Bibliography .………………………………………………………………………….. 166
Appendices ……………………………………………………………………………. 198
Vita ………………………………………………………………………………......... 259

vi

List of Tables
Table 1. Summary of psychosocial interventions for cancer patients using
psychoneuroimmunology (PNI) - based outcome measures ……………………… 29
Table 2. Activities involved in PNI-based psychosocial interventions……………………... 35
Table 3. Theoretical framework of PNI for our expressive writing intervention…………… 40
Table 4. Outcome measures used and the timing of their collection………………………... 50
Table 5. Timing of saliva samples and marking of samples ..…………………………….... 55
Table 6. Study protocol (activities, measures and data sources) ……………………………. 62
Table 7. Patient health questionnaire -2: Telephone screening tool for depression…………. 71
Table 8. Psychometric properties of the patient health questionnaire –PHQ –2 ……………. 71
Table 9. Data sources and research material ………………………………………………... 74
Table 10. Salivary samples selected for assay procedures ………………………………….. 88
Table 11. Sample characteristics ……………………………………………………………. 95
Table 12. Cancer site, stage and treatment ………………………………………………….. 96
Table 13. Health-related symptoms and behaviors …………………………………………. 97
Table 14. Means of outcome variables (Baseline: Day 2) ………………………………….. 98
Table 15. Means of LIWC scores: Positive emotion words (POS_EMO) ………………… 100
Table 16. Means of LIWC scores: Negative emotion words (NEG_EMO) ………………... 100
Table 17. Mean time taken for writing tasks by both groups ………………………………. 102
Table 18. Median values of cortisol variables on Day 49 ………………………………….. 108
Table 19. Mann Whitney Ranks for AUCg (Day 49) ……………………………………… 108
Table 20. Mann Whitney Ranks for CAR (Day 49) ………………………………………... 109
Table 21. Mann Whitney Ranks for DCS (Day 49) ………………………………………… 110
Table 22. Mean salivary a-Amylase levels (Days 2, 7 and 49) ……………………………... 112
Table 23. Mean salivary CRP levels (Days 2, 7 and 49) ……………………………………. 113

vii

Table 24. Mean PSS scores (Days 2, 7 and 49) ………………………………………… 114
Table 25. Mean FCRI-S scores (Days 2, 7 and 49) …………………………………….. 115
Table 26. Mean CBIB scores (Days 2, 7 and 49) ………………………………………. 116
Table 27. Mean a-Amylase levels (Days 2 and 7) ……………………………………… 118
Table 28. Mean CRP levels (Days 2 and 7) …………………………………………….. 119
Table 29. Mean PSS scores (Days 2 and 7) ……………………………………………... 120
Table 30. Mean FCRI-S scores (Days 2 and 7) …………………………………………. 121
Table 31. Mean CBIB scores (Days 2 and 7) …………………………………………… 122
Table 32. Expressive writing and the theoretical framework of PNI …………………… 143

viii

List of Figures
Figure 1. Cancer care trajectory…………………………………………………………….... 3
Figure 2. Stress, HPA axis and immunity…………………………………………………..... 8
Figure 3. Flowchart of literature review…………………………………………………...…. 20
Figure 4. Diurnal cortisol rhythm …………………………………………………………….. 51
Figure 5. Recruitment procedures ………………………………………………………….…. 83
Figure 6. Trapezoidal formula for determining AUCg and CAR of salivary cortisol ….…….. 90
Figure 7. Randomization flow chart of activities completed by participants ………………… 104
Figure 8. Group differences for cortisol AUCg values at Day 49 ……………………………. 109
Figure 9. Group differences for CAR values at Day 49 ……………………………………… 110
Figure 10. Group differences for DCS values at Day 49 ……………………………………... 111
Figure 11. Changes over time for salivary α-amylase (AA) in both groups over the six week
intervention ………………...……………………………………………………… 112
Figure 12. Changes over time for salivary CRP in both groups over the six week intervention.113
Figure 13. Changes over time for PSS scores in both groups over the six week intervention .. 114
Figure 14. Changes over time for FCRIS scores in both groups over the six week intervention115
Figure 15. Changes over time for CBIB scores in both groups over the six week intervention..117
Figure 16. Immediate post-intervention effects for salivary α-amylase (AA) levels ……….... 118
Figure 17. Immediate post-intervention effects for salivary CRP levels ……………………... 119
Figure 18. Immediate post-intervention effects for PSS scores ………………………………. 120
Figure 19. Immediate post-intervention effects for FCRIS scores …………………………… 121
Figure 20. Immediate post-intervention effects for CBIB scores …………………………….. 122

ix

List of Abbreviations
ACS

American Cancer Society

AMSTAR

Assessment of Multiple Systematic Reviews

AUC

Area Under the Curve

BOM

Baseline Outcome Measures

BSCI

Brief Screen for Cognitive Impairment

CAR

Cortisol Awakening Response

CAM

Complementary and Alternative

CBI-B

Cancer Behavior Inventory-Brief version

CBSM

Cognitive Behavioral Stress Management

CDC

Centers of Disease Control and Prevention

CRP

C- Reactive Protein

CS

Cancer Survivors

DCS

Diurnal Cortisol Slope

ELISA

Enzyme Linked Immune Sorbent Assay

EW

Expressive Writing

FCRI-S

Fear of Cancer Recurrence Inventory– Severity subscale

GLM

General Linear Model

HPA

Hypothalamic-Pituitary-Adrenocortical

IOM

Institute of Medicine

LIWC

Linguistic Inquiry and Word Count

LCSW

Licensed Clinical Social Worker

x

MANOVA

Multivariate Analysis of Variance

NCI

National Cancer Institute

PHQ

Patient Health Questionnaire

POM

Post-intervention Outcome Measures

PNI

Psychoneuroimmunology

PSS

Perceived Stress Scale

RCT

Randomized Controlled Trial

SNS

Sympathetic Nervous System

WHO

World Health Organization

Abstract

STRESS MANAGEMENT FOR CANCER SURVIVORS USING A TECHNOLOGICALLY
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Patients with cancer transitioning from completing their final cancer treatments to
survivorship are particularly at risk for experiencing psychosocial stress, and the Institute of
Medicine (IOM) has referred to these cancer patients as “lost in transition.” In this study, patients
with cancer in their transition phase after completing their final radiation treatment were defined

as cancer survivors (CS). CS must deal with chronic stressors such as the fear of cancer
recurrence as well as the resumption of their roles in their family and work lives. Chronic stress
impacts the nervous system and increases secretion of stress hormones (e.g. cortisol) from the
endocrine system, which in turn influences immune function. These systems are particularly
relevant for CS since research has shown associations between abnormal cortisol patterns and
increased mortality in breast CS and immune dysfunction in CS can increase susceptibility to
infections. The theoretical framework of psychoneuroimmunology (PNI), which describes the
interactions between the psychosocial, neuroendocrine and immune systems, guided the choice
of outcomes for this study. The IOM has identified a lack of theory-driven interventions for
managing psychosocial stress in CS. We reviewed the literature and identified two major types
of PNI-based psychosocial interventions for cancer patients, namely cognitive-behavioral and
complementary medical. One promising brief and inexpensive psychosocial intervention was
expressive writing, which involved participants disclosing their deepest thoughts and feelings
regarding their cancer in four 20-30 minute writing sessions over four consecutive days. We
conducted a two-arm randomized controlled trial to determine the efficacy of an online
expressive writing (EW) intervention delivered to CS who were 2-12 months post-radiation
treatment completion. The results of this study revealed that EW was effective in regulating
stress in our sample of CS over a period of six weeks as measured by lowered salivary cortisol
levels and lowered self-reported fear of cancer recurrence. Online EW is a low-cost and
convenient approach for delivering stress-management interventions for CS during survivorship.
However, coordinated efforts are needed from health researchers, professionals and policy
makers to define standardized approaches for testing psychosocial interventions and using PNI
biomarkers to help develop evidence-based psychosocial cancer-care for CS during survivorship.

Keywords: Cancer, Survivors, Stress management intervention, Expressive writing,
Randomized trial, Psychoneuroimmunology, Neuroendocrine-immune biomarkers

Chapter I. Introduction
Cancer remains a significant cause of death and suffering for individuals on physical,
mental and social levels, the world over. In the United States, 41% of individuals are faced with
the possibility of a cancer diagnoses in their lifetime, and more than a million new cancer
diagnoses are projected to occur this year. Advances in early detection and treatments have led to
a consistent increase in individuals that have survived their cancer, currently estimated to be
more than 13 million individuals in the US alone2. Cancer patients experience high levels of
psychosocial stress across the cancer-care continuum, i.e. from diagnosis through survivorship
care and palliative care3. Chronic psychosocial stress in cancer patients can have serious negative
health consequences by impeding patient’s psychosocial functions (e.g. lowered ability to cope
with cancer) as well as biological functions (e.g. increased susceptibility to infection due
immune suppression), and represents a serious public health problem. In this study we describe
psychosocial stressors faced by cancer patients, identify interventions to remediate psychosocial
stress in cancer patients and conduct a randomized trial of psychosocial intervention called
expressive writing for cancer patients who were transitioning off their last radiation treatment.
What Psychosocial Stressors Exist in Patients Diagnosed With Cancer?
Cancer patients are susceptible to mental health problems such as depression and anxiety.
A recent meta-analysis suggest that the prevalence of depression in cancer patients is 16.3%; of
which 14.9% of cancer patients are suffering major depression and 19.2% minor depression, as
defined by DSM criteria4. The same study found the prevalence of adjustment disorder to be
19.4%, anxiety 10.3%, and dysthymia 2.7% in their sample of cancer patients4. In addition to
mental health issues, cancer patients are also faced with a great amount of emotional distress,
and four in ten patients with cancer report experiencing significant distress5. Cancer patients are
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commonly faced with issues such as fear of death and the associated fear of losing close
interpersonal relationships (e.g. family and friends) due to death. Other socio-emotional issues in
cancer patients include interruption of life plans, chronic uncertainty, changes in body image and
self-esteem, fear of cancer recurrence, and hopelessness3. These psychosocial problems affect the
cancer patient’s ability to function productively at work and result in difficulty in maintaining
employment and hence, a decrease in income1,6 A survey study revealed that more than one third
of cancer patients and their family members reported that they were unable to perform at their
job, and 19% lost or changed jobs or needed to work fewer hours because of the illness, while
22% reported a lower income6.
Medical expenses incurred due to cancer can exhaust patients and their families financial
resources, and it is has been established in the United States that 62% of bankruptcies in
Americans are medically related7. These financial problems lead to more stress in cancer patients
and further exacerbate the existing psychosocial problems. Furthermore, physical and mental
impairments (e.g. chronic fatigue and cognitive dysfunction) due to cancer related treatment
regimens also add to the cancer patient’s psychosocial problems8. Treatment-related adverse
effects can impact cancer patients several years after all treatments are completed. For example,
a recent study demonstrated that survivors of breast cancer treated with adjuvant chemotherapy
more than 20 years ago performed worse on neuropsychological tests of immediate and delayed
verbal memory, processing speed, executive functioning and psychomotor speed, when
compared to random population controls 9. Hence, patients with cancer are faced with range of
unmet psychosocial needs depending on where they lie along the continuum of cancer care1.
The Cancer Care Trajectory: Defining Cancer Survivors
The NCI considers the cancer care trajectory to begin “from the time of diagnosis through
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the balance of his or her life,”1[p. 29] and a patient can be considered to lie in one of the phases of
this continuum, see Figure 1. The
major phases of this trajectory are 1)
diagnosis and staging, 2) treatment,
i.e., intended to cure or palliative
treatment, 3) survivorship care, 4)
recurrence (or secondary cancers),
and 5) death. The Institute of
Medicine (IOM) has identified a
Figure 1: Cancer Care Trajectory1

considerable deficiency of cancer care

specifically for the psychosocial issues faced by cancer patients in the survivorship care phase 1.
Moreover, there are a growing number of cancer survivors, with figures from the NCI and CDC
reporting that more than 11 million people are currently living with a history of cancer in the
United States10. The numbers of cancer survivors are expected to increase even more due to
advances in early detection and effective treatments along with an aging population. The office
of survivorship at the NCI considers patients to be cancer survivors after a definitive initial
diagnosis of cancer until the end of life, and this definition also includes family members,
caregivers and friends, since they are affected by the cancer experience as well11. However, the
NCI’s definition lacks specificity for defining cancer survivors for research protocols. This study
directed its research focus towards cancer patients who were in the cancer-free survival phase.
Specifically, we defined our target population as cancer patients who had completed their cancer
treatments (intended to cure) and were declared disease-free (no recurrence or secondary
cancers), and these cancer patients are hereafter referred to as cancer survivors (CS).
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Phases of Cancer Survivorship from a Psychosocial Perspective
From a psychosocial perspective, the period of cancer-free survival can be assumed to
have two phases, called re-entry and long-term survival, which were initially suggested by a
physician who was diagnosed and treated for cancer12,13, and have been subsequently adopted by
some psycho-oncology researchers14-16. The re-entry phase of survivorship is considered to start
from immediately after treatment completion up to approximately 12-18 months of cancer-free
survivorship. Patients beyond 18-24 months of remission are considered to be in the long-term
survivorship phase. Researchers have identified that that the re-entry phase is a period of
heightened distress for CS and patients have many unmet psychosocial needs during this
phase16,17. For example, a longitudinal study of distress in breast CS described that 15% of
women reported experiencing heightened distress beginning at treatment completion until six
months after treatment completion18. Moreover, psychosocial interventions have not been
designed to meet the needs of CS in the re-entry phase. This may be due to the assumption that
individuals in the re-entry survival phase experience relief after completing their treatment and
from being free of their cancer diagnosis. However, these patients are faced with myriad of
psychosocial stressors which includes the fear of cancer recurrence 12.
Stressors Experienced by Cancer Survivors (CS) in the Re-Entry Phase
CS in the re-entry phase experience stress due psychosocial problems and treatment
related adverse effects. Research indicates that some pronounced psychosocial problems for CS
during the re-entry phase include the fear of cancer recurrence, uncertainty about the future,
interruption of life plans, impaired body image and self-esteem, and fear of death 1,3. Another
source of stress for CS in the re-entry phase is the late and long-term adverse effects of cancer
treatment regimens. Late effects of treatment regimens refer to unrecognized toxicities that were
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absent or subclinical at the end of therapy1,19. These late effects manifest during survivorship
subsequent to unseen injury because of any one or more of the following, a) developmental
processes, b) the failure of compensatory mechanisms to act in due course, or c) organ aging1,19.
Late effects can appear anytime, ranging from a few months to years after the completion of
treatment. Long-term effects are side effects or complications of treatment that are recognized
during treatment that continue beyond the end of treatment1,19. Common late and long-term
effects of treatment for CS in re-entry phase include fatigue/ sleep disturbance, pain, sexual
dysfunction, urinary/bowel problems, and cognitive problems1,16 Neuropsychological
impairments such as memory problems and impairments in executive function are also common
in CS9. Cancer treatments involving extensive surgery or radiation can also result in a range of
impairments in physical function in CS, such as restrictions in movement of limbs, chronic pain
and fatigue19. These functional impairments can lead to a decrease in daily activities and
performance, which in turn leads to frustration and chronic stress in survivors.
Why is the Re-Entry Phase a Particularly Stressful Period of Cancer Survivorship?
One reason for increased stress in the re-entry phase is the loss of interaction with health
care providers and caregivers14,16. During the treatment phase, cancer patients are continuously
interacting with their oncology care team, and therefore experience a sense of protection 17,19.
There is also more interpersonal social support from caregivers for cancer patients during the
treatment phase which decreases after completing treatment 20. After treatment regimens are
completed, many patients perceive a decrease in social support because they are no longer in
regular contact with the oncology team16,21. Therefore, the transition from active treatment to the
re-entry phase becomes a particularly stressful period for patients. In addition, there is very little
preparation for the re-entry phase by health care professionals or others, which results in unmet
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needs for information and psychosocial health services1,14,22. During this transition phase, CS are
often confronted with making sense of their identity and learning to cope with the stressful
experiences during their diagnosis and treatment23. Concurrently, CS are expected to return to
life as usual and reassume their original family and work roles and responsibilities. Therefore CS
in the re-entry phase often face multiple stressors related to their cancer diagnosis and learning
how to cope after treatment while perceiving a loss of social support and resources14. CS who are
in the re-entry phase after completing their radiation treatments are particularly at risk for being
distressed and having psychosocial problems.
Psychosocial Stress Experienced by Cancer Survivors after Radiation Therapy
Numerous studies of CS populations have focused on the physical and psychosocial
problems created by chemotherapy (e.g. fatigue and depression) and surgery (e.g. loss of
organ(s) and impaired body image); very few studies have directed their attention to
psychosocial effects of radiation treatments24. There is a growing body of evidence indicating
that CS encounter many psychosocial stressors after completing radiation treatment25. A
comparative study consisting of CS (5 years after initial treatment for cervical cancer, N=114)
that had either received surgery (n=37) or radiation (n=37) and a control group (healthy patients
with no cancer treatment, n=40), found that compared with CS of surgical treatments and the
control group, radiation CS had significantly lower health-related quality of life (physical and
mental health), increased psychosocial distress, and problems in sexual functioning26.
Furthermore, longitudinal studies with cancer patients receiving radiation treatments suggest that
depression and impairment in psychological well-being increase significantly after treatment27-30.
Another longitudinal study found that negative perceptions of the survivorship experience and
worry about the future increased significantly 6 months after completion of radiation therapy31.
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This suggests that CS post-radiation have numerous unmet psychosocial needs that make them
susceptible to chronic stress, which has very serious implications for CS since chronic stress
impacts human biology, e.g. by influencing the nervous, endocrine and immune systems.
How Does Psychosocial Stress Affect Biological Outcomes?
Researchers across a variety of disciplines have investigated the nature versus nurture
explanation for health outcomes in human beings. Advances in health and social sciences have
established the field of bio-behavioral clinical research which investigates interactions between
psychosocial factors and biological outcomes32. Over the past three decades scientists have
specifically explored how chronic psychological stress affects physiological systems,
specifically, the neuroendocrine and immune systems33-35. Chronic stress affects the functioning
of the nervous system, which initiates secretion of glucocorticoids (e.g. cortisol) from the
endocrine system36. Continued exposure to high concentrations of stress mediators causes
decreased expression of glucocorticoid receptors, thereby leading to cortisol resistance37. Thus,
normal cortisol regulation of the immune system is lost, leading to a pro-inflammatory state and
immune system dysregulation37,38.
These systems are particularly relevant for cancer populations because previous research
has demonstrated that abnormal patterns of cortisol secretions (cortisol rhythms) are associated
with increased mortality in breast cancer patients39. Dysfunction of the immune system also has
critical consequences for cancer populations, such as increasing susceptibility to infection, and
impacting the progression of cancer, thereby increasing the likelihood of cancer recurrence and
development of secondary cancers3,40,41. Therefore, neuro-hormonal (e.g. cortisol) and immune
functioning are very critical biological health outcomes for CS. The study of interactions
between the psychological, neuroendocrine and immune systems has given rise to the inter-
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disciplinary field of psychoneuroimmunology (PNI).
Psychoneuroimmunology (PNI) and Immune Function
Studies suggesting the psychosomatic influence of mental disorders on biologic outcome
measures were being published since the 1940s, however substantial progress in PNI research
occurred only after 198042. The term psychoneuroimmunology (PNI) was coined in 198143,44,
and in the subsequent 30 years, science has witnessed major advances in understanding how
psychological factors affect the brain and central nervous system, which influence the production
and release of certain hormones, e.g. glucocorticoids, which in turn affect the function of the
immune system44-46. Two physiological pathways have been studied to understand how chronic
stress exerts influence on immune function.
The first is the hypothalamic-pituitary-adrenocortical (HPA) axis, which is also called the
limbic-hypothalamamic-pituitary-adrenocortical axis (LHPA), due to the role of the limbic
system of the brain (i.e. amygdala and
hippocampus) in the human stress
response47. Multiple hormones are
involved the HPA axis pathway, which are
released from different organ systems in
the body. Acute and chronic psychological
stress initiates the release of corticotropinreleasing hormone (CRH) from the
hypothalamus47. CRH then causes the
release of adreno-corticotropin releasing
Figure 2: Stress, HPA axis and immunity46

hormone (ACTH) from the pituitary gland.
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Subsequently, ACTH activates the release of cortisol and adrenaline from the adrenal gland47,
see Figure 2. The immune system is affected by change in the levels of hormones secreted by the
adrenal gland. Dysregulation of cortisol levels can give rise to persistent inflammation which
alters the capacity of immune cells to combat infections and disease. Glucocorticoid/cortisol
dysregulation causes immune suppression by inhibiting certain transcription factors (NF-κB)
involved in the production of cytokines (e.g. Interleukins), which are cellular signaling
molecules involved in modulating the immune response, see Figure 2.
Another relevant physiologic pathway involved in the human stress response is the
sympathetic nervous system (SNS)47. The SNS affects various systems (e.g. cardiovascular
system) and glands (e.g. lymph nodes, salivary glands) in the body through direct innervation,
which refers to a hardwiring of the body through a network of nerves. Stress causes the SNS to
initiate the fight-or-flight response and releases the hormones epinephrine and norepinephrine.
These hormones have a wide-ranging effect on the body, and also influence immune function,
for example, a reduction in the cytotoxic activity of natural killer (NK) cells. The SNS is known
to initiate secretion of salivary enzyme α-Amylase. This system of interrelated interactions
between psycho-social factors and physiological systems comprises the PNI framework. This
PNI framework views psychosocial factors as moderators of the neuroendocrine system that
together influence immune function48,49. Further evidence in favor of PNI mechanisms is
established through psychosocial intervention research, wherein interventions that were designed
to reduce stress have demonstrated a decrease in cortisol secretion and have improved functional
measures of the immune system such as cytokines 50,51. Studying the neuroendocrine and
immunological effects of psychosocial stress management interventions for CS using the PNI
framework is a needed area of research, since CS are predisposed to have immunosuppression.
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Immune Suppression in Cancer Survivors
It can be posited that the immune systems of cancer survivors are compromised by the
combined impact of 1) late and long-term effects of treatment regimens such as surgery,
chemotherapy and radiation, 2) negative immunologic effects due to the cancer itself and 3)
chronic psychosocial stressors described above. Late effects of chemotherapeutic drugs such as
methotrexate have been implicated to cause a reduction in all types of immune cells and
insidiously affect bone-marrow production of immune cells in cancer survivors many years after
treatment1. Long-term effects, i.e. side-effects or complications of treatment, on immune
function are common in patients that are treated with immunosuppressive agents (e.g.
cyclophosphamide treatment in transplant recipients), or hormonal therapy (e.g. corticosteroid
therapy)1. All the treatment modalities for cancer, which includes surgery, chemotherapy and
radiation, have the potential to cause varying degrees of immune suppression.
Moreover, cancer itself can have immunosuppressive influences on patients. For
example, many hematologic cancers (e.g. leukemia, lymphoma), and cancers that are likely to
become metastatic, are known to alter the production of immune cells resulting in immature cells
entering the blood stream, and this effect can continue into survivorship1,52 . Considering the
evidence for chronic stress impacting immune function, it can be suggested that stress combined
with the late and long-term effects of cancer treatments, and the cancer itself, can work
synergistically to augment the immune suppression in the CS population, which can lead to very
serious health consequences. Therefore, CS need interventions that are designed to regulate
psychological and emotional stress, which in turn can alter the response from the HPA axis and
SNS and result in beneficial changes to their immune function. However, rigorous empirical
research is needed to establish evidence for the efficacy of psychosocial interventions for CS.
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The Need for Psychosocial Intervention Research in Cancer Survivors
Considerable advances have occurred in medical diagnosis and management for patients
with cancer.3 Breakthrough innovations have occurred in areas such as radio-diagnostic imaging
(e.g. positron imaging tomography/PET scan53), surgical procedures (e.g. robotic surgery54) and
chemotherapeutic agents (e.g. targeted chemotherapy55) for cancer patients. However,
interventions to manage the several unmet psychosocial needs of cancer patients and CS have not
witnessed the same advances in their science and technological delivery3. Therefore the IOM has
recommended that researchers and health practitioners in the oncology setting should work
towards enhancing the science and delivery of psychosocial health interventions and generate
evidence that can institutionalize the use of theory-driven psychosocial interventions as a part of
routine cancer care3. Based on the IOM report, “interventions that enable patients, their families,
and health care providers to optimize biomedical health care and to manage the
psychological/behavioral and social aspects of illness and its consequences so as to promote
better health,” 3 (p.69) can be considered to be psychosocial interventions. The PNI theoretical
framework guided the choice of outcome measures for this intervention research study.
However, the first step towards addressing the need for improving the science and delivery of
psychosocial intervention, was identifying gaps in the existing literature pertaining to
psychosocial interventions for patients with cancer.
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Chapter II. Literature review
Cancer is a significant global public health problem, which has caused 7.6 million deaths
world-wide, as estimated by the World Health Organization (WHO) in 200856. In the United
States, the Surveillance, Epidemiology and End Results (SEER) for cancer, published by the
National Cancer Institute (NCI), reports that 41% of Americans face a chance of being diagnosed
with cancer in their lifetime.57 Cancer remains the second most common cause of death in the
United States and this year alone, iSEER estimates 1,638,910 men and women (848,170 men and
790,740 women) will be diagnosed with cancer (of all sites) and there will be 577,190 deaths due
to cancer. This corresponds to 4,490 new diagnoses and a loss of more than 1,500 lives, every
day58. The estimated cost of cancer care amounted to $124 billion in 2010 and is projected to
reach around $158 billion by the year 202059. These data illustrate the public health burden posed
by cancer, related to morbidity, mortality and healthcare costs. However, cancer affects every
aspect of the health and well-being of individuals, i.e. physical, mental and social well-being.
Patients with cancer experience significant psychosocial-emotional trauma that act as
chronic stress stimuli, which negatively impact physical well-being (e.g. immune suppression)
as well as psychosocial well-being (e.g. poor coping with cancer), and poses a major public
health problem 3. In every stage of their disease course, patients with cancer are faced with a
complex set of psychosocial problems. Researchers have highlighted a deficiency of research
evidence related to interventions designed to improve mental and social well-being, i.e.
psychosocial well-being, in patients with cancer. In order to address the psychosocial problems
in cancer patients, researchers and health practitioners have developed a wide range of therapies
and interventions. The first step of this dissertation study was to conduct a comprehensive
critical review of the literature to identify the types of psychosocial interventions that have
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studied in the cancer population and determine how these interventions have influenced
particular health outcomes (specifically PNI-based outcomes) in patients with cancer.
PNI-Based Psychosocial Interventions
Although studies supporting a relationship between psychosocial stress and adverse
health outcomes have been published since the 1940s, substantial progress in PNI research
occurred only after 198042. A study published by Spiegel et al60. (1989) drew considerable
attention to psychosocial intervention research, as it reported an increased survival rate in breast
cancer patients who participated in a group-therapy psychosocial intervention60. The effects of
group therapy on increased survival rate were later attributed to neuroendocrine-immune
mechanisms described in the PNI framework61. Though Spiegel et al.’s study was controversial
and replication studies of their group-therapy intervention failed to demonstrate increased
survival62,63, researchers became interested to explore the neuroendocrine-immune effects of a
variety of psychosocial therapies64, such as Cognitive-Behavioral-Stress-Management (CBSM)
and supportive therapy in persons with cancer64. Subsequent systematic reviews of PNI-based
psychosocial therapies have been conducted64,65, but, these reviews have lacked a comprehensive
approach towards identifying and appraising eligible studies.
Gaps in Literature: Lack of Comprehensive Reviews
Previous reviews have lacked breadth and depth in their approach towards evaluating
PNI-based psychosocial interventions with regards to a) review methodology, b) limited cancer
types evaluated, c) limited descriptions of the types of therapies and d) lack of specificity in
reporting PNI-measures
a) Review methodology. Although early reviews, published in the 1990s66-68, of
psychosocial therapies indicated that the PNI framework could be used to explain the benefits
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(e.g. increased survival) of psychosocial interventions for cancer patients, these reviews did not
use statistical methods to assess the PNI effects of psychosocial interventions. A systematic
review published in 200269 used a more rigorous methodology provided by the evidence-based
medicine (EBM) approach, which involved assessing results of rigorous randomized controlled
trials69. This review concluded that not a single psychosocial intervention strategy could be
recommended for improving immune function in cancer patients69. However, the review authors,
Newell et al. 69, made their conclusion based on a small sample of four qualifying studies that
measured PNI outcomes70-73. The National Cancer Policy Board (NCPB) criticized this review
in a report published in 200474, and determined that, due to very narrow methodological
specifications, many valuable effects of psychosocial interventions, which includes PNI effects,
may have been “missed or undervalued”74(p97).Other health researchers have also suggested that
the EBM methodology may be too restrictive for evaluating psychosocial therapies and have
advocated for reviewers to ensure methodological diversity (described below) in the inclusion of
psychosocial interventions75,76.
b) Cancer population. Reviews of PNI-based psychosocial interventions have most
commonly reported studies conducted for a specific cancer populations, most often women with
breast cancer64,77-79. Reviews that adopt this narrow focus eliminate studies conducted in other
cancer populations and this limits the reach of psychosocial therapies for persons with cancer.
c) Types of therapies. A wide variety of interventions have been developed for
addressing the psychosocial aspects of cancer. A meta-review of psychological interventions
identified 79 distinct modalities of psychosocial therapies80, ranging from education to breathing
exercises. However, reviewers have not appraised the details of psychosocial interventions in
terms of their individual components and activities, methods of delivery or duration of the
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interventions80. Health researchers have been recommended to pay attention to the
aforementioned details of psychosocial therapies in recently provided recommendations for
reviewing complex interventions: assessment and trials implementation of services
(COMPASS)80,81.
d) PNI measures employed. Reviews of psychosocial interventions that included studies
which used PNI biomarkers as outcomes, have not detailed the specifics of the PNI biomarkers
and psychometric scales employed64,79. Also, researchers in this field have noted that many
psychosocial interventions claiming to work through PNI mechanisms have not measured actual
PNI biomarkers68,77,82. For example, even though the landmark study by Spiegel et al. (1989)60
alluded to PNI mechanisms61, it has been noted that biomarkers associated with PNI systems
were not obtained as outcome measures in the original study64. Recent reviews of research
studies designed to determine relationships between psychosocial factors and survival outcomes
of patients with cancer continue to suggest psychoneuroimmunologic mechanisms of actions83,84.
However, these reviews83,84 have included research that did not use PNI-based biomarkers as
outcome measures, and thus calling into question the validity of the claims regarding PNI effects
of therapies targeting psychosocial variables in persons with cancer.
Comprehensive Approach to Literature Review
Thus, a comprehensive approach to conducting a review of the current literature was
undertaken. To this end the directives for conducting evidence reviews of psychosocial
interventions provided by the IOM3,74, the World Health Organization76 and the COMPASS
checklist proposed by Hodges et al80. were followed. These directives were operationalized for
the current review by a) having methodological diversity in study designs, b) including all cancer
populations, c) examining details of the types of psychosocial therapies and d) identifying the
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specific PNI outcome measures employed. The aim of the literature review was to assess the
current state-of-the-science (studies published after 2001) for PNI-based psychosocial therapies
to answer the following questions (Qs):
Q1) Population: In which cancer populations, in terms of type and stage of cancer, have
psychosocial interventions using PNI-based measures been conducted?
Q2) Types of interventions: What types of psychosocial interventions (that used PNI-based
outcomes measures) have been delivered for cancer patients? Particularly,
a) What activities (e.g., relaxation training) did the therapies employ?
b) What were the method(s) of delivery (e.g., individual/group-based) and personnel
involved?
c) What were the durations of the interventions (including length of each session)?
Q3) PNI measures: Which specific measures of PNI subsystems were used as outcomes for
psychosocial interventions in the cancer population?
Review Methodology
Methodology for the review process was based on guidelines provided in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement85. Authors
also reviewed methodological recommendations for conducting literature reviews put forth by
the Cochrane collaboration86, the IOM committee on standards for systematic reviews of
comparative effectiveness research87, and the assessment of multiple systematic reviews
(AMSTAR) checklist88. Methods involved developing a systematic a) search strategy and b)
selection criteria, along with c) screening and identification procedures to eliminate irrelevant
studies, which were followed by d) data extraction procedures.
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a) Search Strategy
The following electronic databases were searched online during November and
December of 2013 to identify the studies: PubMed/Medline, EMBASE, PSYCINFO, CINAHL,
and Google Scholar. Studies were considered if they were published from January, 2001 to
November Week 4, 2013. The search terms (keywords) from a previous systematic review69 and
a meta-analysis89 of psychological interventions were included in our search strategy.
There were three categories of keywords (described in italics) used in combinations to
identify relevant studies related to i) cancer: cancer, neoplas*, oncolog*; ii) psychosocial
intervention: psych*, psychosoc*, interven*, psychotherapy, psycholog*, cognitive therapy,
behav* therapy, self-help-groups, support group*, relax*, hypno*, meditat*, imagery, stress,
psychological, counsel*, group therap*, family therapy, depressive disorder therapy,
treatment(s), therapy/therapies; and (iii) PNI measures: leukocyte, lymphocyte, natural killer
cell, interferon, interleukin, tumor necrosis factor, cortisol, neuroendocrine, hormonal,
psychoneuroimmunology, immune function, where * represents wildcard characters.
Additionally, the reference sections of all relevant papers were examined to identify any
additional relevant studies. This electronic search strategy yielded 403 research records, from
which 112 duplicate records were eliminated. The remaining 291 records were screened based on
our selection criteria to find eligible studies.
b) Selection Criteria
A set of five independent selection criteria related to 1) time-frame and language, 2)
study design, 3) cancer population, 4) types of therapies, and 5) PNI-based measures, were used
to identify, screen and select eligible studies corresponding with the aims of this review.
1) Time-frame and language. Only studies published in peer-reviewed journals after
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January, 2001 until November, 2013 were included in our literature review. For a comprehensive
review of psychosocial therapies for cancer patients that used PNI-based measures published
before 2001, refer to Andersen, 200290. The searches were conducted in English and all the
studies included in this review were either published in English or translated into English
language by the publishers of the journal.
2) Study design. True experimental designs, i.e. randomized controlled trials (RCTs), as
well as studies with rigorous quasi-experimental designs91, such as non-randomized controlled
trials (NRCTs) and pretest-posttest measurement designs were included. RCTs had to include the
number of cancer patients included in the intervention group and in the control group. Nonexperimental designs, such as correlational research studies, were excluded.
Selection criteria relevant to the specific research questions of this review were:
3) Cancer population. Interventions conducted with participants diagnosed with cancer
at any stage beyond initial diagnosis were included. Since this review aimed to evaluate the
impact of psychosocial therapies on the health of patients actually diagnosed with cancer;
interventions conducted exclusively with family members or caregivers of cancer patients were
excluded.
4) Types of interventions. To guide the inclusion of psychosocial therapies, the IOM’s
definition of psychosocial health interventions, which involved therapies that help patients “to
optimize biomedical health care and to manage the psychological/behavioral and social aspects
of illness and its consequences so as to promote better health”3(p69) was adopted. This IOM
definition inherently encompasses therapies employing cognitive and behavioral therapeutic
activities, such as coping skills training. However, therapies that emphasized integrative concepts
of healing body, mind and spirit, which were classified under complementary medical therapies
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by the National Cancer Institute92,93 were also included. Interventions that exclusively involved
behavioral regimens, such as physical exercise, were excluded because the IOM definition
required psychosocial therapies to address psychological and or social problems related to
illness. Interventions delivered by any health professional, and in any setting, using any method
of delivery or duration were included.
5) PNI-based measures. Only those psychosocial intervention studies that reported results of
at least one neuroendocrine or immune outcome measure, as well as described the PNI
framework in the paper’s background section were included. Studies that merely referred to the
PNI framework but only measured psychological constructs (e.g., depression) or global
outcomes (e.g., survival) were excluded.
c) Screening and Identification Procedures
The 291 research records obtained from the search strategy underwent two stages of
screening. Details of the screening and identification process are outlined in Figure 3. In the first
stage of screening, the title and abstracts of the research records were evaluated according to the
five criteria. In this stage 246/291 records were eliminated leaving us with 45 records. These 45
records entered the second stage of screening, where full text papers were further evaluated for
final eligibility. The second screening stage eliminated an additional 23/45 studies leaving 22
studies (Figure 3 below). However, review of the reference lists of full-text research papers
obtained during second screening, revealed 4 additional studies found eligible for review.
Therefore, finally 26 papers were identified and included for review procedures. Of note in this
sample of 26 papers, there were two pairs of manuscripts (2 RCTs94,95 and 2 pretest-posttest
studies47,52) that had reported results during different phases of the same larger intervention.
These 2 pairs of papers were collapsed and considered to be single studies; which led to 24
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original studies (reported in 26 manuscripts) obtained at the end of the search and selection
process. For the review procedures, information was extracted from all 26 manuscripts.

Figure 3: Flowchart of literature review

d) Data Extraction Procedures
The reviewers prepared a detailed data extraction manual. This manual was applied to the
sample of 26 papers. Data were extracted and entered into an Excel spreadsheet. Studies were
categorized based on the strength of their study design as suggested by the evidence-based
approach for therapeutic interventions previously suggested by some health scientists96,97. This
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categorization involved placing RCTs first, followed by NRCTs and finally pretest-posttest
studies (Table 1). One RCT that reported results from only their intervention group participants
was included in the pretest-posttest study group for review procedures98. Data from the
manuscripts of the 2 RCTs94,95 and 2 pretest-posttest studies 47,52 which reported findings from
the same intervention, were pooled and reported collectively in their respective study groups.
The following data were obtained from the research papers: a) first author, year of
publication; b) stage and type of cancer; c) number of participants in the intervention group; d)
the type of control condition and number of participants in control group; e) the type and
duration of intervention and length of each session, f) psychosocial measure(s) used, g)
neuroendocrine measure(s) used and h) immunological measure(s) used. Other noteworthy
points (e.g. adequacy of sample size, analysis of mediators) were included as i) additional
remarks. Since this review aimed to appraise studies with regards to the specific research
questions (stated above), methodological quality scores were not assigned to the studies.
Review Results
This literature review included results from 19 RCTs, 1 NRCT and 4 pretest-posttest
studies of PNI-based psychosocial interventions conducted in the cancer population. Table 1
gives an outline of the type and duration of the interventions and their effects on the respective
psychosocial, neuroendocrine and immunological measures used. Specific findings related to the
research questions posed by this review are presented below.
Q1) Cancer population. Most studies consisted exclusively of women diagnosed with
breast cancer (18/24, 75%). The studies of women with breast cancer consisted of 9 studies that
had patients with early stage breast cancer (stage I or II),99-107 and 7 studies that included patients
with stage III breast cancer94,98,108-112. Only 1 study included patients with metastatic breast
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cancer (stage IV)113 and 2 studies included breast cancer survivors114,115. The next most common
type of cancer population was patients with prostate cancer (4/24, 16.7%). In terms of prostate
cancer staging, 3 studies included patients with early-stage localized prostate cancer
patients99,100,116, while 1 study had prostate cancer survivors116,117. In the aforementioned studies,
2 studies used a mixed population of patients with early-stage breast and prostate cancer99,100.
Only 8.3% (2/24) of PNI-based psychosocial therapies included persons with cancers other than
breast and or prostate cancer. These studies consisted of one study of cervical cancer
survivors118; and another study involving mixed cancer populations including persons with lung
and colorectal cancers, as well as person with prostate and breast cancers in the entire range of
cancer stages, including cancer survivors119.
Q2) Types of psychosocial interventions. The two major types of interventions
identified were i) cognitive-behavioral therapies (15/24, 62.5%) and ii) complementary medical
therapies (9/24, 37.5%). Each study was assessed for the types of therapeutic activities employed
in the psychosocial intervention.
Q2. A) What activities did the interventions employ? All studies used more than one
therapeutic activity during the delivery of their intervention. Table 2 presents a complete list of
activities employed in each study. The two most common activities, used by more than half of all
psychosocial therapies reviewed, were relaxation training and education (Table 2). Descriptions
of the kinds of activities used by psychosocial interventions for cancer patients elucidated by the
IOM3 and National Institutes of Health (NIH)92,120 were reviewed to guide categorization of
interventions. Studies were either classified as a cognitive-behavioral therapy or a
complementary medical therapy based on the activities involved in the intervention.
i) Cognitive-behavioral therapies consisted of interventions that emphasized cognitive

22

and behavioral activities and approaches such as cognitive restructuring, psycho-education and
coping skills training (Table 2). Some studies delivered highly structured cognitive-behavioral
programs, such as CBSM, that were specifically designed to meet the psychosocial needs of
breast cancer patients104,108,113. Few studies used supportive care activities such as individual
supportive care, home care and group social-support (Table 2). Several studies also included
progressive muscle relaxations, meditation, abdominal breathing, and guided imagery (Table 2).
There were 3 cognitive-behavioral studies that particularly emphasized visualizations. Of these,
2 studies asked patients to mentally visualize personal and metaphorical images of their immune
systems effectively removing cancer cells from their bodies103,107, while the third study employed
hypnosis to guide visualizations107. Another intervention included cognitive-behavioral activities
specifically tailored for insomnia and sleep management, e.g., stimulus control121. One study
utilized an expressive writing intervention that asked patients to write about their experience
with prostate cancer and its treatment and other traumatic and upsetting experiences in their
lives117. Finally, a cognitive-behavioral study also included counseling for relationship and
sexual problems faced by their participants118.
ii) Complementary medical therapies involved activities such as yoga, meditation,
qigong, mindfulness-based stress reduction (MBSR) and massage (Table 2). In this group of
therapies, 5 studies emphasized stress-management through meditation. One yoga study
combined activities including breathing exercises, meditations, a set of yoga postures (asanas),
along with relaxation and mental imagery109. Another study delivered an integrated yoga
program at the bedside before and after a surgical operation and provided patients with
audiotapes of instruction for yoga exercises to be practiced at home111. The other 3 studies
delivered a structured MBSR program99-101,122 previously developed by another researcher123.
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MBSR consisted of teaching participants to achieve mindfulness, defined as a “non-elaborative,
non-judgmental present-centered awareness”124(p232) and help participants enhance the acceptance
of their life experiences123. Participants learned MBSR through the use of breath awareness,
sitting and walking meditations and yoga techniques and were also provided with educational
materials and workbooks to help them with cognitive reappraisals and in practicing mindfulness
in daily life.
There were 3 complementary therapies that encouraged stress-reduction through either
active behavioral practices, such as body movements, or passive behavioral techniques such as
massage. One yoga intervention consisted exclusively of performing poses from the “Iyengar
yoga” tradition, that were executed slowly with the help of props to maintain proper orientation
and posture114. One study of medical qigong consisted of body movements during specific
standing postures along with meditation training, visualization and a range of breathing exercises
including chest and abdominal breathing119. One massage intervention employed a protocol that
consisted of a combination of massage and acupressure techniques that promoted relaxation106.
Finally, one study emphasized a body-mind-spirit connection and combined yoga and massage
techniques with psychosocial approaches such as forgiveness therapy115.
Q2. B) What were the method(s) of delivery? Studies delivered their respective
psychosocial therapies to participants either within a group-setting (15/24, 62.5%) or on an
individual basis (9/24. 37.5%). On average 7 participants were included in the group-based
therapies, but group-size ranged between 3 and 15 participants. Most studies involved in-person
interactive (21/24, 87.5%) sessions with participants. There were 3 studies that did not involve
any personal interactions with participants (3/24, 12.5%). Of these, 2 studies delivered their
intervention exclusively through phone-conversations105,118 and one study delivered an
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expressive writing therapy through oral and written instructions given to the patients and
followed-up with patients through a phone call46. The interventions delivered entirely through
phone conversations consisted of one study that used a telephone conference call to deliver
group-therapy105, and another study that conducted individual telephone-counseling sessions
with participants118. It was noteworthy that two studies provided therapy sessions on the morning
of scheduled surgery to mentally prepare patients for surgical procedures111,116, and one
supportive therapy intervention was provided to participants on a residential basis102.
Who delivered the therapies? Half the psychosocial therapies were delivered by clinical
psychologists, while 3 therapies were delivered by nurses, and 2 therapies involved physicians
(Table 1). Supportive care services were delivered by a variety of health professionals including
group therapists, social workers, art therapists and visualization specialists102,105. The
complementary medical therapies, also employed a variety of allied health professionals, such as
clinical massage therapists and instructors trained in yoga and qigong techniques102,106,109,114.
Q2. C) What were the durations of the interventions? The average duration of
interventions using PNI-based psychosocial therapies (taken over all 24 studies) was roughly a
total of 10 hours (600 minutes). The 10 hours of psychosocial intervention were delivered over
an average period of 8 weeks consisting of approximately 8 therapy sessions, with each session
lasting for about 70-75 minutes. However, the duration of interventions, including the time
required for each session varied considerably among the studies. The briefest intervention was
expressive writing, which lasted for a total of 1.3 hours (80 minutes) over a single week, with 4
sessions taking 20 minutes per session over 4 consecutive days117. In contrast, the lengthiest
intervention was 20 times greater in duration, and consisted of a cognitive-behavioral therapy
intervention of 27 hours (1620 minutes) over 18 consecutive weeks, with 18 therapy sessions
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that lasted about 90 minutes per session108.
Q3) PsychoNeuroImmunologic (PNI) outcome measures. Only a third of studies
(8/24) in this review collected outcome measures for all three PNI subsystems. All studies,
except one (23/24) used at least one psychosocial measure. With regards to PNI biomarkers, less
than half (11/24) the studies, employed biomarkers of the neuroendocrine system, as opposed to
the majority (22/24) of studies that used some type of immune biomarker.
Psychosocial measures (P). All studies used self-report scales to measure participants’
psychosocial profiles, except 1 study that did not report measures of any psychosocial
construct98. The most commonly employed measure of psychosocial outcomes was the profile of
mood states, POMS (11/24, 45.8%) scale. Most studies measured negative psychological states
such as depression, negative mood, distress and anxiety102,104,105,108,109,114. Even though most
interventions aimed to reduce stress in patients, only three studies actually used psychometric
measures of stress103,109,112. Studies also assessed psychosocial well-being and function by
measuring of quality of life and functional assessments related to cancer treatments and living
with cancer100,105,119. Some studies were interested in the psychological coping response of
participants and measured constructs such as benefit finding104 (i.e., perceived benefits arising
from the experience of being diagnosed and treated for breast cancer), and coping with
illness101,117. Finally, 3 studies used measures that were closely related to the constructs
emphasized in the therapies; for example, the cognitive-behavioral intervention aimed at
improving sleep behavior measured the severity of insomnia121, one CBSM intervention
measured the specific psychosocial skills that were targeted by the CBSM program95 and one
MBSR study measured mindfulness attention and awareness101.
Neuroendocrine measures (N). The glucocorticoid stress hormone, cortisol, was the
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most common neuroendocrine measure, used in all 11/24 research studies that had
neuroendocrine parameters (45.8%). Studies measured cortisol levels in the participants’ blood
using radioimmunoassay techniques95,101 or in saliva using enzyme linked immunosorbent assay
(ELISA) techniques99,109,114,122. Other neuroendocrine parameters measured included a)
catecholamine stress hormones, including epinephrine, norepinephrine in urine106; b)
neurotransmitters, including urinary dopamine and serotonin106 and salivary melatonin122; and c)
serum levels of the corticosteroid hormone, dehydroepiandrosterone-sulphate (DHEA-S) 122.
Immunological measures (I). The 22/24 studies that reported immunological measures
(91.7%) obtained blood samples for immune analysis. The most commonly measured immune
outcome was the cytotoxic function of natural killer cells (9/24, 37.5%). Most studies typically
evaluated both types of immune measures89, including enumeration of immune cells, e.g. T
lymphocyte counts, and functional measures of the immune system89, e.g. cytokine levels (15/24,
62.55%). However, 6 studies exclusively used functional immune measures (6/24, 25%) and 1
study measured only certain immune cell counts (4.2%),%), namely CD4+ and CD8+ T
lymphocytes and NK cells105. Only a couple of studies did not use any type of immune outcome
measure (2/24, 8.3%). We noted that only one study measured the inflammatory biomarker, Creactive protein (CRP)119 and another study measured serum immunoglobulin (Ig) levels (IgG,
IgM and IgA) 111.
Efficacy of Psychosocial Therapies for Patients with Cancer
Due to the wide diversity of interventions and PNI measures reported, statistical
comparisons required for a meta-analysis were not possible. Hence, limited comment could be
made about the statistical evidence for the efficacy of psychosocial interventions on PNI-based
outcome measures in the cancer population. However, we do deliberate over studies that reported
27

significant changes in PNI outcome measures. Firstly, with respect to psychosocial measures, 20
studies that included 13 RCTs, one NRCT and 3 pretest-posttest studies reported significant
effects on at least one psychosocial measure (Table 1). Secondly, in terms of neuroendocrine
outcomes, 6 studies reported significant results for changes in at least one neuroendocrine
measure, including 4 RCTs, one NRCT and one pretest-posttest study (Table 1). Finally,
regarding immune measures, 16 studies reported effects on at least one immune measure, which
included 11 RCTs, one NRCT and 4 pretest-posttest studies (Table 1).
Effectiveness with respect to types of interventions indicated that more than half the
studies using cognitive-behavioral therapies (10/15, including 8 RCTs) reported significant
findings for at least one neuroendocrine or immune outcome measure. One cognitive-behavioral
intervention reported a significant effect on an immune outcome up to twelve months after
initiating the intervention110. Some cognitive-behavioral therapies statistically modeled the
variables in the PNI framework and demonstrated that psychosocial constructs had an influence
on immune outcomes. For example, one study reported that benefit finding was correlated with
an increase in the T lymphocyte proliferative response to anti-CD3,104 and another study showed
that anxiety and depression mediated the increase in blood levels of the cytokine, interferon-γ121.
Thus, several studies of cognitive-behavioral therapies reported significant effects on
neuroendocrine-immune function through PNI interactions in patients with cancer.
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Table1. Summary of psychosocial interventions for cancer patients using psychoneuroimmunology (PNI) - based outcome measures
No

First author,
year citation

Stage & type
of cancer

Intervention (n)
Psychosocial
Type of therapy b and
Control condition (n) duration of intervention
measure(s) ab
RANDOMIZED CONTROLLED TRIALS (RCTs)

Neuroendocrine
measure(s) ab

1

Rosenbergc,
2002117

Prostate
cancer
survivors

Intervention (n=15)
Assessment only
control (n=15)

Individual expressive writing
intervention. 20 minutes of
continuous writing over four
consecutive days.

(↓) BPI
(X) MOS-SF-36
(X) SCL-90-R
(X) POMS
(X) Ruminationd
(X) WOC-CA
(X) FACT-P

(X) TNFα
(X) IL-4
(X) IL-10
(X) CD4+ T cells
(X) CD8+ T cells

2

Heiney,
2003105

Stage I or II
breast cancer.

Intervention (n=33)
Standard of care
control (n=33)

Therapeutic group intervention
through a telephone conference
call. 6 weekly sessions lasting
90 minutes each.

(↑) POMS total
POMS subscale
(↑) tension
(↑) anger
(X) QOL-BCV

(X) CD4+ T cells
(X) CD8+ T cells
(X) NK cells

3

Andersen,
2004108

Stage II or III
breast cancer.

Intervention (n=114)
Assessment only
control (n=113)

CBT sessions with trained
psychologists in small patient
groups.18 weekly sessions
lasting 90 minutes each.

(↑) PSS-Family
(↓) POMS total
POMS subscale
(↓) anxiety
(X) IES

No (↓) LPR to PHA
(↑) LPR to Con A
(X) T lymphocytes
(X) NK Cell count
(X) NK Cell lysis

4

McGregor,
2004104

Stage I or II
breast cancer.

Intervention (n = 18)
1 day seminar
control (n = 11)

Group-based CBSM program.
10 weekly meetings lasting 120
minutes each.

(↑) BFS
(X) Distresse

(↑) LPR to anti CD3
(X) Lymphocytes

5

HernandezReif,
2004106

Stage I or II
breast cancer.

Intervention (n = 18)
Wait list
control (n = 16)

Individual massage sessions.
3 massages a week for 5 weeks
with every massage session

(↓) POMS
STAI subscale
(↓) Anxiety

(↑) Dopamine
(↑) Serotonin
No (↑) in Nor-

Immunological
measure(s) ab

(↑) NK Cells
(X) NKCC
(X) Lymphocytes

(↑) Significantly higher in: intervention group compared to control group in RCTs; & post-intervention compared to pre-intervention in pretest-posttest studies
(↓) Significantly lower: in intervention group compared to control group in RCTs; & post-intervention compared to pre-intervention in pretest-posttest studies
(X) No differences between: intervention and control groups in RCTs; & post-intervention compared to pre-intervention in pretest-posttest studies
b
Note: Full forms of all abbreviations used in Table 1 are provided in Annexure for Table 1
c
Only a smaller subset of the sample completed immune measures
d
Rumination measured using 10 items from a study assessing moderating effects of goal beliefs that influence rumination, depression and physical complaints
e
A distress index was developed using descriptive adjectives from scales developed in a previous research published by Carver et al.
a
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No

First author,
year citation

Stage & type
of cancer

Intervention (n)
Control condition (n)

Type of therapy b and
duration of intervention
lasting 30 minutes each.

Psychosocial
measure(s) ab
SCL-90-R subscale
(↓) Depression
(↓) Hostility

6

Savard,
2005121

Chronic
insomnia
secondary to
breast cancer

Intervention (n = 27)
Wait list
control (n = 30)

Group-based CBT for insomnia
management. 8 weekly sessions
with psychologists lasting 90
minutes each.

(X) POMS
(X) ISIf
(X) MFI
(X) HADSg

(↑) IFNγ
(↓) Lymphocytes
(X) WBC
(X) Monocytes
(X) CD3+ T cells
(X) CD4+ T cells
(X) CD8+ T cells
(X) NK Cells
(X) IL-1β
(X) NK cell activity

7

Savard,
2006113

Metastatic
breast cancer
patients with
depression

Intervention (n=25)
Wait list control
(n=20)

Individually-based CT
intervention. 8 weekly sessions
with psychologists lasting 60 to
90 minutes each.

(↓) HDRS
(X) BDI
(X) HADS
(X) MFI
(X) ISI
(X) EORTCQLQ-C33

(X) CD3+ T cells
(X) CD4+ T cells
(X) CD8+ T cells
(X) CD16+ T cells
(X) Lymphocytes
(X) WBC
(X) Monocytes
(X) IFNγ
(X) IL-1β
(X) NK cell activity

8

Andersen,
2007110

Stage II or III
breast cancer.

Intervention (n=114)
Assessment only
control (n=113)

8-month maintenance phase
group CBT intervention which
followed-up patients from the
Andersen, 2004 study.108
8 monthly CBT sessions with
trained clinical psychologists
lasting 90 minutes each.

(↓) POMS
(X) IES

No (↓) LPR to PHA
(X) LPR to Con A

f
g

(↓) ISI mediated : (↑) IFNγ, (↑) WBC and (↑) Lymphocytes
(↓) HADS mediated : (↑) IFNγ, (↑) WBC and (↑) Lymphocytes
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Neuroendocrine
measure(s) ab
epinephrine
(X) Epinephrine
(X) Cortisol

Immunological
measure(s) ab

No

First author,
year citation
Nunes,
2007103

Stage & type
of cancer
Stage I or II
breast cancer

Intervention (n)
Control condition (n)
Intervention (n=20)
Assessment only
control (n=14)

Type of therapy b and
duration of intervention
Relaxation and visualization in
groups with psychologists. 30
minute sessions delivered daily
over 24 consecutive days

Psychosocial
measure(s) ab
(↓) ISSL
(↓) STAI
(↓) BAI
(↓) BDI

Neuroendocrine
measure(s) ab
(X) Cortisol

Immunological
measure(s) ab
(X) LPR to PHA
(X) LPR to DEX
(X) LPR to CORT

10

Nelson,
2008118

Cervical
cancer
survivors

Intervention (n=17)
Standard of care
control (n=19)

Psychosocial telephone
counseling therapy. 6 sessions
with psychologists lasting 4550 min each.

(↑) FACT-Cx

(X) Cortisol
(X) DHEA

(↓) IL-10
(X) PBMC
(X) IFN- γ
(X) IL-5

11

Lindemalm,
2008102

Early stage
breast cancer
patients
undergoing
radio/chemotherapy.

Intervention (n= 21)
Assessment only
control (n=20)

Support group consisting of
oncologists, art therapists,
masseuses and person trained in
qigong and mental imagery was
offered on a residential basis.
Week long program with a 4
day follow-up 2 months later.
No information about duration
of sessions.

(X) HADS
(X) NFQ

12

Phillips,
200895
&
Antoni,
200994

Stage I, II and
III breast
cancer

Intervention (n=63)
1-day education
seminar control
(n=65)

Group-based CBSM program.
10 weekly meetings with
psychologists lasting 2 hours
each.

MOCS subscale
(↑) Relaxationh
IES subscale
(↓) Intrusion
(↓) HAM-Anxiety
(X) ABS

13

Rao,
2008111

Stage II and
III breast
cancer

Intervention (n=45)
Supportive therapy
control (n=53)

Integrated yoga program.
4 individual sessions with yoga
instructor at bedside lasting 60
minutes.

(↓) STAI
(↓) BDI
(↑) FLIC

9

h

(↑) Relaxation did not mediate (↓) Cortisol
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(X) NK cells
(X) NKCC
(X) Lymphocytes
(X) IFN-γ
(X) IL-2
(X) IL-4

(↓) Cortisol

(↑) IL-2
(↑) IFN-γ
(↑) IL2:IL4 ratio
(X) IL-4
(X) IFN-γ: IL4 ratio
(X) CD4+ T Cells
(X) CD8+ T Cells
(X) CD56 + T Cells
(↑) CD56 + T Cells
(↓) IgA
(X) CD4+ T Cells
(X) CD8+ T Cells
(X) IgG
(X) IgM

No

First author,
year citation
Raghavendra, 2009109

Stage & type
of cancer
Stage II and
III breast
cancer

Intervention (n)
Control condition (n)
Intervention (n = 44)
Supportive therapy
control (n = 44)

Type of therapy b and
duration of intervention
Yoga education and training
program. 6 weeks program with
3 sessions per week (total 18
sessions) lasting 1 hour each.

Psychosocial
measure(s) ab
(↓) HADS
(↓) PSS

15

Oh,
2010119

Range of
cancers (and
stages)
including
breast, lung,
prostate
cancers

Intervention (n=79)
Assessment only
control (n=83)

Medical Qigong (MQ) group
therapy. 10 week MQ program
with Qigong instructor
consisting of two sessions per
week lasting 90 minutes each.

(↑) FACT-G
(↑) FACT-F
(↓) POMS

(↓) CRP

16

Cohen,
2011116

Prostate
cancer

Intervention (n=38)
Standard of care
control (n=44)

Individual sessions consisting
of CBT with a clinical
psychologist and stress
management information.
Two sessions lasting 60 to 90
minutes each.

(X) POMS

(↑) NKCC
(↑) IL-1β
(X) IL-12p70
(X) TNF-α
(X) IFN-γ
(X) IL-6
(X) IL-8
(X) IL-10

17

Banasik,
2011114

Breast cancer
survivors

Intervention (n=9)i
Wait list
control (n = 9)

Iyengar yoga practice
consisting of different poses.
Group yoga practice sessions
twice a week for 8 weeks
lasting 90 minutes each.

FACT-B subscale
(↓) Fatigue
(X) FACT-B Total

(X) Cortisol

18

Hsiao,
2012115

Breast cancer
survivors

Intervention (n=26)
1-session educationseminar
control (n=22)

Body-mind-spirit (BMS) group
therapy. Weekly sessions over
8 weeks lasting 2 hours each.

MLQ subscale
(↑) Search
(X) BDI-ii

(↓) Cortisol

14

i

Considerably underpowered study
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Neuroendocrine
measure(s) ab
(↓) Cortisol

Immunological
measure(s) ab

No
19

First author,
year citation
Baker,
2012112

Stage & type
of cancer
Stage I, II &
III breast
cancer

Intervention (n)
Control condition (n)
Intervention (n=6)i
Standard of care
control (n=6)

Type of therapy b and
duration of intervention
Integrated support program
consisting of 2 day support
workshop with a maximum 12
hours consultation with
therapist. Exact duration of
intervention not described.

Psychosocial
measure(s) ab
(↑) SOSI
MFI subscale
(↓) mental fatigue
(X) FACT-G total
FACT-G subscale
(↓) endocrinespecific
symptoms
(X) POMS

Neuroendocrine
measure(s) ab
(X) Cortisol

Immunological
measure(s) ab
No (↓) NKCA
No (↓) PBMCArginase
(X) CD4+ T Cells
(X) CD8+ T Cells
(X) NK Cells

(↓) Cortisol

(↑) NKCA
(↑) IFNγ
(↓) IL-4
(↓) IL-6
(↓) IL-10

NON-RANDOMIZED CONTROLLED TRIAL (NRCT)j
20

WitekJanusek,
2008101

Early stage
breast cancer.

Intervention (n=38)
Assessment only
control (n=28)

Group-based MBSR training.
8-weekly (2.5 hours/week)
sessions plus one full day
session held after the 5th week

(↑) QOL- CVIII
JCS subscales
(↑) Supportant &
(↑) Optimistic
effectiveness
(X) MAAS

PRETEST-POSTEST STUDY DESIGNS
21

Bakke,
2002107

Stage I and II
breast cancer

Total N= 25
No control

Individual hypnotic-guided
imagery delivered by medical
doctor. 8 weekly sessions
lasting 60 minutes each

POMS subscale
(↓) Depression
(X) WCC

22

Carlson,
200332
&
Carlson,
2004122

Early stage
breast and
prostate
cancer

Total N=42
No control

Group-based MBSR delivered
by psychologists. 8 weekly
sessions lasting 90 minutes
each and a 3 hour silent retreat
between weeks 6 and 7.

(↓) SOSI
EORTC-QLQ-C30
subscales
(↑) Global QOL
(↑) Appetite
(X) POMS

j

Participants self-selected either treatment or control group

b

Note: Full forms of all abbreviations used in Table 1 are provided below in the Annexure for Table 1.

33

(↑) NK Cells
(X) NKCC

(X) Cortisol
(X) Melatonin
(X) DHEAS
(X) Cortisol/
DHEAS Ratio

(↑) IFNγ
(↑) IL-4T
(↑) Eosinophils
(↓) Monocytes
(X) NK Cells

No
23

24

First author,
year citation
Carlson,
200799

Stage & type
of cancer
Early stage
breast and
prostate
cancer

Intervention (n)
Control condition (n)
Total N=51
No control

Type of therapy b and
duration of intervention
Group-based MBSR delivered
by psychologists. 8 weekly
sessions lasting 90 minutes
each and a 3 hour silent retreat
between weeks 6 and 7.

Kang,
201198

Stage I, II and
III breast
cancer

Intervention (N=49)
Data from control
group not presented

Group-based CBSM
intervention. 8 weekly sessions
lasting 90 minutes each

Psychosocial
measure(s) ab
(↓) SOSI
(X) POMS
(X) EORTC-QLQC30

Neuroendocrine
measure(s) ab
(↓) Cortisol

Immunological
measure(s) ab
(↑) Eosinophils
(↓) Monocytes
(↓) IFNγ T cell
production
(↑) NKCC
(↑) LPR to PHA
(↑) IL-4
(↑) IL-10
(X) IL-2
(X) IL-6
(X) IFN-γ

Annexure for Table 1: Abbreviations = Full Form
Interventions

CBSM = Cognitive Behavioral Stress Management, CBT = Cognitive Behavioral Therapy, CT = Cognitive Therapy, RVT = Relaxation
and Visualization Therapy, BMS = Body-Mind-Spirit, MBSR = Mindfulness Based Stress Reduction.

Psychosocial
Measures

BFS = Benefit Finding Scale, POMS = Profile of Mood States, DES-IV = Differential Emotions Scale-IV, CES-D = Center for
Epidemiological Studies Depression Scale, IES = Impact of Events Scale, LOT = Life Orientation Test, MOS-SF36 = Medical Outcomes
Study—Short Form—36, SCL-90-R = Symptom Checklist—90 Revised, BPI = Brief Pain Inventory, WOC-CA = Ways of Coping
Inventory – Cancer Version, FACT-P = Functional Assessment of Cancer Therapy – Prostate, QOL = Quality of Life, BCV = Breast
Cancer Version, ISSL = Inventory of Stress Symptoms Lipp (for adults), PSS-Family = Perceived Social Support from Family, BAI =
Beck Anxiety Inventory, STAI = State-Trait Anxiety Inventory, ISI = Insomnia Severity Index, MFI = Multidimensional Fatigue Inventory,
HADS = Hospital Anxiety and Depression Scale, HDRS = Hamilton Depression Rating Scale, HAM-anxiety = Hamilton Rating Scale for
Anxiety, ABS = Affects Balance Scale, BDI = Beck Depression Inventory, FLIC = Functional Living Index of Cancer, MLQ = Meaning in
Life Questionnaire, EORTC-QLQ = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, NFQ =
Norwegian Fatigue Questionnaire, MOCS = Measure of Current Status, PSS = Perceived Stress Scale, FACT-B = Functional Assessment of
Cancer Therapy – Breast, QOL-CVIII = Quality of Life Index –Cancer Version III, MAAS = Mindfulness Attention Awareness Scale, JCS
= Jaloweic Coping Scale, WCC = Ways of Coping Checklist, SOSI = Symptoms of Stress Inventory.

Neuroendocrine
Measures

DHEAS = Dehydroepiandrosterone-sulphate

Immunological
Measures

NK = Natural Killer, IFN = Interferon, TNF = Tumor Necrosis Factor, IL = Interleukin, CD = Cluster of Differentiation, LPR =
Lymphocyte Proliferative Response, NKCC = Natural Killer Cell Cytotoxicity, WBC = White Blood Cells, PHA = Phytohaemagglutinin,
ConA = Concavalin A, DEX = Dexamethasone, CORT = Corticosterone.
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Table 2: Activities involved in PNI-based psychosocial interventionsk
Name of activity

Study No.l (Type of therapies) using specified activities
Study No. (Cognitive-behavioral)
Study No. l (Complementary medical )

% of studiesm

3, 4, 8, 9, 11, 12, 16, 19, 21, 24,
- 4, 8, 9, 12, 16, 19, 21, 24,
- 4, 8, 9, 12, 16, 21, 24,
- 3, 4, 8, 9, 12, 16, 21, 24
2, 3, 4, 6, 8, 9, 11, 12, 16, 19, 21, 24
2, 3, 4, 7, 8, 10, 12, 16, 24,
4, 6, 7, 8, 12, 16, 24
19
2, 3, 4, 8, 12, 24,
2, 3, 7, 12, 16
1, 2, 4, 8, 12, 24
4, 8, 9, 12,
3, 11, 19, 24

75% (18/24)
- 67% (16/24)
- 50% (12/24)
- 33% (8/24)
71% (17/24)
50% (12/24)
42% (10/24)
33% (8/24)
38% (9/24)
33% (8/24)
29% (7/24)
29% (7/24)
21% (5/24)
21% (5/24)
8% (4/24)
8% (4/24)
8% (4/24)
8% (4/24)
8% (2/24)
8% (2/24)
8% (2/24)
8% (2/24)
4%(1/24)
4% (1/24)
4% (1/24)
4% (1/24)
4% (1/24)
4% (1/24)
4% (1/24)
4% (1/24)

l

Relaxation training
- Breathing exercises/techniques (e.g. deep breathing)
- Imagery/guided imagery and visualizations
- Progressive muscle relaxation
Psycho-Education
Coping skills training (e.g. problem solving, setting goals)
Cognitive restructuring
Yoga training (e.g. asanas)
Group social-support
Personal stress awareness
Expressing emotions and feelings
Meditation
Physical Exercise
Emphasizing the mind-body connection
Qigong training
Mindfulness meditation training
Conflict resolution and anger management
Assertiveness training
Individual supportive care
Massage
Diet/nutritional advice
Art therapy
Counseling for relationship and sexual problems
Forgiveness therapy
Stimulus control
Expressive writing
Insomnia management (Sleep restriction)
Hypnosis/hypnotherapy
Communication skills training
Specialized homecare and leisure activities

11, 19

13, 14, 15, 17, 18, 20, 22, 23
- 13, 14, 15, 17, 18, 20, 22, 23
- 14, 18, 20, 22, 23
15, 18, 20, 22, 23
13, 14, 18,
20, 22, 23
13, 14, 15, 17, 20, 22, 23
20, 22, 23
20, 22, 23,
18,
13, 14, 15,
17,
17, 18, 20, 22, 23,
15, 18,
18, 20, 22, 23,

12, 4, 8, 12
3, 4, 8, 12
16, 19
5, 18
3, 19
11, 19
10
18
6
1
6
21
3
11

k

Activities listed in Table 2 are based on the types of psychosocial treatments identified in a previous meta-review of psychological interventions in cancer patients41
Study no.’s are referenced in the first column of Table 1
m
Numbers for percentages reported are rounded off to next integer
l
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With regards to complementary medical therapies, two-thirds of the studies (6/9) showed
significant effects on at least one neuroendocrine or immune outcome measure. Though therapies
involving yoga, qigong, and massage were evaluated using RCT designs, only two RCTs that
included the aforementioned therapeutic activities reported significant effects on functional
immune measures111,119. MBSR was not evaluated using a RCT study design; however, all three
studies that used MBSR, involving one NRCT101 and 2 pretest-posttest studies, had significant
impacts on PNI biomarkers99,100. This suggests that complementary medical therapies are
emerging psychosocial therapies which require more investigation regarding their impact on
PNI-based outcomes in patients with cancer. We found a few brief and inexpensive psychosocial
interventions appealing for further investigation in this study.
A Brief and Inexpensive Psychosocial Intervention for Cancer Patients
A significant finding in our review regarding the implementation of psychosocial
interventions was that most interventions were delivered over 60-90 minute sessions conducted
by health professionals over a span of several weeks (commonly 6-8 weeks), thereby, making
most psychosocial interventions expensive and resource intensive. One intervention that emerged
in this review was the expressive writing (EW) intervention, which is a brief (total of 80 minutes
over 4 days) and inexpensive (does not need trained health professionals) psychosocial
intervention which can be technologically adapted (computer-based format using the internet) for
greater access and appeal. EW interventions in cancer patients have demonstrated improvements
in self-reported physical symptoms of cancer patients and other self-reported psychological
outcomes such quality of life125. Only one study was identified that employed EW in CS and
used PNI measures117, which was found to be problematic, since only a smaller subset (N=20) of
the sample completed actual PNI measures. Researchers have proposed that a proactive approach
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to the psychosocial care of CS can help prevent or mitigate stress during re-entry as well as lead
to positively adaptive survivorship14. Therefore, empirically testing the effect of EW on CS
psychological state and neuro-hormonal indices will provide significant advancement in the
science of psychosocial health services for the cancer population, specifically for CS. Previous
research conducted in other populations has demonstrated that EW has an effect on PNI-based
outcome measures.
The Influence of EW on PNI Interactions
Disclosing emotional and stressful experiences through writing has been studied as an
intervention to improve health outcomes in healthy as well as clinical populations. Three metaanalyses published in 1998, 2004 and 2006 have concluded that expressive writing has a
significant positive impact on a variety of health outcomes126-128. EW has shown to impact a
variety of neuroendocrine and immunologic variables. Scientific studies of EW that have used
neuroendocrine measures (i.e. cortisol) have shown that expressive writing decreases cortisol
secretion129. In the landmark study conducted by Pennebaker, Kiecolt-Glaser and Glaser
(1988)130, EW improved the response of two mitogens—phytohemagglutinin (PHA) and
concanavalin A (ConA)–which are proteins that increase the proliferation of T lymphocytes that
are important components of the immune system. Anti-body production was increased by EW
for individuals injected with Hepatitis B vaccine131 as well as those having chronic Epstein Barr
Virus (EBV)132 infection. In HIV infected population, an EW intervention demonstrated a
significant increase in levels of CD4+ T Cells133. EW has demonstrated an improvement in
immune function for healthy individuals as well as certain clinical populations such as posttraumatic stress disorder 129, fibromyalgia 134 and HIV+ patients133. However, researchers are still
working on a robust theory that can explain the psychological and physiological effects of EW.
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How does EW regulate psychosocial stress and impact PNI outcomes? Initially, EW
was considered to work through the expression of inhibited thoughts and feelings (disinhibition
theory) which are disclosed during the process of writing135. Subsequently, further studies of EW
revealed the importance of cognitive processing, wherein EW was thought to help individuals
make sense of or gain insight into stressful events that affected them, as well as organize and
integrate their stressful experiences135. However, there is no consensus among researchers on a
singular theory that adequately explains or predicts the diverse psychobiological effects of EW.
In fact, the pioneer of EW, Dr. James Pennebaker, suggests that a single theory of EW is
unlikely, since EW “affects people on multiple levels—cognitive, emotional, social, and
biological.”136 (p.138) Therefore, decisions on choosing a theory for EW intervention should be
based on the outcomes (that are economically valuable to the population), and the issues faced by
the population of interest135,136. The emotion-regulation of theory of EW137 provides a sound
framework for evaluating the effect of EW on psychosocial as well as PNI outcomes in CS.
Expressive writing helps regulate stress through emotion-regulation. Emotionregulation theory suggests that emotional responses in individuals have three components. The
first is the experiential, which involves positive (e.g. pleasure) or negative (e.g. pain) valence
states, and includes the subjective cognitions and feelings of the individual. The second is the
physiological component, which is involved with the regulation of stress hormone secretions
(e.g. adrenaline and cortisol) through the HPA axis or the SNS. The third is the behavioral
component, which include verbal and bodily responses137. Therefore, unresolved emotional
responses (e.g. fear of cancer recurrence in CS) act as chronic stressors which deregulate stress
hormone secretions and lead poor health behaviors (e.g. smoking). Psychosocial interventions
such as EW help regulate these emotional responses and improve health outcomes.
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Some evidence exists to support the emotion-regulation effects of EW on experiential
(cognitive and affective) and physiological (PNI) outcomes, however, in general EW has had
very low effects on behavioral outcomes128. The EW intervention allows individuals to see their
stressful experiences at a distance and helps them give those experience structure and
meaning137,138. This helps in generating positive coping responses to the stressors and cognitive
reappraisal of negative emotional experiences139 and a reduction in perceived psychological
stress140. Also, the process of observing oneself expressing and controlling emotions during EW,
gives the participant a newfound or greater sense of self-efficacy for regulating emotions128 and
coping with cancer. Emotional self-efficacy makes stressful experiences and emotions more
controllable, and hence reduces negative affect. Regulation of psychological and emotional
stressors reduces the chronic stress stimuli that are acting on the HPA axis and SNS, which
regulate hormonal secretions, and in turn will help in bolstering immune function, as described in
the PNI framework77,141, see Table 3. However, no study of EW in the cancer population has
empirically demonstrated the emotional regulation effects of EW and elicited the pattern of
changes in secretion of neuro-endocrine hormone levels over time.
Cancer survivors are known to have changes in the rhythms of their neuro-hormonal
secretions39,142. Therefore, it is essential to collect data over multiple time points, in order to
empirically demonstrate how EW leads to reduced stress and improves PNI outcomes. The
current study was designed to determine the psychoneuroimmunologic processes that occur over
time, when CS write expressively about their stressful experiences related to cancer, by
collecting repeated measures of neuroendocrine function and psychological status over a 6 week
period. In order to provide increased accessibility and comfort to CS participating in EW, this
study used technology to adapt the traditional pen-paper writing format to a computer-based one.
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Table 3: Theoretical framework of PNI for our expressive writing intervention
Psychosocial
Intervention

Theoretical framework of Psychoneuroimmunology (PNI)
Psychosocial (P)

Expressive
Writing

Neuroendocrine (N)

Immune (I)

Psychosocial Stress
Neuroendocrine system
Immune system

Respective Outcome Measures
i ) Percieved Stress
ii) Fear of cancer
recurrence
iii) Self-efficacy for
coping with cancer

Response from
i) Hypothalamo-pituitary
adrenal (HPA) axis: Cortisol
ii) Sympathetic nervous system
(SNS): α-Amylase

Inflammatory response of immune
system:
i) C-Reactive Protein (CRP)

Possible Mechanisms of Action
Emotion Regulation

Habituation/
Desensitization
Become less
bothered by
intrusive
thoughts about
the stress they
are experiencing

Regulation of neuro-hormonal
Regulation in secretion of
response from HPA and SNS axes inflammatory molecules of the immune
system

Insight
Develop
new
insights
about their
self or the
stressful
experience

.
Emotion Regulation:
Greater working memory
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Chapter III. Specific Aims
For this study, a 20 minute EW intervention for cancer survivors (who have completed
radiation treatment) was implemented over 4 consecutive days delivered using an online
computer-based format. Neuro-hormonal response from the HPA axis as a result of EW was the
primary outcome of interest and was measured by salivary cortisol levels. Secondary outcome
measures of physiological (α-amylase and c-reactive protein; CRP) and psychological function
(perceived psychological stress, negative emotion, and efficacy for coping with cancer) were also
included. Using a two-arm (EW and control-writing) randomized-controlled trial (RCT) study
design, the specific aims and hypotheses of this study were:
Specific Aims and Hypotheses
• Aim 1: Determine the efficacy of EW to impact the HPA axis in CS as measured by
salivary cortisol levels, i.e. the primary outcome of interest.
H1: CS participating in EW (treatment arm) will have lower levels of salivary cortisol
compared to CS participating in control-writing (control arm), 6 weeks post-intervention.
• Aim 2: Determine the efficacy of EW to impact the SNS in CS as measured by salivary
α-amylase levels, i.e. a secondary physiological outcome of interest.
H2: CS participating in EW (treatment arm) will have lower levels of salivary α-amylase
compared to CS participating in control-writing (control arm), 6 weeks post-intervention.
• Aim 3: Determine the efficacy of EW to impact the immune system in CS as measured
by salivary CRP levels, i.e. a secondary physiological outcome of interest.
H3: CS participating in EW (treatment arm) will have lower levels of salivary CRP
compared to CS participating in control-writing (control arm), 6 weeks post-intervention
• Aim 4: Determine the efficacy of EW to impact psychosocial functioning in CS as
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measured by scores on self-report questionnaires: a) PSS (perceived psychological stress), b)
FCRI-S (negative emotion), and c) CBI-B (efficacy for coping with cancer), i.e. secondary
psychosocial outcomes of interest.
H4: CS participating in EW (treatment arm) will have lower scores on the PSS compared
to CS participating in control-writing (control arm), 6 weeks post-intervention.
H5: CS participating in EW (treatment arm) will have lower scores on the FCRI-S
compared to CS participating in control-writing (control arm), 6 weeks post-intervention.
H6: CS participating in EW (treatment arm) will have higher scores on the CBI-B
compared to CS participating in control-writing (control arm), 6 weeks post-intervention
• Aim 5: Determine the effect of EW on the primary and secondary (physiological and
psychosocial) outcomes of interest immediately after the intervention.
H7: CS participating in EW (treatment arm) will have higher levels of salivary cortisol,
compared to CS participating in control-writing (control arm), 24 hours post-intervention.
H8a: CS participating in EW (treatment arm) will have higher levels of salivary αamylase and CRP (secondary physiological outcomes), compared to CS participating in controlwriting (control arm), 24 hours post-intervention.
H8b: CS participating in EW (treatment arm) will have higher scores on the PSS and
FCRI-S and lower CBI-B scores (secondary psychosocial outcomes), compared to CS
participating in control-writing (control arm), 24 hours post-intervention
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Chapter IV. Significance and Innovation
Delivering the Expressive Writing Intervention in an Internet-Based Format
One of the most significant changes in individual lifestyles and societies in the modern
world has been the use of computer technology and the internet. Recent statistics indicate that
more than half the adults in the United States own a computer device that can access the internet,
and 58% own a desktop computer, 61% have a laptop, and 18% own a tablet computer143.
Smartphones are a recent technological innovation that offer a small computer interface and
internet access, in addition to cellular phone use, and 45% of Americans own a smartphone, and
the number goes up to 66% in age group 18-29144. In terms of access to the internet, recent data
indicates that 82% of American adults can access the internet and 66% have a high-speed
broadband connection at home145. In August of 2012, data reveals that 215 million Americans
were active online and spent an average of 29 hours on the Internet that month146.
The above data demonstrate the accessibility and popularity of computer-use and the
internet amongst Americans and suggests it is a suitable medium for delivering psychosocial
interventions such as EW. The computer-based format of EW also provides the participant to
undertake their writing task at their own convenience, comfort and privacy, and the metaanalytic review of EW indicates that the settings in which EW is delivered moderates the
outcome of EW128. Some studies have demonstrated an effective response for a computer-based
and online EW intervention147,148. However, no study of EW has been done using an online
computer-based format in cancer populations. A review of internet interventions in the oncology
setting has suggested that cancer patients find internet based interventions to be highly
acceptable and feasible, and psycho-oncology researchers have suggested that more psychosocial
interventions should be delivered using the internet in the cancer population149.
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Study Innovation
The current EW study was a pioneering research effort designed to move the field of
psychosocial interventions for cancer patients forward in terms of science, technology and
service delivery. This was the first known study to collect repeated PNI based outcome measures
for an EW intervention in CS. This research approach allows scientists to make inferences about
the changes in neuroendocrine hormone secretions and immune parameters caused due to a
psychosocial intervention (EW in this case) over time. Research shows that patterns of cortisol
rhythms are indicators of survival rates in cancer patients142. Therefore, generating evidence to
understand changes in the patterns of hormone secretion resulting from psychosocial
interventions is crucial to our understanding of psycho-emotional effects on the biological
function of CS. This knowledge will provide a significant contribution to the science of
psychosocial health interventions for the CS population.
The NCI and IOM, in their 2008 report3, Cancer Care for the Whole Patient have
encouraged researchers and health practitioners to include psychosocial health of cancer patients
and CS as part of routine cancer care. This study was the first to specifically target CS in the
post-radiation re-entry phase of survivorship. This population (post-radiation CS) was
deliberately chosen at a particular phase (re-entry) in the cancer-care trajectory, since research
indicates an urgent need for psychosocial interventions for these individuals. Results from this
study will contribute to the scientific understanding of patient outcomes from psychosocial
interventions for re-entry phase CS that have completed radiation therapy. Lastly, this was the
first study that takes the EW intervention to the medium of the internet and computers for the CS
population. If online computer-based EW is shown to be effective in improving CS physical and
psychosocial health (measured by PNI based outcomes), this health intervention has the potential

44

to reach millions of CS all over the US and the world over through the medium of computers and
the internet. Therefore, this study also contributes to the knowledge base related to the
technology and delivery of psychosocial health interventions for the cancer population.
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Chapter V. Methods
The ultimate aim of this study was to determine the efficacy of a brief and inexpensive
psychosocial intervention (called expressive writing; EW) for the supportive care of CS after
completion of radiation therapy. In view of this aim, a randomized controlled trial (RCT)
provided an appropriate and rigorous study design that eliminates selection bias and group
differences by way of random allocation of participants. Also, this study constituted an
explanatory trial150, since we aimed to contribute to the scientific understanding of PNI-based
psychosocial interventions for CS. The research team for this study consisted of 1) the first
author and chief research coordinator, Utkarsh B. Subnis (UBS), 2) study mentor and adviser Dr.
Richard F. Brown (RFB), 3) study statistician, Dr. Maureen Wilson-Genderson (MWG), 4)
nursing scientist and nurse practitioner, Dr. Angela R. Starkweather (ARS) and licensed clinical
social worker (LCSW), Connie Macaluso-Dickerson (CMD).
Randomized Controlled Trial (RCT) Study Design
A RCT study design is the gold standard design for determining therapeutic efficacy of a
health intervention. The participants in this study were randomly allocated to either the treatment
condition, or the control group through a randomization protocol to ensure that every participant
had equal chance of getting either the treatment or the control condition. The unit of
randomization in this study was the individual cancer patient.
Randomization protocol. Randomization of participants was performed through a
computerized random numbers generator program. Two sets of random numbers were generated
by the statistical software program SPSS for each group. The list of random numbers in each
group was maintained in a secure location by UBS. These random numbers were then written on
a piece of paper (5cm X 5cm) along with the group to which the random number belonged, for
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example, “33 – Control group”. The random number also served as the participant ID number.
These pieces of papers were folded twice and placed inside opaque envelopes. These opaque
envelopes were then sealed and sequentially numbered. Each participant's name and email was
entered on the front of the envelop (after study enrollment), and the research team was informed
about the participant’s ID number, study group, name and email. The name and emails were deidentified from the participant ID number at the end of the study. There was no alteration in
treatment allocation once random allocation procedures were completed. Measures to ensure
adherence to protocol were taken, and are presented below.
Intervention condition (EW group). The intervention condition consisted of a
prompt that encouraged patients to disclose their deepest possible emotions and feelings about
their experience with cancer. Participants wrote about their stressful experiences over 4
consecutive days. The intervention protocol used in this study had been shown to be efficacious
in improving stress related self-report and immune parameters as reported by previous metaanalyses126-128. Participants were instructed to, “Write your very deepest thoughts and feelings
about your cancer experience.” Participants in the EW group were instructed to write
continuously for between 20 - 30 minutes, and told to not worry about spelling, grammar or
sentence structure. Please refer to Appendix N for the EW prompts.
Control condition (Control group). This study had a control writing condition,
equivalent to a placebo condition in RCTs for drug trials. The participants in the control
condition also performed a writing task over four consecutive days. However, the control
participants were asked to write about more mundane matters, i.e. how they spent their time, and
were encouraged to approach the writing task in a more distanced and objective manner. The
protocol used for the control writing had been developed and used in previous studies151,152. The
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time allotted for writing the control condition was similar to the intervention condition, i.e. 20-30
minutes, over 4 consecutive days. Please refer to Appendix N for the control writing prompts.
Delivery of intervention. Participants in the treatment group and the control group
received the writing prompt through an online link created using the web-based survey delivery
software Qualtrics153 and was delivered via email. Qualtrics is a HIPPA compliant survey
delivery software, and participant’s email addresses were entered in the program to directly
deliver the surveys and writing prompts. Qualitrics generates a unique link for the survey which
prevents spamming. By default, the anonymous survey link collects the user’s IP address to help
detect potential spam responses. However, the setting in Qualtrics was set to “anonymize
responses” from participants; this prevented Qualtrics from obtaining any identifying
information such as the IP address of participants.
Manipulation check. The intervention group was instructed to write about stressful and
emotional experiences and the control group about mundane matters. However, it was important
to determine if experimental manipulation of the intervention and control condition (by giving
different directives for the two groups) was in fact successful. The EW literature suggests that
data obtained from an EW writing intervention differ from data obtained from other writing tasks
in language use. Therefore pronouns, cognitive terms, as well words denoting positive and
negative affect are different. A software program that analyzes text for sentence and word use
that is indicative of emotional expression, called the Linguistic Inquiry and Word Count (LIWC),
has been developed by the pioneering EW researcher, James Pennebaker154. This LIWC software
is able to detect and differentiate words and phrases routinely used when people write
expressively as opposed to other writing tasks155. The LIWC software is updated on a regular
basis and EW researchers have found it a reliable way of performing manipulation checks.
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Therefore in order to check our manipulation, we submitted our participant’s writing responses
to a series of linguistic analyses performed through LIWC154 to assess for use of positive and
negative emotion words. The LIWC software application was available for download from the
developer’s website, http://www.liwc.net/index.php. All writing responses were deleted and
destroyed after completing the text analysis procedures to maintain participant confidentiality.
Trial Outcomes Measures
The outcome measures for this study were chosen to help explain the psychosocial (P),
neuro-endocrine (N) and immune (I) effects of EW. Each measure was carefully selected based
on the scientific evidence regarding the reliability and validity of the measure, its role in the PNI
interactions framework, and its relevance and importance for public health research, health care
professionals and stakeholders, i.e. CS. The physiological measures were selected to provide
information regarding activity of the HPA axis, SNS and immune system. The psychosocial
measures were self-reported and were selected to provide information regarding the
psychological processes influenced by EW and psychosocial functioning of the participant CS.
To determine if EW was indeed helpful in managing stress for CS, we measured levels of
perceived stress and severity of negative emotion. In addition, to determine if EW helped CS
regulate emotions and improve their coping skills, we measured coping self-efficacy.
Primary and secondary outcome measures. Considering the specific aims and study
design, it was appropriate to choose a “single main measure of clinical outcome,” 156 p. 1075 that
constituted the primary end point157 of the RCT, referred to as the primary outcome measure
henceforth. The primary outcome measure for this study was salivary cortisol levels (which
described the activity of the HPA axis). A number of secondary outcomes that indicate both
physiological and psychosocial functioning were also employed to help explain the multi-system
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and PNI effects of psychosocial interventions. Salivary α-amylase levels (marker of SNS
activity), and salivary levels of C- reactive protein—CRP (a parameter for the immune system),
were used as secondary physiological outcome measures. In terms of secondary psychosocial
outcome measures, reliable and valid self-reported psychometric scales were used which
included the: a) Perceived Stress Scale (PSS) for levels of perceived psychological stress; b) Fear
of Cancer Recurrence Inventory – Severity subscale (FCRI-S) for severity of negative emotion
experienced by CS; and c) Cancer Behavior Inventory-Brief Version (CBI-B) for self-efficacy
for coping with cancer.
All measures (primary and secondary) were obtained from each participant in the
intervention and control groups at three time points, 1) 24 hours pre-intervention, i.e. baseline
measure, 2) 24 hours post-intervention, i.e. immediate post-intervention measure and 3) 6 weeks
post intervention, i.e. delayed post-intervention measure, see Table 4 below.
Table 4. Outcome measures used and the timing of their collection
Outcome Measures

Pre Intervention

Post Intervention

24 hours
(Baseline)

24 hours

6 weeks

×

×

×

α-Amylase

×

×

×

C-reactive protein – CRP

×

×

×

Perceived Stress Scale, PSS (14 items)

×

×

×

Fear of Cancer Recurrence Inventory-Severity,
FCRI-S (9 items)

×

×

×

Cancer Behavior Inventory-Brief Version,
CBI-B (12 items)

×

×

×

Primary Outcome (Salivary Specimen)
Cortisol
Secondary Outcomes – Physiological (Salivary Specimens)

Secondary Outcomes – Psychosocial
(Self-reported questionnaires)
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Primary outcome: salivary cortisol. Salivary cortisol was an appropriate primary
outcome for this study, since levels of salivary cortisol have been demonstrated to be highly
correlated with serum cortisol levels (r=0.91)158and is a reliable measure of HPA axis activity.
Also, substantial evidence implicates a direct
relationship between salivary cortisol levels and
immune function159,160. These factors make cortisol
levels a clinically relevant outcome measure for
health researchers and professionals, and for our
population, i.e. CS. Measuring levels of salivary
Figure 4: Diurnal Cortisol Rhythm

cortisol has gained popularity in the social-behavioral

sciences due the non-invasiveness of the procedure. However, it is important to take account the
biological variations in cortisol secretion. Research indicates that there is a diurnal variation in
cortisol level, which means there were considerable difference in a measure of cortisol level
based on what time during the day the measure was collected161. Human beings experience a
large spike in cortisol secretion 45-60 min after waking up from sleep, called the Cortisol
Awakening Response (CAR)162. This initial spike during CAR reaches the peak cortisol release
and is followed by a rapid decline and a gradual decrease and plateauing towards bedtime see
Figure 4. CAR and the diurnal variation (from awakening to bedtime) of cortisol secretion have
been associated with levels of psychosocial stress162.
Therefore, in order to account for these patterns, bio-behavioral researchers recommend
obtaining multiple measures of salivary cortisol during different times of the day163. Participants
were asked to give their saliva samples by drooling into salivette tubes 3 times per day on every
day of data collection, i.e. once at baseline (BOM), which is 24 hours before the intervention,
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and twice after the intervention, specifically, 24 hours (POM1) and 6 weeks (POM2) postintervention, see Table 4. Participants were requested to provide their saliva in their saliva
containers at the following times: 1) immediately after waking up, for the waking response (W),
2) within 30 min after waking, for the peak response (P), and 3) immediately before going to
sleep, for the bedtime response (B).
Secondary physiological outcomes: salivary α-amylase and CRP. Other elements of
the PNI interactions such as the SNS/ANS and the immune system were assessed using two
secondary physiological outcome measures. The procedures for collecting, storage and data
analysis were identical to the salivary cortisol measures and are described below.
1) Salivary α-Amylase. Biomarkers for the activity of the SNS/ANS in saliva have only
recently investigated by researchers. Alpha (α) –amylase is an enzyme produced in the salivary
glands that helps to degrade starch and aid digestion. Studies have shown that production of αamylase in saliva increases in response to psychological stress (e.g., written examinations) and
physical stress (e.g. exercise, heat and cold)164. Some research indicates that the secretion pattern
of α-amylase does often correlate with cortisol levels during stress, suggesting a physiological
stress response separate from the HPA axis165,166. A recent study found that α-Amylase was
significantly correlated with blood levels of norepinephrine (r = 0.33)167. α- Amylase is now
considered a reliable correlate of sympathetic activity under conditions of stress166. Some
research suggests a diurnal rhythm in α-amylase secretion, with pronounced decrease in the first
hour after awakening and a steady increase during the rest of the day.
2) C-Reactive Protein. C-reactive protein (CRP) was used as a secondary physiological
outcome measure of the immune system since it provides information regarding the general level
of inflammation in the body. CRP is a protein synthesized by the liver during inflammation and

52

the acute-phase response, and has been is widely used as a bio-marker of inflammation for a
variety of conditions ranging from cardiovascular disease88,168 (e.g. in myocardial infarction) to
cancer169,170. CRP plays an important role in immune function and increases in levels during the
body’s response to physical stressors (e.g. infection, physical trauma, or malignancy). This
involves a process of inflammation, which starts with recruitment of certain immune cells in the
blood, i.e. white blood cells, WBCs, e.g. neutrophils. These WBCs secrete a number of signaling
molecules called cytokines (e.g. Interleukins, IL) into the bloodstream. IL-6 induces increased
production of CRP in the liver to assist with inflammatory processes171. CRP enhances the
capacity of immune cells to produce more inflammatory cytokines168,172 along with facilitating
production of opsonin, that helps in destruction of pathogens and dead or dying cells171,172.
CRP is also implicated in activation of other immune pathways (the classical complement
pathway) and enhancing tumor-cell killing activity of immune cells (macrophages)172. Evidence
also links psychosocial (chronic stress) and behavioral (exercise) factors with increased levels of
CRP, which lends support to CRP’s role in the PNI framework173,174. The ability to detect CRP
levels in saliva has been a recent scientific development and data regarding correlation between
blood and salivary levels is being established. However psychosocial interventions have found
significant changes in CRP levels after improving participant’s psychosocial functioning174.
Hence, the saliva collected from CS was used to determine levels of CRP.
Procedures for the collection and storage of saliva from participants. Salivette tubes
provided by the Center for Biobehavioral Clinical Research at the VCU School of Nursing were
used for obtaining saliva samples from the participants in this study. This procedure needed a
high level of adherence to protocols; therefore detailed training material was provided to
potential participants to demonstrate how they would collect their saliva by drooling into the
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salivette tube. An information booklet along with a link to a video demonstration of saliva
collection was mailed to the participants prior to the study, see Appendix K. The study staff were
also available to answer any questions participants had over the phone or voice/video chat as
well. Salimetrics Inc.175 Labs, which provide the assay kits for the analytes, recommend
collecting a total volume of approximately 500 micro-liters (μl), when testing for three analytes.
In their instruction and training booklet and video (please see Appendix K), participants were
shown the marking on the salivette tube (Eppendorf tube) which would indicate that an adequate
sample of saliva had been collected (i.e. at least 500 μl) for the purpose of this study.
Salimetrics reports their kits to be highly sensitive, reliable and valid ways to measure
salivary cortisol, α-amylase and C - reactive protein, with a detection range of 0.012 – 3.0
μg/dl176. Also, past studies that have used these kits have reported that the intra-assay coefficient
ranged from 3.35% to 3.65% and inter-assay coefficient ranged from 3.75% to 6.41%177,178.
Participants were mailed the saliva collection kits (salivettes) for all three measures and for all
three days of data collection at least one week before the intervention. The salivette tubes had a
sticker pasted on the surface of the tube (see Appendix L), containing only the participant ID
number along with a box to mark which type of sample it was based on the criteria for the timing
of the sample described below.
Timing of saliva collection on Day 2 (BOM), Day 7 (POM1) and Day 49 (POM 2).
Participants were asked to provide three samples at the following times on the day of outcome
measures data collection:
1) Immediately after waking up, for the waking response (W),
2) Within 30 min after waking, for the peak response (P), and
3) Immediately before going to sleep, for the bedtime response (B).
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Note: Saliva samples given at random times during the day (i.e. that do not meet with
timing requirements of W, P or B) were also be marked as Other (O).
After giving their saliva sample, the participants were instructed to note the timing of their saliva
sample by and checking a box on the labels on the salivette tubes and indicate whether the
sample was W, P, B, or O, please see Table 5 below.
Table 5: Timing of saliva samples and marking of samples
Sample What time during the day to collect your saliva
number sample?
1.

Please provide your first saliva sample immediately
after you wake up. This is when you have opened
your eyes and are ready to get up for the day.

Which box to check on saliva
tube label?
Please check box marked “W”
PID No. _______

W P B O

(Note: You may keep the saliva collection tubes beside
you the night before. This way you can collect your
saliva before you get out of bed. You can also collect this
sample immediately after getting out of bed.)

2.

3.

O

Please collect the second saliva sample at about 30
minutes after you have woken up for the day. The
timing of this sample is particularly important, so
please make attempt to collect exactly 30 minutes
after Sample 1.

Please check box marked “P”

Please collect the third and last saliva sample at
bedtime. The timing for this sample is ideally right
before you get into bed.

Please check box marked “B”

In case you miss the timing for the samples or are
unable to give a sample at any of the above 3 times,
you can still provide your saliva sample at any time
of the day.

Please check box marked “O”

PID No. _______

W P B O

PID No. _______

W P B O

PID No. ______

W  P B O

Participants were also provided with Ziploc freezer bags marked for each day of data
collection, namely, Day 2, Day 7 and Day 49. Participants were instructed to store the saliva
samples in the freezer compartment of their refrigerator. Researchers have indicated that saliva
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samples for testing all three of our measures (cortisol, amylase and CRP) can be frozen for longterm storage (beyond 8 weeks), at negative (–) 20 degrees Celsius in whole, un-centrifuged
salivettes, without loss of substances. Most home freezer compartments provide a temperature
very close to the recommended freezing temperature. Therefore, I collected all samples from the
participant after the entire study protocol was completed, i.e. six to seven weeks after the
intervention. Samples were immediately transported, from the participant’s location to the biobehavioral clinical research laboratory at the School of Nursing at VCU, using temperature
controlled kits. Once they arrived at the laboratory, the samples were centrifuged in order to
remove mucous from the salivary specimens, and were subsequently stored and frozen at –70° F.
Monitoring adherence to protocol of salivary data collection. The following
procedures were employed to ensure adherence to the study protocol:
1) Participants were educated about the timing for each of the three samples (W, P, B)
2) The salivette tubes had a sticker where participants were instructed to write down the time of
the collection and check a box to identify whether the sample was W, P, B, or O.
3) It was emphasized to the participants that the Peak sample (P) must specifically be collected
within 30 minutes of waking up. In case they give the sample beyond 30 minutes of waking
up, they were asked to mark the sample as Other (O). Saliva samples given at random times
during the day (i.e. that do not meet with timing requirements of W, P or B) were also
requested to be marked as Other (O)
4) Participants were provided with an opportunity to enroll in an interactive reminder system.
This involved participants listing their preferred method of communication (e.g. cell-phone
number, email, instant-messaging-IM or landline) for being reminded on the days of data
collection. Participants were also asked to provide the approximate time they wake-up, and
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the time they would prefer a reminder message. On the day of day collection (i.e. baseline
and 2 times post-intervention), participants were sent a text-message (or IM/e-mail) through
a chat engine (e.g. GChat) reminding them about the timing for their salivary sample.
Participants were sent a follow-up text-message asking them if they had given the sample at
the required time point (i.e. W/P/ B/O). They were also sent a message inquiring if they had
placed their samples in their freezer at the end of the day of data collection. Participants had
the opportunity to respond as Yes or No, to this text-message (or IM) through their cellphone (or other technological device). These responses were maintained as a record of
participant’s adherence to protocol. Participants were thanked for their participation at the
end of each communication.
5) Participants were provided a detailed spreadsheet with dates and times for study activities
such as when they would be filling out the online surveys, writing online.
6) Decision for excluding samples: As explained above, the O samples were to be included in
our estimation of average cortisol secretion (Area Under the Curve), but excluded in our
estimation of Cortisol Awakening Response and Diurnal Cortisol Secretion.
7) The survey program time stamped each writing entry (treatment and control) in order to
monitor adherence to writing intervention protocol
8) Participants were informed that they could contact UBS or RFB at any time during the
sample collection if there were any problems or clarifications.
Secondary outcomes: Self-reported psychometric measures. This study also employed
self-report survey items that were administered through an online survey link (Qualtrics) at the
same time points as the biological measures, i.e. Day 2 (Baseline Outcome Measure), Day 7
(Post intervention outcome measure 1), and Day 49 (Post intervention outcome measure 2)
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Previously validated measures were used to detect changes related to reduction in psychological
and emotional stress and quality of life.
1) Perceived Stress Scale (PSS). The levels of perceived psychological stress levels were
assessed using the Perceived Stress Scale (PSS). The PSS is one of the most frequently used
scales in stress research, and scores on the PSS have been correlated with physiological stress
measures (salivary cortisol)179. The scores on the PSS provide information related to the amount
of psychosocial stress as perceived by CS, which would help us determine if EW is indeed
successful in reducing stress. The PSS is designed to detect the degree to which participants
appraise stress in their daily life, and consists of dimensions such as unpredictability, loss of
control, and overwhelm180. This psychometric instrument has 14 items (see Appendix N) that
were answered by the participants on a 5-point Likert scale. This scale has a demonstrated good
reliability in healthy and clinical populations, and has a Chronbach’s alpha value of 0.86180.
2) Fear of cancer recurrence inventory– Severity subscale (FCRI-S). The fear of cancer
recurrence is the most salient emotional stressor faced by CS during survivorship24. Therefore,
the severity of fear of cancer recurrence (FCR) is a good indicator for the level of negative
emotional stress experienced by CS. Interventions designed to regulate psycho-emotional stress
in CS should be able to reduce FCR. Hence, in order to determine whether EW is actually able to
help CS regulate their emotional stress, we used the 9 item severity subscale of the FCRI, the
FCRI-S (see Appendix N). The FCRI is a 42 item multi-dimensional measure of FCR, which has
been recently developed and validated and good reliability has been established181. The FCRI-S
specifically describes the amount of emotional stress experienced by CS due to FCR and is a
suitable instrument to detect the clinical response to psychosocial interventions such as EW24.
FCRI-Severity-Subscale is strongly correlated with the total FCRI score (r = 0.84), and has high
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internal consistency and adequate 1-month test–retest reliability181,182.
3) Cancer Behavior Inventory-Brief Version (CBI-B). The CBI-B, a 12 item selfreported instrument was used to measures the level of self-efficacy among CS for their capacity
to cope with cancer183. The CBI-B has been shortened from its original 33 item long version, the
CBI-L184, to reduce patient burden. This psychometric measure assesses cancer patient’s ability
to cope effectively with cancer, and includes dimensions such (a) beliefs about maintaining
independence and a positive attitude, (b) ability to participate in medical care, (c) coping and
stress management skills, and (d) capacity to manage emotions/affect in stressful situations.
A major advantage of the CBI-B is that it is relevant to the specific psychosocial
problems faced by patient with cancer. The CBI-B scores was chosen to help us determine if EW
can improve coping and emotion regulation in CS. Since this measure was designed primarily for
cancer patients undergoing treatment, we modified one item (i.e. item 7) to relate to cancer
survivorship. All 12 items are rated on a 9-point likert scale that ranges from 1 (“not all
confident”) to 9 (“totally confident”). Reliability evidence for the CBI-B is strong and three large
scale studies in oncology populations have provided a minimum internal consistency value of α
= .84183. The CBI-B is also highly correlated (r=0.95) with the CBI-L183. Table 6 summarizes the
all information that was collected (i.e. cancer information and demographics) and the measures
collected (primary and secondary) along with the timing of collecting those measures with
respect to the intervention.
Statistical Power and Estimation of Sample Size
Since the study used a repeated measures RCT design the statistical test used to analyze
study data needed to account for the correlation between repeated measures (e.g. Day 2 CRP
correlates with Day 7 CRP and Day 49 CRP). Also, since this study used a balanced two-arm
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RCT design, there was an equal number of participants randomized to the treatment or control
condition. Thus, we used GPower statistical program to estimate sample size for our study for a
multivariate analysis of variance (MANOVA) statistical test. The first step in the sample size
calculations was to decide the on the parameters of statistical significance. This study’s sample
size calculation used 80% power (β=0.2) in order to estimate the number of subjects needed to
show significant differences between the intervention and control groups with 95% confidence
(α=0.05). The next step in the power analysis was to determine the expected effect size for the
intervention on the primary outcome measure.
An older meta-analysis of previous EW studies estimated a standardized effect size
for the EW intervention in mixed populations58 and reported a Cohen’s d = 0.47. A more recent
meta-analysis60 reported a smaller standardized effect size, Cohen’s d = 0.15. However,
standardized effect sizes do not take into account variations in treatment effect based on the
population and outcome measures. A standardized effect size for EW interventions within cancer
population has not been estimated, although past studies have reported large effects, such as d =
0.89656. A meta-analysis of EW interventions in clinical populations59 yielded a d = 0.21 for
physical health outcomes, which included cortisol levels. Studies assessing the psychological
determinants of the cortisol stress response116, 117 suggest a standardized effect size of d = 0.3 for
salivary cortisol. Therefore, the initial power analysis considered the primary outcome of interest
(salivary cortisol) to detect a more conservative effect size (between d = .21 and .896) of d = .33
The a priori power analysis conducted by GPower statistical program based on the effect
size for EW chosen (d = .33) indicated that a MANOVA could detect significant effects between
two groups with 80% power in a total sample size of N=52 participants. However, oversampling
was recommended due to the possibility of missing data which is common problem in
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longitudinal RCT designs. Past studies and meta-analyses of EW indicate that an overall 20% of
the study population has attrition and or missing data. This 20% of the population translated into
10 additional participants, which were added to the initial calculation of 52 participants. Thereby
the total sample size estimated a priori for this study was N=62, participants, which translated to
the recruitment and enrollment of 24 participants in each arm, i.e. n=31 in treatment arm (EW
intervention) and n=31 in the control arm (control writing task). During the process of
recruitment and enrollment, the study faced low accrual rates which is commonly encountered in
psychosocial trials in the cancer population185. A preliminary report was conducted to determine
the adequacy of participant completion of the study protocol. Finding that N=40 participants had
completed the study protocol, it was decided to forego oversampling and continue with the
analysis based on 20 participants in each arm.
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Table 6: Study protocol (activities, measures and data sources)
Prior to enrollment

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 49

Provide study
information
+
Screening
+
Informed consent

Confounds
+
Cancerrelated
information

Baseline
outcome
measures
(BOM)

Writing

Writing

Writing

Writing

Postintervention
outcome
measures
(POM1)

Postintervention
outcome
measures
(POM2)

20 – 30
minutes

20 – 30
minutes

20 – 30
minutes

20 – 30
minutes

20 – 30
minutes

Expressive writing
Intervention
Control writing
20 – 30
minutes

20 – 30
minutes

20 – 30
minutes

20 – 30
minutes




Cognitive dysfunction (Brief Screen for Cognitive Impairment: 3 items )
Depression (Patient Health Questionnaire-2: 2 items)







Social support and Perceived social status
Smoking, Alcohol consumption, Sleep, Oral health – gum disease
Use of complementary and alternative medicine (CAM)
Comfort with using computers and internet technology
Demographics: Health insurance status; Employment status; Household income; Education
level; Marital status; Age ; Gender ; Race/Ethnicity

Cancer-related information – 9
questions
(Online survey)





Cancer Diagnosis information (primary site, tumor stage)
Cancer Treatment regimen information (date, toxicity, late and long term effects)
Medication use

BOM, POM1 and POM2
(Salivary Specimens)
BOM, POM1 and POM2 – 33
questions
(Online survey)



Cortisol, α-Amylase and C-reactive protein – CRP





Perceived Stress Scale
Fear of Cancer Recurrence Inventory-Severity subscale
Cancer Behavior Inventory-Brief version

Screening – 5 questions
(Telephone-based)
Confounds – 28 questions
(Online survey)
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Identification of Eligible Patients
Potential participants were identified by using a defined set of inclusion criteria for
patients with cancer at sites that were available for recruitment to this study. Participants
identified through the inclusion criteria could have some characteristics that would be
problematic with the study protocol. For example, participants with radiation treatment to the
face region may be unable to produce adequate saliva (due to damaged salivary glands), and
hence will not be able to complete the primary outcome measure. Therefore, exclusion criteria
were used to help exclude certain participants that were initially eligible.
Inclusion criteria. Patients with cancer having the following characteristics were
considered eligible to participate in our study; patients who: a) had completed their cancer
radiation treatment (intent to cure), b) were cancer free, i.e. not having any diagnosis of
primary/secondary cancer or any recurrence/relapse of cancer, c) were in the re-entry phase of
cancer survivorship, i.e. 2-12 months post-treatment completion, d) had access to a computer and
internet in a private setting, e.g. at home, e) were above the age of 21 years, f) were fluent in
English, and g) were able to provide informed consent. The participants had received radiation as
their final cancer treatment, and could have received other cancer treatments before radiation,
such as surgery or chemotherapy. Participants were provided the option to discontinue their
participation in the study due to any reason at any time during our intervention protocol.
Participants had access to UBS and RFB for any assistance regarding contacting supportive care
services provided to the patients.
Exclusion criteria. Eligible participants were excluded from the study if they met any
one or more of the following criteria: a) scheduled to undergo any type of cancer treatment
(intent to cure/palliative) in the future (e.g. surgery after completing radiation), b) on any kind of
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corticosteroid medication (e.g. long-term prednisone therapy), c) having any condition that
affects function of the adrenal glands (e.g. adrenal hyperplasia), d) limited ability to produce
saliva, e.g. patients that received radiation (or surgery) on the face region or on salivary glands;
or patient’ssuffering from dry mouth (e.g. Sjögren's syndrome), and e) suffering from
inflammation of the oral cavity (e.g. gingivitis). Individuals on corticosteroid medication or those
with diseases of the adrenal glands have irregularities in cortisol secretion that can interfere with
data collection for the primary outcome measure, and hence were excluded from the study.
Patients with limitations in salivary production would be unable to complete the primary
outcome measure and were hence excluded. It was important to exclude patients with oral
inflammation because their salivary measures may erroneously indicate increased inflammation,
resulting from local inflammation in oral cavity, and not from systemic immune processes.
To take into account typing skills, potential participants were also asked if they would be
comfortable typing on a computer for 20 -30 minutes over 4 consecutive days. Only patients that
confirmed they were comfortable typing for that amount of time were included in the study.
Patients were also screened for cognitive impairment and depressive symptoms (Brief Screen for
Cognitive Impairment and Patient Health Questionnaire-2).
Identification procedures. The human subjects involved in this study were cancer
patients who have finished their radiation treatment (intent to cure) and were in the re-entry
phase of cancer survivorship (2-12 months post-radiation treatment completion). Eligible
patients were identified based on the aforementioned set of inclusion and exclusion criteria.
Medical records at the VCU Health system was accessed only for the purpose of identification of
potential participants, no information from the medical records was used for research purposes.
Once potential participants were identified, an initial letter regarding the study was mailed to the
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patient that provided information about the study and contained the full contact information of
the study mentor and UBS, see Appendix D. Subsequently, the potential participant was
contacted by phone. If the potential participant’s voicemail was reached during any phone
interaction, no details about the study were mentioned. A voice message consisting of the name
of the first author (Utkarsh B. Subnis, UBS) and affiliated institution (i.e. VCU), along with a
call back number was left, see Appendix G. UBS was in communication with potential
participants through email or their preferred method of communication (phone or mail) after the
initial call.
Recruitment Plan
Firstly, we obtained permission from the Chair of the Dept. of Radiation Oncology at
Massey Cancer Center (MCC), Dr. Mitch Anscher, to recruit patients from MCC. Support was
also obtained from Clinical Research Nurses (CRN) at Virginia Cancer Institute (VCI), and Bon
Secours Health System, Richmond, VA, to assist with recruitment. The research team identified
potential participants, by working collaboratively with oncologists, nursing staff and CRNs at the
Radiation Oncology Department at MCC and VCI and Bon Secours. Active and passive
strategies (described in detail below) were used to recruit patients to this study.
Active recruitment: Electronic health records. Active recruitment was conducted by
identifying eligible patients using the electronic records of the Virginia Commonwealth
University Health System (VCUHS), which is a HIPPA compliant electronic medical
information database as well as working with oncologists and research nurse personnel. The
research team identified all potentially eligible cancer patients who had completed their primary
radiation treatment through the VCUHS electronic health record database. The research team
worked with the administrators at the VCUHS to organize access for to the relevant VCUHS
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systems, Cerner and IDX. Access to these systems was obtained on a weekly basis to identify
patients who were scheduled for follow up radiation therapy appointments, assess the time since
last appointment and identify those patients whose last appointment was between 2 months and
12 months prior to the access date. This process involved creating patient lists of those who were
discharged after radiation in the last 10 months. For example, if the VCUHS scheduling data
base IDX was accessed on July 1, 2013, patients were identified whose last radiation therapy
appointment was between June 1, 2013 and August 1, 2012, see Appendix C.
The radiation oncologist/nurse at the clinic from where the patients were discharged were
contacted to inquire if the patients were eligible for the study. If patients were considered eligible
by the oncologist, the patient’s contact information, which included their name, phone number
and mailing address was collected. Patient medical records were not accessed once eligibility
was determined. An initial letter regarding the study was mailed to the patient containing the full
contact information of UBS and RFB, see Appendix D. A “do not contact” return-addressed
postage paid opt-out mail-card was sent along with the initial letter, see Appendix E. Two weeks
after the recruitment letter was mailed, UBS attempted to reach the eligible participants by
phone. In the first phone call, UBS asked the potential participant about the letter regarding the
study. In case the participant mentioned that s/he did not receive the letter, UBS informed the
potential participant that the letter would be mailed to them again, and that UBS would contact
them again. If the potential participant acknowledged receiving the letter, UBS then explained
the study in some more detail, conducted screening procedures (i.e. the BSCI and PHQ-2),
answered any questions the participant may have, and requested for the participant’s preferred
email address.
Subsequently, UBS confirmed if the potential participant was interested in taking part in
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the study on the phone and a hard copy of the informed consent document was mailed to the
participant, see Appendix I. The participants were requested to mail the informed consent form
back to UBS after signing it. An extra copy of the informed consent form was mailed along with
the consent form. Also, a returned addressed postage-paid mail envelope was provided for
participants to mail the consent form back, see Appendix I. Participants were enrolled once the
signed consent forms were received. Potential study participants were in communication with
UBS through email or the patient's preferred method of communication (phone or mail) after the
initial call. UBS also offered a home visit or visit at a convenient location to the participants for
explaining the study more in detail and having personal contact with the participant. UBS
provided the participants with his full contact information, and the participants were able to
contact UBS at any time for any doubts or reservations.
Passive recruitment: Flyers. A recruitment flyer containing some basic information
about the study and with UBS’s contact information was prepared. Also, UBS informed the
nursing staff at MCC, VCI and Bon Secours about the details, inclusion and exclusion criteria for
the study and provide the staff with the flyers, see Appendix A. The nurses handed out the
recruitment flyers at the radiotherapy consultation departments to potential patients. UBS also
visited and presented the study’s flyer to community support groups for cancer patients in
Richmond, VA, such as support groups at the VCU Massey Cancer Center; and bulletin boards
of community health centers, such as the VCU community health education center. The
information from the flyers was also posted on the VCU e-listserv for ongoing studies. CS
interested in this study had the necessary information to contact UBS. If patient’s contacted UBS
regarding the study, UBS then explained the study in some more detail and conducted identical
recruitment procedures (as described above), and answered any questions that potential

67

participants may have and request for contact details such as email and mailing address. UBS
verbally ascertained interest in study participation on the phone and participants were mailed the
informed consent form. Participants were kept informed about the study through their preferred
mode of communication (i.e. email/phone/postal mail). UBS offered a home visit or visit at a
convenient location to the participants for explaining the study more in detail and having
personal contact with the participant. UBS also provided the participants with his contact
information, and the participants were able to contact him for any doubts or reservations
regarding the study.
Recruitment at non-VCU sites. Virginia Cancer Institute and Bon Secours Health
System, both have radiation oncology units for treating patients in Richmond and surrounding
counties. These Non-VCU centers were used only for passive recruitment of participants, and
hence were considered not engaged. They only performed the following activities as described in
OHRP’s guidelines:
The Clinical Research Nurses and related health professionals at non-VCU sites:
a. informed prospective subjects about the availability of this research study;
b. provided prospective subjects with information about the research (which included a copy of
IRB approved recruitment flyer) but did not obtain subjects’ consent for the research or act
as representatives of the investigators;
c. provided prospective subjects with information about contacting investigators for
information or enrollment; and/or
d. sought or obtained the prospective subjects’ permission for investigators to contact them.
UBS undertook liaising efforts with clinical research nurses and health professionals to
identify patients based on inclusion and exclusion criteria. The identified potential participants
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were handed flyers with information about the study. Those participants who were interested in
the study contacted UBS. No medical records were accessed at Non-VCU institutions. The same
precautions for the safety and protection of participants and their data (described above) were
used for participants from Non-VCU institutions. Participants were informed that the study is
primarily through VCU, being conducted by UBS.
Screening patients before recruitment. Potential participants were screened for
cognitive dysfunction using the Brief Screen for Cognitive Impairment and depression using the
Patient Health Questionnaire-2, before inviting patients to participate in the study. Screening for
cognitive impairment and depression took place over the phone during the initial recruitment
call. Potential participants having moderate to severe cognitive dysfunction were excluded from
the study. Patients were also screened for depressive symptoms prior to consent using a validated
depression screening questionnaire (Patient Health Questionnaire –PHQ –2). Using the PHQ-2
has been described in the literature as a suitable "first step" approach to screen for depressive
symptoms and is not used for diagnosis and monitoring of depressive symptoms.
Screening for cognitive dysfunction. Cognitive impairment can impact the ability of
patients to provide informed consent, as well as this intervention requires a certain degree of
cognitive effort and cognitive ability. Therefore excluded patients with cognitive dysfunction,
and screened for cognitive impairment. Screening for cognitive dysfunction was performed
before obtaining verbal assent from the eligible participants during the initial telephone
conversation. The Brief Screen for Cognitive Impairment (BSCI), a previously validated (Hill et
al., 2005) three item screening instrument for administration during a telephone conversation,
was used for screening out cancer survivors with significant cognitive impairment. The time
required to administer the BSCI is approximately 80 sec.
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The first item on the BSCI consists of memory recall question is: 1) the participants were
told three unrelated words (dog, apple, and house) after describing the purpose of the
conversation to the participants. Then the participants were asked to repeat those three words
after the details of the study were described to them. The responses from the participants were
scored from a perfect score of 0 (no mistakes in recalling the three words correctly) to the worst
score of 3 (none of the three words correctly recalled).
The other two items on BSCI included the following: 2) how frequently do you need
help with planning trips for errands?; and 3) How frequently do you need help for remembering
to take medications? Both these items were scored from 0 (never needs help) to 4 (frequently
needs help). Finally, the scores were weighted and summed to arrive at the final BSCI score
(scores from delayed recall and frequency of help with remembering to take medications was
assigned a weight of 2.0 and the score from frequency of help with a trip for errands was
assigned a weight of 1.0.). Patients with a score of >6 on the BSCI were considered to have
significant cognitive impairment and were excluded from the study. The scores on BSCI have
shown to be significantly correlated with scores for other tests of cognitive function such as the
Mini Mental State Examination (r= −0.83) and the Alzheimer’s Disease Assessment Scale
(r=0.65).
Screening for depression. Patients were also screened prior to enrollment for depressive
symptoms using validated depression screening questionnaire (Patient Health Questionnaire –
PHQ –2). The 2 items PHQ-2 depression scale is a very brief and extensively researched
instrument for screening of depression. The PHQ 2 has 2 items and is rated from 0 – 6. The
recommended cut off score for screening is  3. During the initial recruitment call, UBS scored
potential participants on the PHQ-2 questionnaire in real-time on the phone after completing the
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cognitive dysfunction questions. The actual questionnaire and scoring sheet is provided below in
Table 7 and the psychometric properties of the PHQ-2 are described below in Table 8.
Table 7: Patient Health Questionnaire -2 Telephone Screening tool for Depression
Over the past 2 weeks, how often have you been bothered by any of the following problems?
Not at
all

Several
days

More than half
the days

Nearly
every day

Little interest or pleasure in doing things

0

1

2

3

Feeling down, depressed or hopeless

0

1

2

3

We did not expect to be contacting clinically depressed patients, or receiving responses from
depressed patients. However the PHQ-2 enabled us to screen out patients who were in need of
intensive mental health care.
Table 8: Psychometric Properties of the Patient Health Questionnaire –PHQ –2a
Major Depressive Disorder (7% prevalence)

Any Depressive Disorder (18% prevalence)

PHQ-2
score

Sensitivity

Specificity

Positive
Predictive
Value (PPV*)

PHQ-2
score

Sensitivity

Specificity

Positive
Predictive
Value (PPV*)

1

97.6

59.2

15.4

1

90.6

65.4

36.9

2

92.7

73.7

21.1

2

82. 1

80.4

48.3

3

82.9

90.0

38.4

3

62.3

95.4

75.0

4

73.2

93.3

45.5

4

50.9

97.9

81.2

5

53.7

96.8

56.4

5

31.1

98.7

84.6

6

26.8

99.4

78.6

6

12.3

99.8

92.9

* Because the PPV varies with the prevalence of depression, the PPV will be higher in settings with a higher
prevalence of depression and lower in settings with a lower prevalence.
a

Kroenke K, Spitzer RL, Williams LB. The Patient Health Questionnaire-2: Validity of a Two Item Depression
Screener. Medical Care. 2003; (41) 1284-1294.

Patients that were found to have PHQ2  3 were not included in this study. These participants
were advised to not participate in the study at that time and were provided information about
supportive care services. UBS also offered a referral plan for these patients (see below) and were
asked if they would like to be contacted at a later time regarding their psychosocial needs.
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Referral plan after screening procedures. Scores on the BSCI and PHQ-2
questionnaire were estimated by UBS in real time during the phone conversation. Based on
standards provided for using the PHQ-2, patients with PHQ-2 scores above 3 are recommended
to be further evaluated for a depressive disorder. Participants that had PHQ-2 scores 3 were
advised to not participate in the study and were provided information about supportive care
services. During the call, UBS offered to immediately conference call Connie Macaluso, for
further evaluation. Connie Macaluso is a licensed clinical social worker (LCSW) and trained in
dealing with mental health issues of cancer patients. In case the patient refused to be conference
called to Connie Macaluso, UBS asked the participants if he could refer them to Ms. Macaluso
for additional evaluation. The participant’s response regarding this matter was honored and their
right to refuse further assistance was respected. No further contact with the participant occurred.
Since this was a student research project, limitations in resources precluded us from employing a
trained neuropsychiatry health professional. Also, since UBS did not have training required for
clinical management of mental health issues in patients, referring patients to a trained and
licensed clinical social worker was considered an appropriate approach. For patients who were
eligible after screening, UBS proceeded with assessing their interest in participating in the study.
Assessing interest in study participation. UBS again asked if there were any
unanswered questions, as well as provided more details of the study as needed. Then UBS asked
the patient if they would be interested in participating in the study. If the patient expressed
interest in the study, UBS requested for their preferred email address (and other preferred modes
of communication). The potential participant was then told that s/he would need to sign the
informed consent form for this study before s/he could be enrolled in the study. After the initial
call, UBS was in communication with potential participants who expressed interest in the study
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through email or their preferred method of communication (phone or mail). Patients who
declined participation were thanked for their time, and participants who wanted more time to
think about the study, were contacted again at their convenience.
Informed Consent Procedures
A paper copy of the informed consent document was mailed to the participant along with
additional copy of the consent document and a return addressed postage-paid envelope, see
Appendices H and I. The participant then signed the consent document and mailed it back to
UBS. Up to 3 reminders were sent to patients about their potential participation. The reminders
informed patients that, a) UBS was following up about potential participation in this research
study focusing on stress management or cancer survivors after radiation therapy using expressive
writing, b) a consent form was mailed to the participant but UBS had not heard back from him or
her yet, c) if the patient is interested in participating, they should please return the signed consent
form in the reply envelope provided, and d) if the patient has any questions, please feel free to
contact study staff. The contact information for UBS and RFB was provided on the consent
document and UBS was available to further clarify any details of the study.
Enrolment in study. After receiving the signed informed consent document from the
participant, the participant was enrolled in the study and mailed the salivette kits and study
materials, see Appendix J and K. UBS offered home visits to the participants to personally
deliver the salivary kits and go over the study procedures. Participants who provided written
consent were enrolled in the study, and a Participant ID number was generated for them, using a
random number generator computer program. The participants were requested to indicate 4 days
in their upcoming time schedule for the writing intervention. Based on their preferred days, a
schedule with specific dates and activities (including data collection) using the protocol (Table 6)
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was prepared, see Appendix M. Participants were offered to enroll in the interactive reminder
system. All data obtained from the participants was connected with the Participant ID number.
The salivette kits and information booklets were subsequently mailed to the participant’s home
address. A web-link for the instructional video showing how to collect saliva in the salivette
tubes was emailed to participants. The salivettes had the participant ID number printed on the
labels; no identifying information was present on these salivette kits. The salivette kits were
recovered from the participant’s home at the end of the study.
Data Sources
The sources of data for this study were all from the participant’s in the form of 1) selfreport questionnaires, 2) responses from the writing prompts and 3) salivary specimens, see
Table 9.
Table 9: Data sources and research material
1) Self-report questionnaires (administered online)
Health-related symptoms and behaviors: Social support, Perceived social status, Smoking, Alcohol
consumption, Sleep, Oral health – gum disease, Use of complementary and alternative medicine
(CAM), Comfort with using computers and internet technology
Demographics: Health insurance status; Employment status; Household income; Education level;
Marital status; Age; Gender; Race/Ethnicity
Cancer-related information: Cancer Diagnosis information (primary site, tumor stage); Cancer
Treatment regimen information (date, toxicity, late and long term effects); Medication use
Outcome Measures (BOM, POM1 and POM2): PSS, FCRI-S and CBI-B
2) Responses from the writing prompts (administered online):
Responses to expressive writing prompt
Responses to control writing prompt
3) Salivary specimens (provided at home, collected at the end of study)
Outcome Measures (BOM, POM1 and POM2): Cortisol, α-amylase and C-reactive protein – CRP
Compensation of Participants
Since this was a student dissertation project, limited funds were available for this
research. Participants were thanked in appreciation for their time and effort devoted to this study.
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Participants also had an opportunity to indicate if they would be interested in periodic updates
about the study results, progress and publication. Participants did not receive any monetary
compensation for their participation. The participants had the opportunity to join a listserv that
updates participants about the study results, publication and dissemination activities.
Minimizing Potential Risks for Participants
In the unlikely event that participants got distressed to the point of needing an
intervention during their expressive writing activity, we ensured that adequate measures were
taken to reduce risk for participants. The following measures were taken during the intervention
process.
1. Phone contact with participants during the intervention. UBS contacted all
participants on Day 2 and Day 7 to check if they were doing well during the intervention.
If participants report requiring any additional support services, these were provided by
actively referring these patients to Connie Macaluso, LCSW. UBS was available to the
participants at any time, and UBS informed the participants that he would be available for
phone contact or home visits at any point during the intervention. Patients with
depression were not included in the study.
2. Monitoring the participants writing responses for concerning depressive symptoms.
The participants writing responses were read as soon as they submitted them through the
Qualtrics survey link. UBS was sent a notification whenever a participant submitted a
response to their writing prompts. UBS then read the content for any statements that
would be concerning, such as threat to harm themselves or others. Additionally, we also
monitored the participants writing responses using the Linguistic Inquiry and Word
Count (LIWC) software. The LIWC is composed of almost 4,500 words in different
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categories. Below is an excerpt from the LIWC manual which gives details of the word
categories of affective processes. The essays were monitored for negative emotion words.
This helped us identify any concerning writing responses that may have been in the initial
reading and monitoring. Participants with writing responses containing several negative
emotion words identified by the LIWC were read again. Any participant with concerning
symptoms was referred to the research clinical social worker, who is part of this study, to
assess if they were in need of any psychosocial support services.
LIWC software word categories
Process

Abbrev

Word examples

No. of words

Validity

3. Information about support services. Participants were provided with information
about supportive care services from the start of the intervention (provided on the consent
form) as well as they had the contact information available on their computer screens
while writing. The following information was available on the screen of the participants
on the survey link while they were performing their writing tasks.
i) The screen of the writing task prompt had a hyperlink to the National Cancer Institute’s
Support Services Locator, http://supportorgs.cancer.gov/ . The Toll-free phone
number for NCI cancer support information was also be provided, 1-800-4-CANCER (1800-422-6237). The NCI provides this service in English and Spanish, Monday through
Friday, 8:00 a.m. to 8:00 p.m. ET. The NCI provides a comprehensive list of
psychosocial and other supportive care services to meet the supportive care needs of
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patients with cancer.
ii) Additionally, the writing prompt screen also contained the toll-free phone number for the
Cancer Information and Counseling Line, 1-800-525-3777. The Cancer Information
and Counseling Line (CICL) is a free nationally recognized telephone counseling service
that provides a range of psychosocial supportive services to patients anywhere along the
cancer continuum, Monday – Friday, 8:30 a.m - 5 p.m. MT. CICL services range from
providing emotional support to resource referrals and medical information for patients
and caregivers affected by cancer. CICL counselors are master’s-level psychosocial
professionals that offer brief, personalized and professional counseling over the phone.
They can support and assist with managing feelings, resolving challenges related to
having cancer and communicating with doctors and loved ones.
iii) In case participants needed information at odd hours, the American Cancer Society
(ACS) hotline was also provided to them, 1-800-227-2345, http://www.cancer.org/ .
The ACS provides information and referral on various issues related to cancer treatment,
services, literature, transportation, equipment, encouragement and support, 24 hours a
day seven days a week at 1-800-227-2345.
4. Referral plan in case of depressive symptoms. Although steps were put in place to
prevent contacting clinically depressed patients, or receiving responses from depressed
patients, the PHQ-2 was used to screen out patients who were in need of intensive mental
health. All phone calls to the participants were made during regular business hours.
Referral to Connie Macaluso, LCSW occurred in case the following scenarios take place.
i) Participants at initial eligibility screening had scores 3 on the PHQ-2.
 UBS offered to immediately conference call Connie Macaluso, LCSW at support
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services at Massey Cancer center. Ms. Macaluso is trained in managing psychosocial
needs of cancer patients and survivors. Ms. Macaluso is also trained in connecting
patients with appropriate mental health services. UBS also offered to conference call
Ms. Macaluso or intake and referral the VCU psychiatric services, to patients at any
time during the intervention or course of the study. Contact information for VCU
Department of psychiatry was made available to the participants along contact
information with other supportive care services. (The Dept. of Psychiatry at VCU
School of Medicine is available at (804) 828-2000 or (800) 232-0901 (Select option 2
for appointments or Option 3 for admissions; and has a system of Intake and Referral
Service that expeditiously screen, evaluate and admit clinically appropriate patients to
the various inpatient teams.
i) Participants who experienced depressive symptoms or needed any mental health services
or support services during the intervention
 UBS contacted the participants on Day 2 and Day 7 of the intervention to inquire how
participants were doing in the intervention. The referral plan in case patients need
additional support services were identical to that described above, and involved followup by Connie Macaluso, LCSW. Participants were also informed about the possible
support services they can use if they need assistance with any mental health problem.
The participants were provided UBS’s contact information if any assistance is needed
for them for using any supportive care services.
A list of all support services provided by the NCI were given to the participants along
with the informed consent forms, see Appendix I. Participants could make use of these services
during as well as after the intervention. At the end of the intervention, i.e. at 6 weeks post-
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intervention, participants were asked if they used any of the support services they were informed
about. Finally, participants had the contact information of UBS at all times and could contact
him at any point during the intervention. Participants were informed of their choice of
withdrawing from the study at any point in time. Participants were assured that no contact would
be made with their employer, insurance provider or health care provider. Hence, several
measures were taken to minimize potential risks to the participants in this study. The research
team used rigorous procedures for assuring subject anonymity as described above and in the
training of research staff. The risks to subjects were minimal compared to the benefits of the
research. Participants were free to withdraw at any time. The study protocol is scheduled as per
participants’ convenience. By using computers and the internet, the participants could complete
the writing tasks and provide data at their own comfort and convenience.
Protection of Patient Privacy
The following steps were taken to ensure the privacy of participants.
1. UBS conducted all patient phone interactions, including recruitment and follow up
calls, in a designated private office space. Participants were reminded that their privacy would
be maintained at all times. If we reached the participant’s voicemail during any phone
interaction, no details about the study were mentioned. A voice message consisting of the name
of RC and affiliated institution (i.e. VCU), along with a call back number was left.
2. Participants were informed that their writing responses and data were stored in secured
HIPPA compliant servers at all time. Participants were also assured that no communication
would occur with their employer, insurance provider, or health care professional. All participants
were informed about their privacy and confidentiality and their right to discontinue the study at
any time.

79

3. The surveys and writing responses were sent using Qualtrics. Qualtrics is web-based
survey application that uses secure web authentication, data logging, and Secure Sockets Layer
(SSL) encryption which ensures security and confidentiality. Qualtrics has SAS 70 Certification
and meets the rigorous privacy standards imposed on health care records by the Health Insurance
Portability and Accountability Act (HIPAA). All Qualtrics accounts are hidden behind
passwords and all data is protected with real-time data replication. Qualtrics service meets the
standards for security required by CFR 45.46 (Federal Guidelines for Human Research) and by
VITA (Virginia Information Technology Agency).
4. All salivette kits and mailing materials were affixed with the randomly generated
participant ID number. This ensured that no salivary specimen could be linked back to the
participant. Even the transportation containers for the salivary specimens had only the Participant
ID numbers, and no other identifying information, in case of misplaced salivette tubes or
containers.
5. All email communication was conducted through UBS’s VCU email account that is
secured by VCU Central Authentication Service, which is a centralized login system for Web
applications at Virginia Commonwealth University. All data were stored in computers having
firewalls and virus protection. The email communications were archived and downloaded and
stored along with the study data. All these data will be destroyed within 3 years.
6. The temperature controlled transportation container for the salivette kits was labeled
with Participant ID number, no other identifying information was present on the transportation
container, in case it is misplaced or damaged due to any unforeseen circumstances.
7. A physical lock was placed on the Central Processing Unit (CPU) of the computers
used for storing and accessing data, which secured the CPU to the physical location of the office,
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and thus prevent loss due to theft or other circumstances. All stored data will be destroyed within
3 years of completing the study.
Data Safety and Monitoring Plan
The data and safety monitoring plan included: i) data security procedures, ii)
identification of adverse effects, iii) quality assurance activities and iv) investigator-initiated
procedures for data and safety monitoring.
Security Procedures for Transfer, Implementation and Storage of Data. All computers
used to collect and send data during implementation of the study or to receive or store data at the
central location were password protected. Patient surveys and expressive writing were web-based
and stored within a secure, dedicated server with appropriate firewalls. Servers were routinely
scanned for viruses and systems were in-place to detect attempts at unauthorized entry. All
phone interactions and online surveys were conducted from a central location therefore data
transfer were not be necessary.
Identification of Adverse Effects. The study staff monitored all adverse events identified
during implementation of the trial. Adverse effects were monitored through 1) reading the
writing prompts after participants complete their writing task online, and 2) phone interactions
with the patient on Day 2 and Day 7 of the protocol. UBS documented any adverse effects
reported to them by the patient. The research team also met weekly as a team to discuss any
potential for an adverse event. In addition, patients were given UBS’s direct telephone number so
that any adverse events could be reported spontaneously by the subject. Participants were also
provided with contact information for a variety of supportive care services, which included a
telephone counseling service for cancer patients and survivors.
Quality Assurance Activities. UBS was available for questions on weekends and during

81

the evenings. If problems arose, the research team were instructed to call Utkarsh Subnis (UBS)
or study mentor, Dr. Richard Brown (RFB). UBS was evaluated by the study mentor in areas
such as the time management, inter-personal skills, participant recruitment procedures and how
closely he adhered to set procedures such as checking call attempts. Booster training session
were held as needed based on the quality assessment. Weekly meetings were held between the
study mentor and UBS to address UBS’s concerns and give project updates, as well as role-play
different possible scenarios. UBS was given memos on any new procedures or protocols when
necessary. Private one-to-one meetings were held with the research team as needed.
Investigator-Initiated Data and Safety Monitoring Plan. The research team for this study
were responsible for oversight of the quality of the RCT. All violations of protocols were noted.
If any adverse effects were reported or detected from the interventions, the study mentor was
notified immediately. The study mentor and the study statistician determined if any portion of
the protocol was violated and why and how such a violation may be related to the adverse event.
A referral plan was is place in case of any inadvertent emotional harm due to study involvement
was noted and the LCSW who was part of the research team had arranged to contact the study
participant to determine safety of continuing in the study.
Accrual to Study
Study recruitment using both active and passive strategies was undertaken after receiving
approval from the Institutional Review Board (IRB) of VCU. UBS and study mentor first
contacted all the radiation oncologists at MCC by email. Most psychosocial interventions have
been targeted towards surgical and chemotherapy patients, most commonly breast cancer.
Therefore, we received acceptance and approval from all health professionals working in
radiation therapy at MCC as anticipated. We identified N=372 patients in the cancer registries
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through the VCUHS by mining data regarding cancer patients who have completed radiation
treatments. We sent these 372 patients an initial contact letter and followed-up with them by
phone. From these 372 patients, n=20 patients agreed to participate in our study, see figure 5.
Reasons for the high refusal rates included 1) collection and provision of salivary data, 2)
commitment of time since the study protocol involved four days of writing and three days of
salivary data collection (three times a day), 3) mistrust with the government and collection of
biological specimens, 4) disinterest in the study and 5) commitments to other research studies.

Figure 5: Recruitment procedures
After encountering low accrual from contacting participants by mail and following-up by
phone, the research team decided to modify recruitment efforts. UBS liaised with multiple health
professionals at the MCC, and VCI radiation oncology centers to advertise our study. UBS began
following up with patients in the waiting rooms and follow-up consultations at MCC, downtown
and Stony point cancer-care centers with patients who have completed their radiation treatments.
This approach yielded another n=20 patients who agreed to participate in our study, see figure 5
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of recruitment procedures. The EW meta-analysis described that 75% of EW studies reported
less than 20% attrition rates128. Continued engagement with participants during and after the 4
day writing tasks was maintained to retain participants in this study. During the study, frequent
contact was made with study participants to determine if they were encountering any problems
with the study protocol, salivary data collection or had any general questions.
Data Analysis Plan
The unit of analysis in this study was the individual cancer survivor. Data were
analyzed using the statistical software packages, SPSS186 and JMP187. The first step for analyzing
the study data was examining the distribution of the data for normality and for descriptive
statistics, which included measures of central tendency and dispersion, e.g. mean, standard
deviation, standard error, for each variable measured in this study. To assess if the randomization
was successful, initial analyses were conducted to detect any significant differences in the EW
and control groups based on the data obtained at baseline, i.e. demographics, confounds and
primary and secondary outcome measures. This consisted of t-tests for continuous variables (e.g.
treatment dosage) and χ2 analyses for categorical variables (e.g. sex). Any variable significantly
different in the two groups would be used as a covariate for further analytic procedures.
Hypothesis testing was planned using the Multivariate Analysis of Variance
(MANOVA), statistical test to determine differences between the EW and control writing groups
based on the outcomes measures collected on Days 2, 7 and 49. Since this study design involves
repeated measures, this type of data violates the analysis of variance’s (ANOVA) assumption of
independence of measures, due to the correlations that occur among subsequent repeated
measures. Therefore, a multivariate repeated measures analysis of variance (MANOVA) can
model each of the mean stress measures over time separately for each group, and was considered
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an appropriate statistical approach.
Intent to Treat Analysis. Data related to recruitment, participation and drop-out rates
were reported according to the guidelines given by the Consolidated Standards of Reporting
Trials (CONSORT) statement188. All participants that entered our study were included in our
analyses and were retained in the arm (treatment or control) to which they were originally
randomly allocated. Participants were included in our analyses, regardless of their alignment
with the inclusion criteria, the treatment they received, and if they withdrew from the
intervention protocol (attrition) completely or deviated from the protocol (non-adherence).
Therefore this study had an intent to treat (ITT) analysis design188,189. However, RCTs
commonly have participants who were non-adherent to the protocol, which must be accounted
for, since non-adherence interferes with the integrity of the design and determining the efficacy
of the intervention.
Therefore this study also employed a modified intent-to-treat (MITT) approach, in which
we included participants that received a minimum amount of the intervention and provided a
minimum number of measures. The most recent meta-analysis of EW describes that participants
who completed a minimum of two days of emotional disclosure were more likely to experience
the effects of EW128. Also, previous studies of EW have excluded participant if they failed to
give less than one post-intervention measure. Therefore, our MITT sample consisted of
participants that completed at least two days of EW writing, and provided at least one postintervention measure (i.e. either at 24 hours or six weeks, post-intervention). Statistical analyses
from both, the ITT and MITT samples were presented and described in our results. A plan for
handling missing data was also essential due to the repeated-measures design of this study.
Management of missing data. A meticulous record of all missing data was kept, and
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reported in the results as per suggested guidelines. The CONSORT statement states that no
universally accepted strategies exist for dealing with missing data188; however there are some
suggested guidelines. We adopted the systematic approach to manage missing data in trials190,
which started with assessing the nature and mechanism of missingness. This involved
determining if data were missing completely at random (MCAR), missing at random (MAR), or
missing not at random (MNAR). Data were considered MCAR if data were missing for reasons
that were not related to any inferences about intervention effects, e.g. saliva collection tube is
lost for a measure, and is as likely to occur for every participant. MAR data is dependent on
other variables in the study and the possibility of an association variable linking the probability
of patient drop-out and the missing value, e.g. patients with a particular staging of cancer (e.g.
Stage III) may not have responded well to EW and withdraw. The assumption for data
considered MCAR and MAR is that missing cases were independent of the value of the
unobserved (missing) data point.
Finally, data that were MNAR indicate a probabilistic relationship between the
missing value and the time point at which it is missing, e.g. participants with lower levels of
perceived stress (or negative emotion) at baseline may not experience the benefits of EW and not
give the six month follow-up measure. Therefore, in data MNAR missing cases were dependent
on the value of the unobserved (missing) data point, and cannot be ignored. To account for
missing values, and approach called multiple imputations has gained considerable support from
statisticians191. This approach allows for the uncertainty about the missing values by generating
several different, plausible, imputed data sets (that replace the missing values with predicted or
imputed values), and can appropriately combine results obtained from each data set191. In the
systematic approach to managing missing data, all the investigators of this study first discussed

86

the possible mechanisms for missingness in the observed data set and rank their plausibility.
Statistical models were generated based on the plausibility of missingness: 1) the most plausible
missingness model, 2) similar missingness models and 3) least plausible missigness models.
Statistical analyses were performed on data sets generated under the aforementioned categories
and the investigators reconvened to discuss conclusions from the analyses and arrived at a valid
interpretation of the data obtained for this study.
Manipulation check. In order to determine if our experimental manipulation of
participants to the expressive writing and control writing conditions was successful, we analyzed
participants writing responses for use of emotion words. The literature suggests that since EW
encourages people to write their deepest thoughts and feelings, so EW participants typically use
strong emotion words in their writing128. In this study, we expected to find that the EW group
would use significantly more positive and negative emotion words in their writing tasks when
compared to the control writing group. The Linguistic Inquiry and Word Count (LIWC) was
used to analyze writing responses from both the EW group and control writing group on all 4
days of the writing tasks. The LIWC estimates the level to which people use different types of
words in a given text. The text from the writing responses of all participants was analyzed using
the LIWC to assess the use of positive and negative emotion words. We used one-way analysis
of variance (ANOVA) tests to assess for differences with regards to usage of positive emotion
words (POS_EMO) and negative emotion words (NEG_EMO) between the intervention and
control groups for all fours days of the writing tasks (Days 3, 4, 5 and 6) during the intervention.
Preparing salivary data for assay procedures. The salivary data collection process
yielded a total of 357 saliva samples, with the exception of one participant (from a total N=40)
on one day of data collection, each participant providing a total of 9 samples over three days of
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data collection (Days 2, 7 and 49). However, resource constraints allowed for the assay testing of
all three salivary analytes, namely cortisol, α-amylase and CRP for 120 (out of 357) salivary
samples. We decided to use our limited resources parsimoniously and chose to analyze specific
sets of saliva samples from our data. The primary end outcome for our study was salivary
cortisol levels at Day 49 ( six weeks post-intervention). Cortisol is known to have changes in
secretion patterns based on time of the day. Research has shown that different biological
mechanisms may determine the cortisol response within the first 30 minutes of awakening,
referred to as the cortisol awakening response (CAR) as opposed to average cortisol secretion
over the entire day, determined by calculating area under the curve (AUC)162,192. Thus, all three
salivary samples (W, P, B, or O) obtained on Day 49 were essential for statistical modeling of
CAR and AUC of salivary cortisol, and were selected for assay procedures, see Table 10 below.
Table 10: Salivary samples selected for assay procedures
Assay

Day 2 samples

Day 7 samples

Day 49 samples

Cortisol

PID No. _______
W P B O

PID No. _______
W P B O

PID No. _______
W P B O

a-Amylase

PID No. _______
W P B O

PID No. _______
W P B O

PID No. _______
W P B O

C-Reactive Protein PID No. _______
W P B O

PID No. _______
W P B O

PID No. _______
W P B O

Determining diurnal variations in secretion of salivary α-amylase and CRP were not
critical to answer the study’s primary aim. Also, there is some research evidence indicating that
levels of salivary α-amylase and salivary cortisol are correlated193,194. Thus we assumed that
values of salivary α-amylase estimated at baseline and immediately post-intervention could serve
as surrogate values for salivary cortisol as well. Therefore, only one salivary sample each (W)
was assayed for secondary physiological outcome measures (salivary α-amylase and CRP) on all
three days of data collection (Days, 2, 7 and 49), see Table 10.
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Assay procedure. All assay procedures were conducted in the Center for Biobehavioral
Clinical Research laboratory in the VCU School of Nursing building located at 1100 East Leigh
Street, Richmond, VA 23059-0567. The director of this laboratory, Dr. Jamie Sturgill had been
informed about this study and supervised the assay procedures. The first step for the assay
procedure involved thawing the frozen samples and centrifuging them at 2500 rpm for 15
minutes. The supernatant fluid available after thawing was used for assessment of cortisol and αamylase levels. The levels were assessed using an enzyme linked immune sorbent assay (ELISA)
method for cortisol, α-amylase and CRP. At the conclusion of the assay procedures, the assay
kits were disposed of using protocols currently in place and utilized by the Center for
Biobehavioral Clinical Research Laboratory. Data values from the assay procedures were
provided in excel sheets for every participant and were entered into the statistical software
programs JMP and SPSS for statistical modeling and analyses.
Transforming Physiological Data for Statistical Analysis
Determining AUC. Calculating AUC is a regularly used method in endocrinology
research for data obtained from repeated measurement of a hormone during the same day195. It
allows for making meaningful comparisons of data between groups, and collapses data for
physiological measures by giving a single average value for each day of measurement.
Therefore, AUC also limits the number of statistical comparisons that need to be done between
groups. AUC allows researchers to determine the intensity or magnitude of the physiological
response (i.e. distance from the ground) to a stimulus or intervention, and also assess the
sensitivity of that response (i.e. called change over time). The formula employed commonly in
PNI research were used, called area under the curve with respect to ground (AUCg). The AUCg
values for both groups were estimated using the trapezoidal formula195, see Figure 6. This is a
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trapezoidal formulas that breaks down cortisol secretion as areas of triangles and rectangles in
the area under the curve for the
measures taken at W, P and B on Day

Cortisol (pg./dl)

49. The AUCg accounts for all

P

measures (W, P and B) i.e. the total
area under the curve, and describes

B
W

a1

the magnitude of the average cortisol

a3

response over the entire day and was

a2

determined by summing all areas in
the trapezoid (a1 + a2 + a3), see

Time
Figure 6: Trapezoidal formula for determining
AUCg and CAR of salivary cortisol

Figure 6. AUCg was calculated for
Day 49 of data collection, and the

AUCg values for the Day 49 measure were the primary end outcome measure for the analysis.
Modeling CAR and diurnal cortisol slope. The CAR is the difference between the peak
cortisol measure collected 30-45 min after waking up (P) and the measure collected immediately
after waking up (W), i.e. P-W. Thus CAR is estimated in the similar way as AUC by estimating
the triangle under the curve between the W and P measure (only a1), see Figure 6. CAR is
considered to be mediated by different neurobiological mechanisms and is known to be relatively
stable across time196. Next, the diurnal cortisol slope was determined which consisted of the rate
of decline in cortisol levels across the day, i.e. wakeup to bedtime. Therefore slope for the simple
regression equation that was anchored on the waking cortisol measure (W) and the end point is
the bedtime measure (B) provided the diurnal cortisol slope (DCS) values for both groups. The
CAR and diurnal cortisol slope for the 6 week measure (Day 49) were the end outcome. Next, all
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three cortisol variables AUC, CAR and DCS were tested for normality of distribution.
Hypothesis Testing
We planned for using the multivariate analysis of variance (MANOVA) statistical test for
testing all hypotheses since it accommodates the effects of repeated measurements. The
MANOVA statistical formula used the variances of the groups (and not just the mean values, as
in the case of t-tests) and provided F values within the degrees of freedom to determine if the
hypotheses were significant, i.e. p<.05. Specific data analytic plan for each hypothesis is
described below.
Hypothesis one (H1). Neuro-hormonal response from the HPA axis to EW was the
primary outcome of interest, and cortisol levels at 6 weeks post-intervention was the primary end
outcome measure. Data included for testing the hypothesis were AUCg, CAR and DCS for
cortisol at 6 weeks after the 4 day intervention. Since, baseline and immediate post-intervention
data were not available for cortisol, analytic plan was modified to use independent sample t-test
and one-way analysis of variance to test differences between the EW group and control writing
group with respect to average values of AUCg, CAR and DCS on Day 49. Group differences for
all cortisol values at Day 49 were planned to be reported with p-values.
Hypothesis two (H2) and Hypothesis three (H3). Hypotheses 2 and 3 were regarding
the values for secondary physiological outcomes (salivary α-amylase and CRP) at six weeks
post-intervention. For H2 and H3, the MANOVA model had two predictor variables
(intervention and control group) and three levels of the outcome variables (salivary α-amylase
and CRP), namely 1) at baseline (Day 2), 2) immediate post-intervention outcomes (Day 7), and
3) delayed post-intervention outcomes (Day 49). The MANOVA estimated differences between
factors (the EW group and control writing group) based on all three levels of the secondary

91

physiological outcome variables (baseline, Day 7 and Day 49), with a significance level of α <
0.05 that were reported with the F-value within the degrees of freedom and respective p-values.
The MANOVA model also tested for differences within factors for the repeated outcome
measures at all three time points (baseline, Day 7 and Day 49) to determine changes over time
for salivary α-amylase and CRP.
Hypothesis four (H4), Hypothesis five (H5), and Hypothesis six (H6). Hypotheses 4, 5
and 6 were pertaining to the values for secondary psychosocial outcome measures (scores on the
PSS, FCRI-S and CBI-B) at six weeks post-intervention. For H4, H5 and H6, the MANOVA
model had two predictor variables (intervention and control group) and three levels of the
outcome variables (PSS, FCRI-S and CBI-B), namely scores at 1) baseline (Day 2), 2)
immediate post-intervention outcomes (Day 7), and 3) delayed post-intervention outcomes (Day
49). The MANOVA estimated differences between factors (the EW group and control writing
group) based on all three levels of the secondary psychosocial outcome variables (baseline, Day
7 and Day 49), with a significance level of α < 0.05, that were reported with the F-value within
the degrees of freedom and p-values. The MANOVA model also tested for differences within
factors for the repeated outcome measures at all three time points (baseline, Day 7 and Day 49)
to determine changes over time for PSS, FCRI-S and CBI-B scores.
Hypothesis seven (H7). Testing H7 was not possible due to unavailability of baseline
cortisol data.
Hypothesis eight (H8). In the last hypothesis, H8, we wanted to assess the immediate
post-intervention effects of expressive writing. The literature indicates that EW participants
typically experience increased stress immediately after completing their writing tasks due to
experiencing pent-up emotions137. Thus we expected to find increased stress in EW participants
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immediately after the intervention (Day 7) with regards to their secondary physiological
outcomes (salivary α-amylase and CRP; H8a) as well as their secondary psychosocial outcomes
(PSS, FCRI-S and CBI-B scores; H8b). For H8, the MANOVA model had two predictor
variables (intervention and control group) and two levels of the outcome variables (H8a: salivary
α-amylase and CRP; H8b: PSS, FCRI-S and CBI-B scores), at 1) baseline (Day 2) and 2)
immediate post-intervention outcomes (Day 7). The MANOVA estimated differences between
factors (the EW group and control writing group) based on two levels of the secondary outcome
variables (baseline and Day 7), with a significance level of α < 0.05, that were reported with the
F-value within the degrees of freedom and p-values. The MANOVA model also tested for
differences within factors for the repeated outcome measures at two time points (baseline and
Day 7) to determine changes over time for all the secondary outcome measures.
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Chapter VI. Results
Results of this study are reported under two major sections, namely descriptive analyses
and hypothesis testing. The measured variables for this study are reported under four categories
which include 1) sample characteristics, 2) disease and treatment characteristics, 3) health related
symptoms and behaviors and 4) outcome variables (primary and secondary).
Descriptive Analyses
Sample characteristics. The participants in this study had a mean age of 52.1 years
(S.D., 14.74; range, 28 to 80 years) and were mostly white (29/40, 72.5%) women (25/40,
62.5%) that were married (22/40, 55%), see Table 11. Most participants were privately insured
(25/40, 62.5%), employed full time (24/40, 60%) with a four year college education or postgraduate education (30/40, 75%) and were in the income range of $50,000 to $100,000 and
above (20/40, 50%), see Table 11 for details of all sample characteristics.
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Table 11: Sample characteristics
Variable Name [Results of bivariate t-tests/ and chi-square
test (2 ) between the EW and control groups]
Gender [2 (1, N=40) = 0.107, p = .74]



Male
Female

Marital Status [2 (3, N=40) = 5.82, p = .12]
 Single
 Divorced/separated
 Married
 Living together with a partner
Race [2 (3, N=40) = 3.534, p = .2]
 White
 Black or African American
 Asian or Native Hawaiian or Pacific Islander

Intervention Grp (n=20)
Count (% of Total)

Control Grp (n=20)
Count (% of Total)

Total
(% of Total)

8 (20%)
12 (30%)

7 (17.5%)
13 (32.5%)

15 (37.5%)
25 (62.5%)

5 (12.5%)
1 (2.5%)
11 (27.5%)
3 (7.5%)

1 (2.5%)
5 (12.5%)
11 (27.5%)
3 (7.5%)

6 (15 %)
6 (15 %)
22 (55%)
6 (15%)

14 (35%)
3 (7.5%)
2 (5%)

15 (37.5%)
5 (12.5%)
0

29 (72.5%)
8 (20%)
2 (5%)

12 (30%)
6 (15%)
2 (5%)

13 (32.5%)
4 (10%)
0 (0%)

25 (62.5%)
10 (25%)
2 (5%)

13 (32.5%)
3 (7.5%)
3 (7.5%)

11 (27.5%)
5 (12.5%)
3 (7.5%)

24 (60%)
8 (20%)
6 (15%)

10 (25%)
10 25(%)

8 (20%)
12 (30%)

18 (45%)
22 (55%)

4 (10%)
2 (5%)
14 (35%)

1 (2.5%)
3 (7.5%)
16 (40%)

5 (12.5%)
5 (12.5%)
30 (75%)

Insurance type [2 (6, N=40) = 9.04, p = .06]




Private Health Insurance
Medicare/Medicaid/ State-Sponsored Health Plan
No Coverage of Any Type

Employment type [2 (5, N=40) = 1.8, p = .9]




Employed Full time
Employed Part time / Self-employed
Retired / Unable to work

Income [2 (4, N=40) = 6.75, p = .1]
 Up to $50,000
 $50,000 and above
Education [2 (3, N=40) = 4.2, p = .24]
 Grade 12 or GED
 College 1 year to 3 years
 College 4 years or more
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Disease and treatment characteristics. With regards to cancer site, about half the
participants were diagnosed with breast cancer (21/40, 52.5%), and other cancer diagnoses
included, prostate, lung, brain and bone cancer, see Table 12. In terms of cancer stage, majority
participants reported having a Stage II diagnosis (20/40, 50%), see Table 12, and had completed
their last radiation treatment about 6-8 months (22/40, 55%) prior to study enrollment.
Table 12: Cancer Site, Stage and Treatment
Variable Name [Results of bivariate chi-square
tests (2 ) between EW and control groups]

Intervention Grp
(n=20)

Control Grp
(n=20)

Total

Count (% of Total) Count (% of Total) (% of Total)

Cancer Site [2 (3, N=40) = 3.83, p = .43]
 Breast

12 (30%)

9 (22.5%)

21 (52.5%)

2 (5 %)

5 (12.5%)



Prostate

3 (7.5%)



Lung

2 (5%)

1 (2.50%)

3 (7.5%)



Brain

1 (2.5%)

5 (12.50%)

6 (15%)



Other (Bone)

2 (5 %)

3 (7.50%)

5 (12.5%)

6 (15%)

2 (5%)

8 (20%)

Cancer Stage [2 (3, N=40) = 2.67, p = .26]
 Stage I


Stage II

10 (25%)

14 (35%)

24 (60%)



Stage III

4 (10%)

4 (10%)

8 (20%)

20 (100%)

20 (100%)

40 (100%)

4 (10%)

3 (7.5%)

7 (17.5%)

5 (12.5%)

Cancer Treatments


Radiation [2 (3, N=40) = 0]



Chemotherapy [2 (3, N=40) = 0.17, p
= .68]



Surgery [2 (3, N=40) = 0.5, p = .49

Health related symptoms and behaviors. Participants reported having social support
(e.g. someone to help with daily chores) available to them a little of the time (mean =2.07, S.D. =
0.75, scores ranging from 1 to 5). The average subjective social status (measured on a scale of 110) of participants in this study was 5. 23 (S.D. = 1.05). Participants were mainly non-smokers
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(34/40, 85%) that reported consuming alcohol on a monthly basis or less (12/40, 52.5%). On
average participants reported sleeping for 7.53 hours (SD=0.96) every day and having sleep
related problems on some of the days (mean=2.04, SD=0.56). Participants reported being very
comfortable using a computer (mean=1.18, 0.46), and on average used a computer almost
weekly (mean=3.8, SD=1.56). Finally, participants reported using at least one type of CAM
therapy once a month or less than once a month (mean=1.6, SD=0.6), please refer to Table 13.
Table 13: Health-related symptoms and behaviors
Variable Name [Results of bivariate t-tests and chisquare tests (2 ) between the EW and control groups]

Intervention Grp (n=20)
Mean (SD) or
Count (% of Total)
3.7 (1.34)

Control Grp (n=20)
Mean (SD)
Count (% of Total)
3.55 (1.4)

Depressive symptoms (PHQ2) [t (32.6) = -0.82, p =
.42]

1.1 (0.45)

0.95 (0.69)

Social support (MOSS) [t (37.8) = -1006, p = .0]

2.2 (0.72)

1.95 (0.78)

Perceived social status [t (38) = 1.056, p = .3]

5.05 (1.05)

5.4 (1.05)

1 (4.47)
5 (22.36)

0
0

12 (20%)
5 (12.5%)
3 (7.5%)

9 (22.5%)
9 (22.5%)
2 (5%)

Sleep Hours [t (30.7) = -2.65, p = .0125*]

7.9 (0.64)

7.15 (1.1)

Sleep Problems [t (38) = -0.66, p = .514]

6.3 (1.72)

5.95 (1.64)

2 (5%)
12 (30%)
6 (15%)

0 (0%)
10 (25%)
10 (25%)

CAM Use [t (37.4) = 1.24, p = .22]

8.85 (3.22)

10.2 (3.64)

Comfort with using computers [t (36.051) = - 0.45,
p = .66]

3.65 (1.14)

3.45 (1.6)

Cognitive Impairment (BSCI) [t (38) = -0.35, p =
.73]

Smoking behaviors
Smoking- frequency
Daily [2 (1, N=40) = 1.03, p = .24]
Weekly [2 (1, N=40) = 1.03, p = .31]
Alcohol consumption
Frequency [2 (3, N=40) = 9.11, p = .105]
Monthly or less
≥2 to 4 times a month
Prefer not to answer
Sleep Related Behaviors

Oral health – gum disease [2 (3, N=40) = 3.8, p =
.3]
Yes
No
Don’t know/PNTA
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Outcome variables (primary and secondary). Baseline data for the primary outcome
measure cortisol was not available. The means (and S.D.) of measurements for all secondary
baseline outcome variables is reported in Table 14.
Table 14: Means of outcome variables (Baseline: Day 2)
Variable Name [Results of t-tests
between the EW and control groups]

Intervention grp (n=20)
mean (SD)

Control grp (n= 20)
mean (SD)

Cortisol (pg/dl) [Data N/A]

Data N/A

Data N/A

a-Amylase (U/ml) [t (38) = -1.58, p = .12]

1.16 (0.73)

0.793 (0.74)

994.05 (455.12)

1020.70 (581.84)

PSS [t (38) = -0.61, p = .55]

31.95 (5.32)

31.05 (3.89)

FCRI-S [t (38) = 0.33, p = .74]

24.4 (3.62)

24.7500 (3.06)

CBI-B [t (38) = 1.115, p = .27]

75.45 (6.67)

78.45 (10.013)

CRP (pg/dl) [t (36) = 0.16 , p = .87]

Distribution and tests of normality. Study data pertaining to all variables in the study,
sample characteristics, disease and treatment characteristics, health related symptoms and
behaviors and outcome variables (primary and secondary) were analyzed for normality and
outliers by using centered leverages and visual inspection of the data plotted on normal quantile
plots. Outliers n=2 were found for CRP levels on Day 7 (z = 3.8) and Day 49 (z = 3.6) and were
replaced with values 3 standard deviation above the mean. The Shapiro-Wilk test was used to
assess if the data for all variables in the study were normally distributed. The Shapiro-Wilk
goodness of fit test revealed that with the exception of cortisol, data for all variables in the study
were normally distributed. All three variables related to salivary cortisol secretion on Day 49 did
not follow a normal distribution, area under the curve (AUCg), W = 0.39, p<.0001, cortisol
awakening response (CAR) W = 0.39, p<.0001 and Diurnal cortisol slope (DCS), W=0.81,
p<.0001, please see figures of normal quantile plots in Appendix O. Since our study’s primary
aim was to determine EW’s efficacy to reduce stress in CS as measured by salivary cortisol, we
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expected to find that cortisol data on Day 49 would be skewed.
Success of Randomization
Of the n = 40 participants that were enrolled in the study, n = 20 were randomized to the
EW group, and n = 20 were randomized to the control writing group. In order to assess if the
randomization procedures were successful, we tested for group differences between the EW
group and control group with regards to all four categories of variables, 1) sample characteristics,
2) disease and treatment characteristics, 3) health-related symptoms and behaviors and 4)
baseline outcome variables. The first three categories of variables had variables measured as
categorical as well as continuous, while baseline outcome measures were only continuous
measures. Statistical comparisons between patients randomized to the expressive writing and
control writing groups were made using t-tests for continuous measures and chi-square analyses
for categorical measures. The null hypothesis ( H0 ) for these tests stated that there would be no
differences between groups with regards to all four categories of variables. Results showed that
with the exception of one variable related to sleep behaviors, the null hypothesis was retained for
all variables in the study and there were no significant differences between the EW group and
control writing groups at baseline, please refer to Tables 11 – 14.
The only significant group difference at baseline was regarding sleep hours, see Table 13.
Participants in the intervention group reported sleeping for an average of 7.9 hours (S.D. 0.641,
SE 0.143, CI, 7.6, 8.2) and control group participants reported an average of 7.15 hours of sleep
(S.D. 1.089, SE 0.243, CI 6.64, 7.66). Thus, intervention group participants reported sleeping
approximately 0.75 hours (45 minutes) longer than the control writing group, t (38) = -2.654, p <
.05. However, when participants were asked specific questions regarding sleep-related problems,
such as difficulty falling asleep, difficulty staying asleep or problems waking up, no differences
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emerged between the intervention and control groups. Therefore, the marginal difference in sleep
hours between the two groups was not used as a covariate for further statistical analyses, and
randomization was considered successful.
Manipulation Check
Experimental manipulation of participants to either the EW or control writing conditions
was evaluated by assessing participants writing responses for use of positive and negative
emotion words using the LIWC software. The average (mean and SD) use of positive emotion
words for each group is described in Table 15, and the average (mean and SD) use of positive
emotion words for each group is described in Table 16.
Table 15: Means of LIWC Scores: Positive Emotion Words (POS_EMO)
Intervention Day

Intervention grp
mean (SD)

Control grp
mean (SD)

Day 3

4.69 (0.96)

1.75 (0.41)

Day 4

3.48 (0.97)

2.71 (1.13)

Day 5

3.47 (1.29)

2.35 (1.09)

Day 6

4.34 (0.91)

1.86 (0.67)

Table 16: Means of LIWC Scores: Negative Emotion Words (NEG_EMO)
Intervention Day

Intervention grp
mean (SD)

Control grp
mean (SD)

Day 3

3.8 (0.92)

1.94 (0.52)

Day 4

3.44 (0.84)

2.32 (1.3)

Day 5

3.41 (1.35)

2.2 (0.98)

Day 6

4.91 (0.79)

1.97 (0.86)

Results of the ANOVAs conducted to test for group differences regarding LIWC scores
showed that participants in the EW group used significantly more positive emotion words
compared to the control writing group, on three days of writing Day 3 [F (1, 38) = 157.4, p

100

<.0001], Day 4 [F (1, 37) = 6.4, p <.05] and Day 6 [F (1, 24) = 18.24, p <.0001]. Results also
revealed that the EW group used significantly more negative emotion words compared to the
control writing group on Day 3, [F (1, 38) = 61.4, p <.0001], Day 4 [F (1, 37) = 11.93, p <.05]
and Day 6. [F (1, 24) = 20.4, p <.0001], see Appendix P for mean difference plots for both
groups with respect to LIWC scores. Only on one day, Day 5, there were no differences between
the EW group and control writing group with regards to usage of either positive emotion words
[F (1, 31) = 2.4, p =.13], or negative emotion words [F (1, 31) = 3.01, p <.1], see Appendix P for
mean difference plots. Results of the differences in LIWC scores confirmed that the EW group
overall used significantly more positive and negative emotions in their writing responses
compared to the control writing group. Thus, we inferred that our experimental manipulation of
participants was successful.
Attrition Rates
Overall participants in the study showed high rates of compliance with regards to
completing the writing tasks as well as completing the outcome measures which included
answering online survey questions and providing their saliva in Eppendorf tubes. All participants
(n=40, 100%) provided information regarding demographics, disease and treatment information,
health related symptoms and behaviors (Day 1) as well as baseline outcome measures (Day 2),
see Figure 7. All participants completed their online post-intervention psychosocial outcome
measures, i.e. immediate (Day 7) as well as the delayed 6 week post-intervention measure (Day
49). Specific rates of attrition regarding writing tasks and salivary outcomes measures are
described below.
Writing tasks. With regards to their writing tasks all participants in both EW and control
writing groups (N=40) completed the first day of writing. On the second day of writing only one
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participant (n=1) in the control writing group did not complete their schedule writing task, all
participants in the EW group completed their writing tasks. On the third day of the writing
intervention, there were n=4 (10%) participants in the EW group and n=3 (7.5%) participants in
the control writing who did not complete their writing tasks. Finally on the fourth and last day of
writing, n=5 participants from the EW group and n=3 participants from the control writing group
did not complete their writing tasks. Thus, almost all participants (n=39, 97.5%) completed at
least two writing sessions, and majority of participants (n=33, 82.5%) completed at least three
days of writing tasks. Thus participants demonstrated a satisfactory compliance with the writing
interventions and both groups complete the minimum required two days of writing.
The average time (and SD) that participants in each group took for completing their
respective writing assignments are described in the Table 17 below. To assess for differences in
Table 17: Mean time taken for writing tasks by both groups
Day

n

Intervention grp min (SD)

n Control grp min (SD)

Day 3

20

28.4 (5.92)

20

29.34 (5.96)

Day 4

20

33.98 (6.05)

19

31.77 (5.56)

Day 5

16

32.35 (5.81)

17

29.91 (5.57)

Day 6

15

33.53 (4.49)

11

31.75 (4.37)

writing time between the EW group and control writing groups, we again used one-way analysis
of variance (ANOVA) tests for all fours days of the writing tasks (Days 3, 4, 5 and 6) during the
intervention. Results of the ANOVAs were unable to detect significant difference in the amount
of time spent writing between participants in the EW group and participants in the control
writing group on all four days of writing Day 3 [F (1, 38) = 0.25, p =.64], Day 4 [F (1, 37) = 1.4,
p =.24], Day 5 [F (1, 31) = 1.52, p=.23], and Day 6 [F (1, 24) = 1.03, p =.32]. Thus participants
in both groups of this study, the EW and control writing groups, contributed equal amount of
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time for their writing tasks.
Outcome measures: Salivary specimens. With regards to salivary specimens, all
participants (n=40, 100%) provided baseline (Day 2) and immediate post-intervention (Day 7)
measures. For the delayed 6 week post-intervention measure (Day 49) only one participant (n=1,
2.5%) from the intervention group did not provide their salivary specimens. In terms of
following the schedule for providing the three salivary specimens (waking, peak, bedtime and
other), most participants (n=36, 90%) followed the instructions and provided samples marked at
waking (W), peak (P) and bedtime (B). There were n=2 (5%) participants (n=1 from the EW
group and n=1 from the control group) that provided samples marked as Other (O) for their Day
7 measure. Finally, n=1 participant from the EW group provided two samples marked as peak
(P) on their Day 49 measure; one peak (P) sample was considered as Other (O) for data analysis.
Overall, participants showed very low attrition with regards to completing the salivary outcome
measures, see Figure 7.
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Figure 7: Randomization flow chart of activities completed by participants
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Statistical Tests
Statistical tests on cortisol levels (AUCg, CAR and DCS) on Day 49 revealed that data
were not normally distributed. Therefore, in order to compare the EW and control writing groups
with data having a non-normal distribution, the nonparametric Mann-Whitney statistical test was
chosen. The Mann-Whitney U test was used to compare mean ranks of AUCg, CAR and DCS
between the EW and control writing groups and results for hypothesis one are reported under
each respective cortisol variable. However t-tests were also conducted to compare results of both
non-parametric (Mann-Whitney) and parametric (t-test) tests.
Mann-Whitney (U) test. The Mann-Whitney U test is employed when comparing
differences between two independent groups when the outcome variable is measured as ordinal
or continuous, but is not normally distributed. The Mann-Whitney U test ranks all the values in
both groups from low to high, and then compares the mean ranks. Specifically, the MannWhitney U test assesses, what is the likelihood that a randomly selected value from the group
with the higher mean rank will be greater than a randomly selected value from the other group.
The null hypothesis (H0) of the Mann-Whitney test posits that there will be no difference in the
ranks of the two groups. A significant P value indicates that the null hypothesis is rejected and
the mean rank of the one group is lower than the mean rank of the comparison group (here EW
group vs control writing group).
However, there are three assumptions that have to be met when using the Mann-Whitney
U test. The first assumption is that the outcome variable(s) must be measured at the continuous
or ordinal level. This assumption is met by the study data, since cortisol concentration was
measured as a continuous variable in units of pictograms/deciliter (pg/dl) in saliva. The second
assumption is that the predictor variable must consist of two categorical, independent groups.
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This assumption is also met by the study data, since this study is a randomized trial, the
intervention and control groups are the categorical, independent groups operating as predictor
variables. Finally, the last assumption requires the independence of observations, which means
that there must be no relationship between the observations of the predictor variables or between
the groups themselves. This means that the Mann-Whitney U test requires that there must be
different participants in each group with no participant being in more than one group. Study data
meet the last assumption as well, as randomization procedures ensured that participants had an
equal chance of being assigned to either the intervention or control group at the start of the study.
General Linear Model (GLM). For hypothesis testing with respect to the secondary
outcome variables, a General Linear Model accounting for repeated measures was selected. The
study design for this research project consisted of two predictor variables (EW and control
writing groups) and five outcome variables (amylase, CRP, PSS, FCRIS and CBIB) that were
repeatedly measured at three time points (Days 2, 7 and 49). For this multivariate repeated
measures design, the General Linear Model (GLM) test was selected to compare the two
predictor variables, the intervention (EW) group and control (control writing) group, on each of
the five outcome variables measured at baseline (Day 2), immediately after the writing tasks
(Day 7) and a six weeks after the writing tasks (Day 49). The General Linear Model (GLM) test
accounts for the variance that occurs in measures that are collected repeatedly over time as well
as accounts for unequal n in predictor variables. The null hypothesis (H0) of the GLM test posits
that there will be no difference in the predictor variables with regards to the outcome variables of
two groups. A significant P value in the GLM indicates that the null hypothesis is rejected and
the mean of one group is lower than the mean of the comparison group (here EW group vs
control writing group) with a respective effect size statistic (partial eta squared).
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The GLM for this study assumed independence of observations data and normal
distribution of data for all secondary outcome variables, physiological and psychosocial.
Random allocation ensured that no participant completed both writing tasks and thus provided
independent observations. The second assumption of the GLM was that the data for observations
on the outcome variables had a multivariate normal distribution, which can decrease the chances
of encountering Type I error. The multivariate normal distribution was assessed by reviewing the
normal quantile plots for each variable, please see Appendix O. The graphs for all five outcome
variables displayed an elliptical shape that is characteristic of normal distribution for each
respective variable. Based on the results of these analyses, a multivariate normal distribution was
assumed. The GLM also allows for groups to be unequal, since our final sample had unequal
numbers of participants (Intervention (EW) group: n=19; Control (Control writing) group:
n=20). The GLM allows for testing differences both within and between predictor groups. The
GLM was used for primarily testing differences between the predictor variables (Intervention
(EW) group, Control (Control writing) group) with respect to all secondary outcome variables
involving hypotheses two through eight.
Hypotheses Testing
Hypothesis one. Hypothesis one was related to the primary outcome measure for this
study which was cortisol. Research evidence indicates that salivary cortisol is a reliable measure
of the HPA axis activity in human physiological stress response. In hypothesis one we expected
that cancer survivors who participated in the expressive writing (EW group) stress-management
intervention will have lower levels of salivary cortisol at 6 weeks post-intervention (Day 49)
when compared with cancer survivors who participated in control-writing (control group). The
first step in testing hypothesis one was to extrapolate the amount and rate of cortisol secretion
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from the raw data cortisol data. This step involved determining the area under the curve (AUCg),
cortisol awakening response (CAR) and diurnal cortisol slope (DCS) as described in the
methods. The median values for AUCg, CAR and DCS for both groups is reported in Table 18.
Table 18: Median values of cortisol variables on Day 49
Day

Intervention group (n=19)
median (IQR)

Control group (n= 20)
median (IQR)

AUCg

0.32 (0.18, 0.91)

0.98 (0.36, 4.58)

CAR

0.013 (0.01, 0.03)

0.04 (0.02, 0.2)

DCS

0.001 (-0.004, 0.004)

-0.003 (-0.01, 0.005)

Cortisol: Area Under the Curve (AUCg). The AUCg estimation described that the EW
group had a median secretion of 0.32 (IQR= 0.18, 0.91) pg/dl of cortisol over the course of a 14
hour day (Day 49), while the control group secreted a median of 0.98 (IQR = 0.36, 4.58) pg/dl
of cortisol over the course of a 14 hour day (Day 49). The Mann-Whitney mean ranks of AUCg
values for both groups are reported in the Table 19 below.
Table 19: Mann Whitney Ranks for AUCg (Day 49)
Intervention group (n=19)

Control group (n=20)

14.95

24.80

Expected Ranks

380

400

Sum of Ranks

284

496

Mean Rank

The results for the Mann-Whitney-Wilcoxon test for AUCg showed a statistically significant
difference between AUCg values of the EW group and control writing groups for the 6 week
post-intervention measure and the null hypothesis was rejected. On Day 49 the EW group
participants had significantly lower AUCg values compared with the control group participants,
U=94, p=0.006, r=0.432, see Figure 8. A t-test also confirmed that the mean AUCg values of the
EW group participants were significantly lower than control group participants, t (37) = 2.2,
p<.05 at Day 49.
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Figure 8: Group differences for cortisol AUCg values at Day 49
Cortisol: Cortisol Awakening Response (CAR). CAR evaluation described that over a
period of half an hour (from waking to peak) on Day 49, the EW group secreted a median of
0.013 (IQR = 0.01, 0.03) pg/dl of cortisol and the control writing group had a median secretion
0.04 (IQR = 0.02, 0.2) pg/dl of cortisol. The Day 49 Mann Whitney mean ranks of CAR values
for both groups are reported in Table 20 below.
Table 20: Mann Whitney Ranks for CAR (Day 49)
Intervention group (n=19)
Mean Rank

Control group (n=20)

14.79

24.95

Expected Ranks

380

400

Sum of Ranks

281

499

Parallel to the results for AUCg, the Mann-Whitney U test for CAR on Day 49 also reported a
statistically significant difference between the CAR of EW participants and control writing
participants. On the 6 week post-intervention measure the intervention group participants had
significantly lower CAR values compared with the control group participants, U=91, p=0.005,
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r=0.45, see Figure 9 below. Similarly, a t-test confirmed that the mean CAR values of the EW
group participants were significantly lower than control group participants, t (37) = 2.2, p<.05.

Figure 9: Group differences for CAR values at Day 49

Cortisol: Diurnal Cortisol Slope. The median DCS for the treatment arm was 0.001 (IQR
= -0.004, 0.004) and the control arm median DCS was -0.003 (IQR = -0.01, 0.005). The Day 49
Mann-Whitney mean ranks of CAR values for both groups are reported in Table 21 below.
Table 21: Mann Whitney Ranks for DCS (Day 49)
Intervention group (n=19)
Mean Rank

Control group (n=20)

21.74

18.35

Expected Ranks

380

400

Sum of Ranks

367

413

With regards to DCS the null hypothesis (H0) for the Mann-Whitney U test for CAR on Day 49
was retained and no statistically significant differences were found between the DCS values of
EW group participants and control group participants. On the 6 week post-intervention measure
the EW group participants had similar DCS values compared with the control group participants,
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U = 157, p=0.365, r=0.15, please see Figure 10 below. A t-test also confirmed that the mean
DCS values of the EW group participants were similar to the DCS values of control group
participants, t (37) = -.7, p=0.5.

Figure 10: Group differences for DCS values at Day 49
The lack of baseline outcome measures and immediate post-intervention outcome
measures for cortisol limits the inferences that can be made from the data for hypothesis one. For
example, we could not estimate if control group participants had higher levels of cortisol than
EW group participants at baseline before the intervention. Nevertheless, randomization was
successful with all other variables in this study, including salivary α-amylase (sAA) and research
indicates to a correlation between levels of cortisol and sAA in healthy subjects as well as
clinical populations193,194. Thus we can assume that cortisol levels were not significantly
different at the start of the study. A post-hoc power analysis using Gpower showed that we had
89% power (β) to detect differences between intervention and control groups (N=39, α=0.05)
using the Mann-Whitney U test (effect size of r=0.43; d=0.96).
Hypothesis two. A novel aspect of this study was that in addition to measuring outcomes
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of the HPA axis (salivary cortisol), we also measured the SNS (salivary α-amylase). The second
hypothesis of this study stated that CS participating in EW (intervention arm) would have lower
levels of salivary α-amylase (sAA) when compared to CS participating in control-writing
(control arm) at 6 weeks post-intervention The mean sAA levels for both groups on all three
days of data collection are presented in the Table 22 below.
Table 22: Mean salivary a-Amylase levels (Days 2, 7 and 49)
Day

n

Intervention group U/ml (SD)

n

Control group U/ml (SD)

Day 2

20

1.15965 (0.73)

20

0.7928 (0.74)

Day 7

20

1.52910 (0.75)

20

0.89695 (0.83)

Day 49

19

1.53242 (0.64)

20

0.9388 (0.82)

The GLM findings for hypothesis two did not support our anticipated results of lower sAA in
EW group compared to the control group. Instead we found that the EW group had higher levels
of sAA compared to the control group, F (1, 37) = 8.117, p<0.05, partial eta-squared (ηp2 ) =
.180, at six weeks post-intervention. However, it is important to note that baseline sAA was
higher in the EW group compared to the control group. There was a significant effect of time on
the sAA concentration, with an increase in AA on Day 7 and then a plateauing of sAA
concentration by Day 49, F (2, 36) = 4.145, p<0.05, ηp2 = .178, please see Figure 11.

Figure 11: Changes over time for salivary α-amylase (AA) in both
groups over the six week intervention
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Hypothesis three: Another aim of this study was to investigate the effects of EW on
immune function. CRP was the chosen outcome measure of immune function. The third
hypothesis of this study stated that at 6 weeks post-intervention CS participating in EW
(treatment arm) will have lower levels of salivary CRP when compared with CS participating in
control-writing (control arm). The mean CRP levels for all three days of data collection (Day 2, 7
and 49 for both groups are presented in the Table 23 below.
Table 23: Mean salivary CRP levels (Days 2, 7 and 49)
Day

n

Intervention group pg/dl (SD)

n

Control group pg/dl (SD)

Day 2

20

994.05 (455.12)

20

1020.70 (581.84)

Day 7

20

1164.73 (571.38)

20

1049.17 (575.99)

Day 49

19

986.73 (383.86)

20

1012.59 (383.86)

The GLM for hypothesis three revealed no significant differences in CRP levels between
intervention and control group participants on Day 49 of the intervention, F (1, 37) = 0.009, p =
0.927, ηp2 = .0, see Figure 12. The data also indicates that there was no impact of time on CRP
levels for both groups, F (2, 36) = 1.877, p=0.168, ηp2 = .094, see Figure 12.

Figure 12: Changes over time for salivary CRP in both groups over the
six week intervention

Hypothesis four. Hypothesis four was related to the psychosocial outcome measure of
perceived stress as measured by the perceived stress scale (PSS). The mean PSS scores for both
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groups on all three days of data collection are presented in the Table 24 below.
Table 24: Mean PSS scores (Days 2, 7 and 49)
Day

Intervention group (n=20)
mean (SD)

Control group (n= 20)
mean (SD)

Day 2

31.95 (5.32)

31.05 (3.89)

Day 7

36.1 (2.69)

35.65 (2.6)

Day 49

23.9 (1.97)

24.1 (1.99)

Hypothesis four stated that CS in the EW group will have lower perceived stress indicated by
lower scores on the PSS at 6 weeks post-intervention compared to CS in the control group. The
results of the GLM for hypothesis four revealed no statistically significant results for group
differences in PSS scores on Day 49 F (1, 38) = 0.48, p=0.495, ηp2 = .012 , see Figure 13.
However the data did reveal a significant effect of time for PSS scores in both groups, F (2, 37) =
254.74, p<0.0001, ηp2 = .932. There was an increase in perceived stress immediately after the
intervention (Day 7) and a significant decrease in perceived stress for both groups at 6 weeks
post-intervention, please see Figure 13 below.

Figure 13: Changes over time for PSS scores in both groups over the
six week intervention
Hypothesis five. One critical aim of this study was to test if EW is effective in emotion
regulation by actually measuring levels of a relevant emotion for CS, which was fear of cancer
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recurrence over time. The fear of cancer recurrence inventory – severity (FCRI-S) subscale was
used to measure fear of cancer recurrence in the participants of this study. The mean FCRI-S
scores for both groups on all three days of data collection are presented in the Table 25 below.
Table 25: Mean FCRI-S scores (Days 2, 7 and 49)
Day

Intervention group (n=20)
mean (SD)

Control group (n= 20)
mean (SD)

Day 2

24.4 (3.62)

24.7500 (3.06)

Day 7

31.35 (2.37)

30.85 (3.2)

Day 49

18.2 (2.4)

24.7 (5.2)

Hypothesis five stated that on Day 49 (6 weeks post-intervention) CS participating in EW will
have lower scores on the FCRI-S compared to CS participating in control-writing. The GLM test
for hypothesis five demonstrated that fear of cancer recurrence was significantly reduced in the
EW participants when compared to the control group participants, F (1, 38) = 9.654, p=0.004, ηp2
= .993, at six weeks post-intervention (Day 49), see Figure 14 below. The data also showed that

FCRI-S scores changes significantly with time for both groups, F (2, 37) = 97.06, p<0.0001, ηp2
= .84, where both groups reported increases in FCRI-S scores immediately after the writing
intervention (Day 7), followed by a significant decrease on Day 49, which was more pronounced
for the EW group, please see Figure 14 below.

Figure 14: Changes over time for FCRIS scores in both groups over the
six week intervention
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Hypothesis six. An important way in which EW benefits participants is by boosting
participants self-efficacy to cope with stressful experiences and stressful life events. Participants
in this study completed a measure of their self-efficacy to cope with cancer called the cancer
behavior inventory – brief version (CBI-B). The mean CBI-B scores for both groups on all three
days of data collection are presented in the Table 26 below.
Table 26: Mean CBIB scores (Days 2, 7 and 49)
Day

Intervention group (n=20)
mean (SD)

Control group (n= 20)
mean (SD)

Day 2

75.45 (6.67)

78.45 (10.013)

Day 7

72.2 (3.43)

71.05 (3.17)

Day 49

96.7 (6.26)

89.4 (8.52)

In hypothesis six we anticipated that CS who participated in EW will have greater self-efficacy
to cope with cancer measured by higher scores on the CBI-B at 6 weeks post-intervention (Day
49) when compared to CS participating in control-writing. The GLM test for hypothesis six
showed no significant overall group differences between the EW group and control group
participants for CBI-B scores, F (1, 38) = 2.765, p = 0.11, ηp2 = .068 on Day 49., see Figure 15.
However, there was a significant effect of time on CBI-B scores for both groups, with a decrease
in CBI-B scores immediately after the intervention (Day 7) and a significant increase in CBI-B
scores on Day 49, F (2, 37) =118.115, p<0.0001, ηp2 = .865, see Figure 15.
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Figure 15: Changes over time for CBIB scores in both groups over the six week intervention
levels
Hypothesis seven. Hypothesis seven was related to cortisol levels immediately after the
intervention. Based on the literature, we expected an increase in stress immediately postintervention (Day7). Hypothesis seven posited that CS participating in EW (treatment arm)
would have higher levels of salivary cortisol, compared to CS participating in control-writing
(control arm) at 24 hours post-intervention (Day 7). Hypothesis seven was not testable due to
unavailability of data pertaining to cortisol for Baseline (Day 2) and immediately postintervention (Day 7) due to resource constraints.
Hypothesis eight. An important aspect of this research study was that we wanted to
establish the differential impact of EW on stress outcomes over time. The research literature
related to EW suggests that there is an initial increase in stress since individuals to confronting
pent-up emotions related to the stressful experiences and stressful life events. We wanted to
demonstrate this by seeing how EW impacts stress outcomes immediately after the intervention.
In hypothesis eight we expected an increase in stress immediately post-intervention (Day 7) as
measured by physiological outcomes a-amylase, CRP (Hypothesis 8a) as well as by psychosocial
outcomes PSS, FCRI-S, CBI-B (Hypothesis 8b)
Hypothesis 8a: α-amylase. In hypothesis 8a we anticipated that salivary α-amylase
(sAA) levels measured at 24 hours post-intervention (Day 7) will be higher in the EW group
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participants compared to CS participating in control-writing (control group). The mean sAA
levels for both groups on days 2 and 7 of data collection are presented in Table 27 below.
Table 27: Mean a-Amylase levels (Days 2 and 7)
Day

Intervention group (n=20)
mean sAA U/ml (SD)

Control group (n=20)
mean sAA U/ml (SD)

Day 2

1.15965 (0.73)

0.7928 (0.74)

Day 7

1.52910 (0.75)

0.89695 (0.83)

Data indicated that baseline levels of sAA were higher in the EW group compared to the control
group. The GLM for hypothesis 8a showed that α-amylase levels were higher in the EW group
participants at Day 7 compared to the control writing group participants, F (1, 38) = 4.84,
p=0.034, ηp2 = .113, see Figure 16. However, this result could be attributed to preexisting higher
levels of sAA in the EW group. A significant effect of time was also detected for α-amylase
levels in both groups, and α-amylase secretion increased on 24 hours post-intervention (Day 7)
as compared with their baseline (Day 2) levels, F (1,38)=8.145, p=0.007, ηp2 = .177, refer to
Figure 16.

Figure 16: Immediate post-intervention effects for salivary α-amylase (AA) levels
Hypothesis 8a: CRP. In hypothesis 8a we also expected that increased stress immediately
post-intervention would impact immune function by increasing inflammation in CS in the EW
group and will result in higher levels of salivary CRP at 24 hours post-intervention (Day 7). The
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mean CRP levels for both groups on days 2 and 7 of data collection are presented in Table 28.
Table 28: Mean CRP levels (Days 2 and 7)
Day

Intervention group (n=20)
mean CRP pg/dl (SD)

Intervention group (n=20)
mean CRP pg/dl (SD)

Day 2

994.05 (455.12)

1020.70 (581.84)

Day 7

1164.73 (571.38)

1049.17 (575.99)

Hypothesis 8a postulated that CRP levels at 24 hours post-intervention (Day 7) would be higher
in EW group participants when compared with CS participating in control-writing (control
group). The GLM for hypothesis 8a showed no significant difference in CRP levels between the
EW and control group participants at 24 hours post-intervention Day 7, F (1, 38) = 0.083,
p=0.775, ηp2 = .002, see Figure 17. Results of the GLM also revealed that there was no impact of
time on CRP levels for both groups at 24 hours post-intervention (Day 7), F (1, 38) =1.561,
p=0.22, ηp2 = .039, with both groups remaining close to their baseline CRP levels, see Figure 17.

Figure 17: Immediate post-intervention effects for salivary CRP levels
Hypothesis 8b: PSS. The second aspect of hypothesis eight was related to the
psychosocial outcome measures. The first of the psychosocial outcomes was perceived stress
measured by the PSS. The mean PSS scores for both groups on days 2 and 7 of data collection
are presented in the Table 29 below.
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Table 29: Mean PSS scores (Days 2 and 7)
Day

Intervention group (n=20)
mean (SD)

Control group (n= 20)
mean (SD)

Day 2

31.95 (5.32)

31.05 (3.89)

Day 7

36.1 (2.69)

35.65 (2.6)

We anticipated an increase in perceived stress measured by the PSS in CS that participated in
EW (EW group) compared to CS participating in control-writing (control group) at 24 hours
post-intervention (Day 7). Results of the GLM test indicated no significant differences between
the two groups with regards to PSS scores on Day 7, 24 hours post-intervention, F (1, 38) = 0.64,
p=0.43, ηp2 = .017, see Figure 18. However, the GLM did demonstrate that in both groups there
was a significant increase in PSS scores from baseline (Day 2) to 24 hours post-intervention
(Day 7), F (1, 38) = 26.56, p<0.0001, ηp2 = .411, please see Figure 18.

Figure 18: Immediate post-intervention effects for PSS scores
Hypothesis 8b: FCRI-S. The second psychosocial outcome measure in hypothesis eight
was fear of cancer recurrence. The mean FCRI-S scores for both groups on days 2 and 7 of data
collection are presented in the Table 30 below. In hypothesis 8b we expected an increase in fear
of cancer recurrence (measured by FCRI-S) immediately after the expressive writing
intervention (Day 7). Hypothesis 8b also postulated that FCRI-S scores at 24 hours post-
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intervention (Day 7) would be higher in EW group participants compared to CS participating in
control-writing (control group).
Table 30: Mean FCRI-S scores (Days 2 and 7)
Day

Intervention group (n=20)
mean (SD)

Control group (n= 20)
mean (SD)

Day 2

24.4 (3.62)

24.7500 (3.06)

Day 7

31.35 (2.37)

30.85 (3.2)

The GLM for FCRI-S scores at 24 hours post-intervention (Day 7) also reported that there were
no significant differences between the two groups, F (1, 38) = 0.011, p=0.92, ηp2 = .92, see
Figure 19. Though, the GLM did describe that both the EW and control groups reported a
significant increase in fear of cancer recurrence after the writing tasks, indicated by higher FCRIS scores on Day 7 in comparison their baseline FCRI-S scores (Day 2) values, F (1, 38) = 100.1,
p<0.0001, ηp2 = .725, please see Figure 19 below.

Figure 19: Immediate post-intervention effects for FCRIS scores
Hypothesis 8b: CBIB. Finally, the last psychosocial outcome was self-efficacy with
coping with cancer measured by the CBI-B. In this hypothesis 8b, we expected to find a decrease
in self-efficacy with coping immediately after the intervention due to the stress-induced from the
EW. The mean scores for CBI-B for baseline (Day 2 ) and immediate post-intervention (Day 7)
are reported in the Table 31 below.
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Table 31: Mean CBIB scores (Days 2 and 7)
Day

Intervention group (n=20)
mean (SD)

Control group (n= 20)
mean (SD)

Day 2

75.45 (6.67)

78.45 (10.013)

Day 7

72.2 (3.43)

71.05 (3.17)

In hypothesis 8b we anticipated that EW participants (EW group) will have lower CBI-B scores
compared to control-writing participants (control group) at 24 hours post-intervention (Day 7).
The GLM test for this hypothesis also did not find any significant group differences with regards
to CBI-B scores immediately after the intervention (Day 7), F (1, 38) = 0.42, p=0.522, ηp2 =
0.011, see Figure 20. However, both groups showed a significant decrease in CBI-B over time,
i.e. from baseline to immediately post-intervention, F (1, 38) = 13.42, p=.001, ηp2 = .261, see
Figure 20 below.

Figure 20: Immediate post-intervention effects for CBIB scores
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Chapter VII. Discussion
Chronic stress has been implicated in an array of negative impacts on the physical and
mental health of individuals and is especially relevant to the cancer patients transitioning from
completing their treatments to reassuming their roles in their family and work environments,
defined as cancer survivors in this study. We conducted a two-arm randomized controlled trial
(RCT) to determine the efficacy of expressive writing as a stress-management intervention for
cancer survivors who were 2-12 months post-radiation treatment completion. The theoretical
framework for this study was psychoneuroimmunology (PNI), which guided our choice of health
outcome measures, that included salivary biomarkers of the neuroendocrine and immune systems
as well as psychometric measures of psychosocial function. The results of this study revealed
that expressive writing was effective in regulating stress over a period of six weeks in our
samples of cancer survivors. Expressive writing (EW) is a very brief and inexpensive
psychosocial intervention that can help manage stress in cancer survivors (CS). Results from this
study have important implications for theory, practice and future research with regards to PNIbased psychosocial interventions such as EW in the growing population of CS worldwide.
Aims and Hypotheses
This research study had five major aims and eight related hypotheses. The first three aims
of this study were related to determining the delayed neuroendocrine and immune effects of EW
for our sample of cancer survivors (CS) which were measured six weeks post-intervention (Day
49). The fourth aim was to determine the delayed impact of EW on the psychosocial outcomes of
CS which were measured six weeks post-intervention (Day 49). The last aim of this study was to
investigate the immediate post-intervention psychobiological effects of EW on CS which were
measured immediately post-intervention (Day 7).
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Aim one: Hypothesis one. The first aim of this study was to determine the effectiveness
of EW to regulate stress in cancer survivors as measured by salivary cortisol levels which was
the biomarker chosen to indicate HPA axis activity and the primary outcome for this study. In
the first hypothesis we expected to find that CS that completed EW would have lower levels of
salivary cortisol compared with CS that completed control writing when measured six weeks
after completing the writing intervention. The EW literature indicates that EW’s beneficial health
impacts take effect after a period of approximately 6-8 weeks post-intervention126. During the 68 week period after completing their EW writing tasks, participants process the negative
emotions and stressful experiences brought to their attention by EW as well as experience
desensitization from repeated exposures to their emotions128. This emotion processing helps
decrease arousal of the HPA axis and subsequent regulation of neuro-hormonal physiological
stress responses of EW participants137. Results from our study demonstrated that EW
successfully affected the HPA axis of CS in our sample as shown by significantly lower levels of
salivary average cortisol secretion (area under the curve, AUC) and cortisol awakening response
(CAR) in the EW group CS compared to CS in the control writing group at six weeks postintervention.
Furthermore, results from this study report medium to large effect sizes (ES) for our
online EW intervention with regards to our primary outcome variable, salivary cortisol (r=0.43
for AUC; r=0.45 for CAR) in a sample of CS post-radiation. The ES obtained in this study are
equal to and even greater than those reported in the three key meta-analyses of EW interventions
that we used for our sample size and power calculation (r=0.21 in healthy samples126, r=0.1 in
clinical samples127 and r=0.075 based on wide ranging group of EW studies128. Salivary cortisol
is an objective biomarker of stress and has been extensively studied by researchers163. This study
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is an important contribution to the literature which demonstrates that EW is a brief and low-cost
intervention that successfully reduced stress in CS which was objectively measured in saliva and
which can be made readily accessible to a wide range of cancer patients and survivors through
the internet. This study also lends support for the evidence-base with regards to the
neuroendocrine effects of EW’s stress-regulation mechanism of action41. In our literature review
we noted that several studies of psychosocial interventions, including EW interventions, only
mentioned the PNI framework as a mechanism of action without actually measuring
corresponding PNI biomarkers197. This study will fill an important gap in the literature since this
is one of the first studies of an online EW intervention in the cancer survivor population to report
significant effects for neuroendocrine outcomes.
However, the results for our primary outcome should be viewed with restraint since we
did not have the measures for baseline and immediate post-intervention for salivary cortisol.
Thus, data for the six week post-intervention outcome measures does not reflect the correlations
for repeated measures. Also, with respect to salivary cortisol, only AUC and CAR were
significantly lower in the EW group compared to the control writing, however cortisol diurnal
slope (DCS) was not significantly different for both groups. Previous studies have suggested that
patients with comorbid psychological problems such as depression can have flatter and less
responsive DCS profiles198. Further research is needed to investigate the DCS profile of the CS
population and relationships between salivary AUC, CAR and DCS for CS post-radiation.
Finally, though the delayed stress-regulating effects of EW are well-documented in the
literature128, however we still do not know how long these effects last. Future EW studies should
incorporate more delayed post-intervention measures, e.g. 3 and 6 months post-intervention.
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Aim two: Hypothesis two. In the second aim of this study we wanted to determine the
effectiveness of EW to regulate stress in CS as measured by salivary α-amylase levels which was
the biomarker chosen to indicate SNS activity. In the second hypothesis we anticipated that EW
participants would have lower levels of salivary α-amylase (sAA) compared with participants
that completed control writing measured at six weeks post- intervention. The rationale for
hypothesis two was that we expected EW to have a delayed stress- regulating impact on the SNS
similar to EW’s effect on the HPA axis (hypothesis one) However, results for hypothesis two
were opposite to what we had anticipated, and CS in the EW group had significantly higher
levels of sAA compared to control writing participants at 6 weeks post-intervention. However,
the data indicated that baseline levels of sAA were higher in the EW group compared to the
control group. Therefore, the difference in sAA between the groups at Day 49 could be attributed
to higher baseline levels of sAA, which plateaued after the expected increase in stress
immediately after the EW intervention (Day 7).
Also, the SNS is a more rapid stress-response pathway responsive to acute stressors in
contrast to the HPA axis which is involved in a more gradual and delayed stress response166.
Therefore the SNS is more susceptible to be influenced by a range of stressors in the immediate
physical and social environment of participants such as temperature or daily stress of commuting
to and from work. Additionally, SNS reactivity is known to have individual variation in
individuals with respect to acute and chronic responses. Thus, the higher sAA levels of the CS in
the EW group at six weeks post-intervention may not be reflective of a response to the writing
intervention. Also, sAA data with regards to average sAA secretion was not available for all
three days that salivary data was collected. Future research is needed with regards to the impact
of stress-regulation interventions on sAA and SNS activity. Researchers also need to examine
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differential relationships between responsiveness of HPA axis biomarkers and SNS biomarkers
to acute stress and chronic stress stimuli.
Aim three: Hypothesis three. In the third aim of this study, we wanted to determine the
impact of EW on the immune system of CS as measured by salivary C - reactive protein (CRP)
levels. CRP is an acute-phase response protein that is a biomarker of inflammation in the
immune system. We expected to find lower CRP levels in CS that participated in EW compared
to those participating in control writing at six weeks post-intervention. The rationale for
hypothesis three was similar to the first and second hypothesis, where we expected EW to
influence delayed neuroendocrine regulation in CS over six weeks, would in turn decrease
inflammation in the immune system as measured by lower salivary CRP. The study results
indicated that there was no impact of EW on CRP levels of CS, and participants in both groups,
EW and control writing, had similar levels of CRP at six weeks post-intervention. CRP levels are
also affected by a range of other conditions such as cardiovascular disorders, infections and
inflammation and shares a complex relationship to glucocorticoids such as cortisol199. Moreover,
the immune profiles of cancer patients and CS are affected in very complex ways due to
treatments and the cancer itself.
The absence of an effect of EW on salivary CRP levels of CS in our sample could be due
to 1) the CRP levels in the CS were sustained due to post-radiation inflammation, or 2) EW may
exert a selective impact on the HPA axis activity, which may not have a mediating or moderating
influence on inflammation in the immune system. This was one of the first EW studies to
incorporate CRP as an outcome measure in the cancer population. A recent study of a
psychosocial intervention in a population of youth in foster care showed a significant decrease in
salivary CRP after the intervention200. Also, research indicates that cortisol exerts a
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downregulating influence on CRP levels in populations faced with pneumonia and respiratory
disorders201. Our study found no impact of EW on salivary CRP levels of CS post-radiation over
six weeks. Thus more psychosocial interventions in the cancer population need to measure
salivary CRP to assess CRP’s responsiveness as well as determine the correlation of salivary
CRP levels with levels of CRP in blood and other measures of the immune system that include
functional immune measures such as cytokines and immune cell counts such as T lymphocyte
counts. Future observational studies should also investigate the association between levels of
glucocorticoids such as cortisol on levels of CRP in cancer patients, as well as in healthy
individuals.
Aim four: Hypothesis four. The fourth aim of this study was to determine the efficacy
of EW to impact psychosocial functioning in CS as measured by scores on self-report
questionnaires: a) PSS (perceived psychological stress), b) FCRI-S (negative emotion), and c)
CBI-B (efficacy for coping with cancer). Data for aim four was tested in three hypotheses, for
each self-report outcome measure, i.e. PSS, FCRI-S, CBI-B. In hypothesis four, we expected to
find lower PSS scores for the EW group compared to the control group on Day 49. Results were
contrary to what we predicted, and in hypothesis four we found no significant differences
between the EW and control writing groups with regards to scores on the perceived stress scale
(PSS). However, the data showed that that in both groups, there was a significant effect of time
and PSS scores increased immediately after the intervention followed by a significant decrease at
six weeks post-intervention. This impact of time on perceived stress in CS could be attribute to
the PSS scale and the natural impact that time has on stress and coping.
The PSS is an extensively used measure of stress which assesses the degree to which the
participants regard their life circumstances to be stressful180. In this study, the PSS assessed more
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global factors leading to stress such as how unpredictable, or overloaded the CS found their lives
to be. Research indicates that CS gain coping skills and strategies as they transition through
survivorship and these are incremental gains across the survivorship phase. Previous studies of
EW have also demonstrated that EW initially increases perceived stress in participants
immediately after the intervention which is followed by a delayed decrease (over a period of 6-8
weeks) in perceived stress128,202. Thus, decrease in PSS scores for both groups at the end of the
intervention could be attributed to the natural coping strategies that CS adopt over time to cope
with life stressors while reassuming their roles in their family and workplace. Also, the EW
literature suggests that EW’s mechanism of action is backed by research evidence with regards to
only specific dimensions of psychosocial functioning, such as emotion regulation and cognitive
restructuring, while excluding others such as stress perception and coping137,203. Future studies of
EW should employing more precise measures of stress as they relate to EW’s mechanism of
action.
Aim four: Hypothesis five. The fifth hypothesis of this study was related to determining
the efficacy of EW to regulate negative emotions, specifically the fear of cancer recurrence in
CS. In the fifth hypothesis we aimed to generate evidence for EW’s emotion regulation
mechanism of action by demonstrating a decrease in the severity of a relevant and specific
emotion for our sample of CS, which was fear of cancer recurrence (measured by the FCRI-S).
As anticipated by our study, the EW group reported significantly lowered fear of cancer
recurrence (FCR) compared to the control writing group at six weeks post-intervention. Results
for hypothesis five is an important finding as this was one of the first studies of EW in the cancer
population to measure the severity of a relevant negative emotion, i.e. FCR which particularly
affects CS, and demonstrate that EW was effective in reducing the severity of that negative
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emotion. This study will be a significant contribution to the EW and psycho-oncology literature
since very few psychosocial intervention studies in the cancer survivor population have been
conducted that have evaluated and assessed severity of FCR.
The fear of cancer recurrence is one of the most frequently reported problems in CS181.
The research literature indicates that FCR is currently an important area of unmet psychosocial
needs for CS1. The American Cancer Society website reports that CS commonly express
concerns with regards to FCR, especially immediately after completion of treatments204. For
example, the stress and tension induced by FCR is illustrated in the following story of a CS,
I feel like if I knew my exact chances of the cancer coming back, I could deal with it. But
when I ask my doctor, he gives me a range of statistics over a number of years. I can’t
live like this. I need more specifics205.
In previous research conducted by the first author, a CS expressed her fear of cancer recurrence
metaphorically such as, “Because parathyroid cancer has such a high recurrence, it’s like having
a Rottweiler on a short leash. Right now, I’m fine, but wary, always wary206 (p.62).” Both these
narratives from CS describe a constant sense of uncertainty and fear with regards to cancer
returning, but what both CS truly wished to know was that their cancer would never come back.
With a growing CS population in the United States and the world over, FCR is an
important psychosocial stressor that needs to be extensively researched. Further research is
needed with regards to the dimensions of FCR as well as the management of FCR throughout
survivorship . Future studies should incorporate measures of FCR and include specific activities
in psychosocial interventions e.g. FCR management in cognitive behavioral therapies (CBT) and
coping strategies for CS to manage FCR immediately post-treatment as well as over the rest of
their lifespan. This study provides evidence for the use of EW, a simple and inexpensive
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psychosocial intervention, for reducing FCR in the CS population. Another approach for
managing FCR could be providing CS with regularly updated information with regards to cancer
survival rates. Finally, epidemiological studies are also needed to provide information with
regards to the prevalence, severity and impact of FCR in the cancer survivor population.
Aim four: Hypothesis six. The sixth hypothesis was pertaining to the impact of EW on
CS self-efficacy for coping with cancer. The EW research literature suggests that writing about
ones deepest thoughts and emotions over four days gives EW participants repeated exposure to
stressful stimuli137. During the practice of writing ones thoughts and feelings, participants gain a
psychological distance from where they can process their thoughts and emotions as well as
confidence for managing their emotions when they resurface207. Thus, we posited that EW would
enhance CS self-efficacy for coping with cancer (measured using the CBI-B) over the period of
six weeks post-intervention. The results from the analyses revealed that there were no significant
differences between the EW group and control-writing groups with regards to CBI-B scores at
six weeks post-intervention. However, there was a significant effect of time for CBI-B scores in
both groups and the data indicated that there was a significant decrease in CBIB-B for both
groups immediately after the intervention (Day 7) followed by a significant increase in CBI-B
scores immediately after the intervention. The results for hypothesis six for CS self-efficacy for
coping with cancer (CBI-B) followed a similar pattern to the results for hypothesis four (PSS).
Increases in CBI-B scores for both groups at the end of six weeks could be attributed to
similar mechanisms that resulted in lower PSS scores for both groups at the end of six weeks.
Majority of participants in both groups (EW and control writing) were CS who had completed
their final radiation treatment six to eight months prior to being enrolled in this study. This phase
has been referred to as the re-entry phase of cancer survivorship, since CS must reenter their
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previously disrupted family and work lives12,15. During this transition phase, cancer survivors are
known to experience stress with regards to reassuming their life roles and dealing with daily
stressors1. During this transition period CS must also adopt coping skills and strategies over time
to handle their daily responsibilities and life roles. The data for this study indicated that both, the
EW and control writing groups, reported a significant increase in self-efficacy for coping with
cancer (and significant decrease in perceived stress) six weeks after completing their
intervention. Therefore, CS in both groups could have acquired coping strategies over the six
weeks following their writing tasks and experienced increased self-efficacy for coping with
cancer (CBI-B scores) and lower perceived stress (PSS scores) at the end of the six week period.
Another possible reason for both groups to have experienced an increase in self-efficacy for
coping with cancer (and lower perceived stress) could be that the control writing intervention
inadvertently provided CS with coping skills. The control writing condition asked CS to write
how they spent their time on four days, this writing task could have provided CS with practice
with regards to listing their daily chores, activities and stressors. Thus CS in the control writing
group could unintendedly have learned coping skills during their control writing tasks. Future
longitudinal studies are required in the CS populations which can determine the specific coping
strategies and psychosocial approaches that CS adopt over time across the survivorship phase.
Aim five: Hypothesis seven. The fifth aim of this study was related to eliciting the
effects of EW on CS stress levels immediately after the intervention. The EW research literature
consistently indicates that EW increases stress in participants immediately after the writing
tasks128,208. In hypothesis seven we expected to see higher levels of salivary cortisol in the EW
group compared to the control-writing group. However, hypothesis seven was not testable due to
the unavailability of data for baseline and immediate post-intervention salivary cortisol due to
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resource constraints, and was the only study hypothesis that was not tested.
Aim five: Hypothesis eight. In the final hypothesis of this study we wanted to determine
the effect of EW on the secondary physiological outcomes (α-Amylase and CRP; hypothesis 8a)
and the secondary psychosocial outcomes (PSS, FCRI-S and CBI-B; hypothesis 8b) of interest
immediately after the intervention (Day 7). The literature consistently reports that EW increases
stress during the intervention period128. In the course of completing the EW writing tasks,
participants re-experience their past stressful events and bring back to attention the negative
emotions associated with those stressful experiences. Therefore, EW participants are expected to
have increased psychosocial stress immediately after the EW intervention. This increase in
psychosocial stress in turn stimulates the HPA axis leading to secretion of stress hormones as
well as autonomic arousal and increased SNS activity209. Previous meta-analyses of EW have
reported small to medium effect sizes with regards to its post-intervention impacts on physical
and psychological outcomes126-128. In this study, we expected that on Day 7, the EW group will
have higher salivary α-Amylase and CRP levels (physiological outcomes) and higher PSS and
FCRI-S scores and lower CBI-B scores (psychosocial outcomes) in comparison to the control
writing group.
The results for the physiological outcomes for hypothesis eight showed that α-Amylase
was found to be significantly higher in the EW group compared to the control group immediately
after the intervention (Day 7). However, the data showed that α-Amylase was higher in the EW
group at baseline. Hence the difference in α-Amylase levels between the EW group and control
groups at Day 7 could be due to the preexisting higher levels of α-Amylase in the EW group.
Salivary α-amylase is a reflection of the immediate SNS response to stressful stimuli in human
beings and is correlated with other acute stress hormones such as adrenaline. The bio-behavioral
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research literature indicates that short-term stressors typically increase salivary α-amylase levels
in healthy as well as clinical populations164,166. Although, α-Amylase levels rose on Day 7 in the
EW group compared to the control group, no conclusive statement could be made regarding the
SNS reactivity of our sample to the EW intervention. Additional data regarding changes to αamylase levels during the day (e.g. diurnal variation) would have provided a clearer picture of
the SNS reactivity of the CS in our sample to EW. Future studies of EW should further
investigate EW’s impact on SNS reactivity by employing measures similar to salivary αamylase, e.g. adrenaline.
The second physiological outcome in hypothesis eight was salivary CRP. We assumed
that EW would increase CRP levels in CS immediately after the intervention based on the fact
that CRP is an acute phase response protein which increases within a couple of hours after the
onset of inflammation210. The results indicated there was almost no change in CRP levels for
both groups after completing their intervention. These results indicate that CRP may not be
responsive to short-term increases in stress. It is noteworthy that both salivary α-amylase and
CRP are new biomarkers in PNI research and more data are needed with regards to mediators
and moderators of their salivary secretion patterns. Also, further data are needed with regards to
the sensitivity and specificity of salivary α-amylase and CRP and their correlation with other
biomarkers of stress and inflammation. Future research is needed with regards to EW’s influence
on CRP levels in healthy and clinical populations, e.g. cardiovascular disorders.
The results for the psychosocial outcomes for hypothesis 8 showed that both groups, EW
and control writing, experienced a significant increase in perceived stress (higher PSS scores)
and fear of cancer recurrence (higher FCRI-S scores) immediately after the intervention (Day 7).
Results also described that both groups, EW and control writing, reported a significant decrease
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in self-efficacy for coping with cancer (lower CBI-B scores) immediately after the intervention
(Day 7). We had expected to find the changes in the psychosocial outcomes for CS in the EW
group only. A possible explanation for increases in perceived stress and fear of cancer recurrence
(FCR) in both groups could be that the questions in the surveys may have sensitized CS to
experience stress and negative emotions. For examples the FCRI-S asked questions such as,
“how often do you think about the possibility of cancer recurrence?” Answering questions
pertaining to stressful experiences and emotions can trigger those negative emotions in the minds
of participants. Since both participants answered the surveys at baseline (Day 2) and immediately
after the writing intervention (Day 7), participants in both groups could have been sensitized to
increased stress and FCR. Having increased in stress and FCR could also explain the inverse
decrease in self-efficacy for coping with cancer found in both groups on Day 7. Further research
is needed with regards to EW’s differential impact on specific psychosocial outcomes
immediately after the intervention. We recommend future EW studies to include psychosocial
outcomes that are closely aligned with aims of the intervention, for example in our study we
measured of severity of emotions (FCR) that were relevant to our study sample (CS).
Overall, the results from the aims and hypothesis provided partial support for our
theoretical model which posited that EW would have a stress-regulating impact for CS as
measured by their PNI outcomes. The results of this study cannot be interpreted as confirming or
disconfirming EW’s stress-regulating capacity, but instead as offering evidence for particular
assumptions while raising questions about others. Specifically, we found evidence for EW's
ability to impact cortisol secretion in saliva (HPA axis) and reduce fear of cancer recurrence in
CS during a six week period after the intervention. We support existing consensus in the
literature with regards to EW’s initial stress-inducing impact on participants immediately after
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the writing tasks, which is followed by a delayed stress-regulating influence over a six week
period128,211. Almost three decades of research have provided consistent evidence for EW as a
short-duration and low-cost intervention that can be easily administered to a variety of clinical
populations128. EW seems even more attractive with the advent of the internet and EW’s
adaptability to technology. However, more research evidence is required in the literature with
regards to the theoretical aspects of EW’s mechanisms of action. This study lends support for the
emotion-regulation theory for explaining EW’s stress-regulating effects.
Expressive Writing and Psychoneuroimmunology: Implications for Theory
A critical aspect of this study was that we wanted to understand the stress-regulating
effects of EW from the theoretical perspective of PNI. This study is one of the first studies that
employed outcome measures for all three parts of the PNI framework, which were the
psychosocial (P), neuroendocrine (N) and the immune (I) systems. The results of this study
partially supported the tripartite PNI theoretical model, see Table 32. In the first part, we
anticipated that through the process of emotion regulation, EW would help CS regulate negative
emotions (FCR). In the second part, we posited that emotion regulation impact CS
neuroendocrine response (from the HPA axis and SNS). In the third part, we expected that
neuroendocrine regulation would decrease inflammation in the immune system. We discuss
finding from our study with respect to each part of the PNI theoretical framework.
EW and psychosocial function: Emotion-regulation. The disclosure literature as well
as other clinical studies describe that EW facilitates emotion regulation through two main
processes, namely emotional habituation and cognitive reappraisal of emotions137. Emotional
habituation refers to the concept that during EW, participants repeatedly confront their negative
emotions regarding stressful experiences, thereby the physiological and possibly the perceived
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intensity of those negative emotions decreases over time137. Empirical studies of EW in the
patients having post-traumatic stress disorder (PTSD) indicate that in effective habituation,
participants initially experience strong negative emotions, with decreases in negative emotion
within and across writing sessions212-214. Results for this study lend evidence for the emotion
habituation component of EW’s emotion-regulation mechanism of action. Participants in this
study reported a significant increase in FCR immediately after their four day writing tasks, and
then a significant decrease in FCR across 6 weeks. Thus, CS showed habituation by first
experiencing high FCR after their writing and subsequently having significantly decreased FCR
after 6 weeks. This is one of the first studies of EW to measure the intensity of a negative
emotion (FCRI-S) that is specific to a cancer population (CS). We suggest future EW studies to
adopt population specific measures of the intensity of negative emotions and demonstrate
habituation by collecting longitudinal data.
The second component of emotion-regulation theory involves the cognitive reappraisal of
emotions. The cognitive reappraisal of emotions describes that during EW, participants must
actively face and process negative emotions which could strengthen their self-efficacy for
managing those negative emotions137,215. Also, EW provides participants with psychological
distance to view their stressful experiences and a lens from which they can observe themselves
better understand, validate and accept their emotional reactions and to those stressful
experiences137. Previous research of supportive-expressive group therapy for cancer patients has
reported that disclosing emotions related to their cancer and fears of dying during group therapy
sessions improved cancer patients self-efficacy to manage those emotions216. In this study we
found that inconclusive results with regards to EW’s ability to improve cancer patients selfefficacy for coping with cancer (measured using the CBI-B). However, the data did indicate a
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significant effect of time on self-efficacy for coping with cancer. CS who participated in EW had
lower CBI-B scores immediately after the intervention and significantly higher CBI-B scores six
weeks after completing EW. This study lends limited support to the cognitive reappraisal
component of EW’s emotion regulation mechanism of action. Future studies of EW should
incorporate measures of self-efficacy for managing emotions and test the duration to which EW
helps participants improve self-efficacy for coping with cancer.
EW and neuroendocrine function: HPA axis and SNS. The psychophysiological
effects of EW have been well documented in an extensive body of research128. EW has been
shown to have wide-ranging effects on the nervous system and related hormones and
neuropeptides as well as associated effects on the cardiovascular system217. Research evidence
demonstrates that EW affects cortisol and epinephrine secretion, heart rate, blood pressure and
heart rate variability127. The most extensively studied stress-response pathway in PNI research
has been the HPA axis218. In this study we employed salivary cortisol as our primary outcome
measure indicating HPA axis activity. Based on findings in previous research, we expected that
EW would manifest its stress-regulating effects in CS over a period of six weeks. The results
from this study showed that EW was successful in regulating the stress-response from the HPA
axis in CS demonstrated by significantly lower salivary cortisol levels in EW group CS
compared with control writing group CS. This study provides support to the growing evidencebase for EW’s neuroendocrine effects.
The impact of EW on the HPA axis can be explained as a resulting effect of the
emotional habituation described above. The evolution of the HPA axis is specifically related to
fear and the fight or flight response219. Human beings evolved the fight or flight response to deal
with stimuli that threatened our survival during early evolution, such as wild animals. This
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neurobiological fight or flight response is activated by fear emotions leading to chronic stress
which keeps the HPA axis activated. This leads to higher levels of blood cortisol which has
negative impacts on multiple systems in body including the immune system. During EW
participants repeatedly confront and re-experience their negative emotions which leads to
desensitization and habituation. Also, EW helps participants gain more self-efficacy to manage
their emotions. This study demonstrated that EW significantly lowered the negative emotion of
FCR as well as lowered cortisol in CS over a period of six weeks, see Table 32. This study is an
important contribution to the literature which demonstrates in the same study that EW was
effective in regulating negative emotions (FCR) as well as HPA axis activity which will further
our understanding of EW’s mechanism of action. Future studies should investigate dose-response
effects of EW intervention on the HPA axis.
Evaluating dose-response effects of EW on the HPA axis. Studies of other psychosocial
interventions involving emotional disclosure such as supportive expressive-group therapy and
cognitive behavioral stress management (CBSM) have shown that emotional expression has been
successful with reducing serum cortisol levels in cancer patients95,220. Moreover, participants that
had greater involvement in emotional expression (e.g. lower repressive defensiveness and greater
expression of negative emotions) during group therapy had steeper cortisol slopes among
metastatic breast cancer patients78,221,222. Meta-analyses of EW have also indicated to a doseresponse association between EW and health outcomes127,128. This study supports previous
research indicating that the HPA axis is most responsive to psychosocial interventions208,223. An
average dose-effect of EW was not estimated in this study since limited measures were employed
to reduce patient burden. Moving forward, quantitative evidence is needed with regards to doseresponse associations between a) type of EW intervention, b) extent of involvement in EW, c)
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duration of EW intervention and d) PNI outcomes, that can help guide clinical decisions
regarding implementing EW in the therapeutic setting. Therefore, future studies should employ
data collection procedures to assess dose-response effects of EW interventions in persons with
cancer.
An innovative aspect of this study was that we also measured the impact of EW on the
SNS by assessing salivary α-Amylase in CS. However, data revealed no significant stressregulating effects of EW on salivary α-Amylase in CS. As described above, this may have been
because the SNS is a pathway that is more responsive to acute stress and not as responsive to
chronic stress stimuli. This finding suggest that perhaps EW’s habituation and cognitive
restructuring may be psychological mechanisms that are successful in reducing burden from
chronic stress stimuli such as FCR and not acute stress stimuli. However, EW studies in healthy
participants have demonstrated that the cardiovascular system, which is innervated by the SNS,
is response to EW224. The negative results with regards to sAA in our study may also be
attributed to the fact that sAA is a relatively new biomarker in bio-behavioral clinical research
and data regarding its sensitivity and specificity needs further investigation. Further research is
needed with regards to EW and SNS activity and we encourage researchers to use biomarkers of
both HPA and SNS axes to provide a comprehensive picture of EW and stress reactivity.
EW and immune function: Inflammatory response. Studies of EW have shown to
impact all aspects of the immune system. Major advances in immunology research over the past
decades have allowed researchers to measure various components of the immune system. At the
broadest level, the immune system in humans consists of a) innate immunity, which includes
cells (e.g. natural killer cells) inherently present to provide an immediate, but non-specific
response against toxins or microorganisms, and b) adaptive immunity, which adapts its response
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to the specific toxins or microorganism to improve detection and has two components, namely
humoral immunity (mediated by antibodies generated by B lymphocytes) and cell-mediated
immunity (mediated by T lymphocytes). The earliest research evidence with regards EW’s
impact on the immune system comes from the landmark EW study in college students that
demonstrated that EW increased the mitogen-induced T-lymphocyte responses (adaptive
immunity: cell-mediated)130. Similarly, other studies of EW in college undergraduates have
found immune impacts of EW on antibodies against Epstein-Barr virus (EBV) and hepatitis B
antigens, as well as in HIV positive patients EW demonstrated an increase in CD4+ T
lymphocytes (adaptive immunity: humoral)131-133. With regards to EW’s impact on innate
immunity, research has found that an EW intervention in patients with depression and anxiety
patients decreased natural killer (NK) cell activity (innate immunity: NK cells)225.
However, due to the complex nature of the immune system it is difficult to establish
whether EW can actually enhance or boost immune function but rather that EW has the ability to
influence immune behaviors in varied ways. Additionally, due to the heterogeneous immune
profiles of EW study populations makes inferences regarding EW’s impact on immune function
problematic. For example, cancer patients and CS have different immune profiles than HIV+
patients and healthy individuals and the results of EW’s influence on different immune profiles
may not comparable. Results from this study indicate that EW was unsuccessful in affecting the
immune system of CS which was measured by salivary CRP. Although CRP has been regularly
used as an measure of inflammation, testing CRP levels in saliva is a relatively new biomarker of
the immune system. CRP is an acute phase reactant and is considered to be a link between innate
and adaptive immune systems. Further research is needed with regards to EW’s influence on the
immune pathways of cancer patients and CS. Past research indicates that participants that had
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greater involvement in the EW disclosure process had a greater immune response. Future studies
need to specifically explore the extent to which participants involve themselves into the EW
process as well as individual differences in immune profiles of participants.
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Table 32: Expressive writing and the theoretical framework of PNI
Psychosocial
Intervention

Theoretical framework of Psychoneuroimmunology (PNI)
Psychosocial (P)

Expressive
Writing

Neuroendocrine (N)

Immune (I)

Psychosocial Stress
Neuroendocrine system
Immune system

BOM (Day 2)
Writing (Day 3)
Writing (Day 4)
Writing (Day 5)
Writing (Day 6)

Respective Outcome Measures
PSS
FCRI-S
CBI-B

Cortisol
α-Amylase

C-Reactive Protein (CRP)

Possible Mechanisms of Action

POM1 (Day 7)
Emotion Regulation

Habituation/
Desensitization

Regulation in secretion of inflammatory
molecules of the immune system

Insight

POM2 (Day 49)

14

Regulation of neuro-hormonal
response from HPA and SNS axes

Results after the intervention14
Psychosocial

HPA Axis

SNS Axis

Immune system

(X) PSS
(↓) FCRIS
(X) CBIB

(↓) Cortisol

(X) Amylase

(X) CRP

(↑) Significantly higher or (↓) significantly lower in intervention group compared to control group
(X) No significant differences between intervention and control groups
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Recommendations for validating the PNI causal framework. This study provided
partial support for the theoretical framework of PNI to explain the effects of the psychosocial
intervention, EW in our sample of CS, see Table 32. In order to advance the science and theory
of psychosocial interventions such as EW it is critical for researchers to understand the
mechanisms of action of psychosocial interventions by using PNI as a causal theoretical
framework. In general, we encourage researchers in this field to pay greater attention to
methodological and implementation aspects of PNI-based psychosocial interventions for cancer
patients and survivors. We suggest that future studies of EW and other psychosocial
interventions can improve validity of evidence for the PNI causal theoretical framework by 1)
employing outcome measures related to PNI processes, 2) defining the direction of change in
PNI outcomes, 3) demonstrating statistical interactions between PNI subsystems, 4) accounting
for missing data for PNI biomarkers, 5) collecting data regarding integrity of biomarkers
collection procedures, 6) preventing publication bias: reporting negative results.
1. Employing outcome measures related to PNI processes. In the literature review for this
study we noted that very few studies of psychosocial interventions specifically used outcome
measures that were the focus of their intervention, such as the insomnia management cognitivebehavioral intervention.121 In studies of PNI-based psychosocial therapies, different types of
psychosocial factors may trigger differential PNI responses and several other external factors can
influence the findings of a particular study69. An innovative aspect of this study was that we
employed relevant outcome measures for all three parts of the PNI framework and measured the
impact of EW on both the HPA axis and SNS. We recommend future studies also employ PNI
measures associated with the specific aims of the study and measure all three aspects of the PNI
framework. This will provide research evidence for PNI as a causal theoretical framework for the
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stress-regulating effects of psychosocial interventions such as EW. Testing all three parts of the
PNI framework will also assist future reviewers who can collectively appraise findings across
studies that use PNI process related outcomes and provide a comprehensive understanding of the
PNI effects of psychosocial intervention across cancer populations including cancer survivors.
2. Defining the direction of change in PNI outcomes. In our literature review we noted
that some studies did not clearly report the direction in which they expected their PNI outcome
measures to change. Postulating a trend in PNI outcomes is difficult in the cancer population,
because factors such as stage of disease and treatment variations (e.g. chemotherapy vs.
radiation) can affect PNI measures, particularly immune outcomes.90,226 In this study we defined
the direction of change for each PNI outcome measure and conducted one-tailed hypothesis
testing. However, as explained above the neuroendocrine-immune systems are very complex to
interpret and future intervention studies using PNI outcomes should clearly define the expected
direction of change with regards to neuro-immune outcomes. Also, large scale epidemiological
evidence for the normal average levels of PNI measures across specific populations is needed to
enable researchers to make decisions about the expected direction of change in PNI outcomes.
3. Demonstrating statistical interactions between PNI subsystems. In this study we
conducted statistical analyses to determine average differences in PNI outcome measures
between the EW group and control groups. Due to limitations with regards to study design, we
did not conduct statistical analyses to test for interactions among the three subsystems of the PNI
framework. Recent advances in statistical modeling (e.g., structural equation modeling and
hierarchical linear modeling) can help researchers make better inferences with regards to
interactions among multiple variables and components of PNI framework. We recommend future
researchers identify mediators and moderators of the PNI outcomes of psychosocial interventions
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to understand their mechanisms of action.207,227 Forthcoming studies of psychosocial
interventions should attempt to demonstrate changes in psychosocial outcomes measures to
predict changes (or show associations) in neuroendocrine-immune biomarkers over time to
provide evidence for their mechanism of action. Studies should also attempt to measure the
strength of association between level of participation in psychosocial interventions (e.g. extent of
involvement in disclosure interventions) and PNI outcomes.
4. Accounting for missing data for PNI biomarkers. In this study we did not encounter
any significant missing data with regards to completing the saliva measures for testing PNI
biomarkers. However, we did encounter problems with maintaining our original sample size,
which has also been reported in other studies of PNI-based psychosocial interventions, where
studies were able to collect PNI biomarkers from only a smaller subset of their original sample.
Having a smaller sample size to report certain outcomes, such as PNI biomarkers, can decrease
the power of the statistical tests used to report results of those outcomes.89 However, since PNI
biomarkers need to be collected over multiple time points, sometimes blood draws, studies of
PNI-based psychosocial therapies are faced with the likelihood of having missing data. Hence,
future interventions should account for attrition and missing data during their power analysis
(e.g., by oversampling) stage and establish a plan for handling missing data.
5. Collecting data regarding integrity of biomarkers collection procedures. In this study
we also encountered a high degree of compliance with the collection procedures for saliva.
However, since the data were reported by participants, there was no other way of verifying the
validity of the participant’s responses. Other psychosocial interventions have used similar ways
of checking adherence to the PNI-measurement protocol; for example, one study gave
participants wrist watches with preset alarms and asked participants to record the time when they
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provided saliva samples on measurement tracking forms.114 Researchers should be aware of
more sophisticated ways of collecting protocol adherence data, such as the use of MEMS™ IV
tracking caps on the saliva collection containers which have microcircuits that record times and
dates.118 Research shows that considerable methodological variation exists in relation to timing
of collection PNI biomarkers, for example diurnal variations in cortisol production.161 Therefore
forthcoming research should employ more rigorous ways of collecting data with regards to
assessing the integrity of measurement protocols regarding time-sensitive PNI-based outcomes.
6. Preventing publication bias: Reporting negative results. It is important for researchers
to note that there continues to be discordance in the literature with regards to interpreting results
related to the neuroendocrine-immune effects of psychosocial interventions for cancer patients.
A systematic review of PNI-based psychosocial interventions for breast cancer patients
published in 2009 concluded that there is evidence to suggest that cognitive-behavioral therapies
impact neuroendocrine and immune measures.64 However, other researchers that reviewed the
same literature published a critical review in 2010 reporting that the evidence for psychological
interventions having clinically significant impacts on the immune function of cancer patients is
still “limited and unconvincing.”228(p21) Therefore, it is important that researchers report negative
findings with regards to the PNI effects of psychosocial interventions to avoid publication bias
for positive results and the resulting file drawer effect229.
Study Limitations
This study does have some limitations that need to be acknowledged. The first area of
limitations is related to the outcome measures for this study. The primary outcome of this study
was salivary cortisol and due to limitations in financial resources, we could not estimate the
baseline and immediate post-intervention values for salivary cortisol. Although, we found that
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salivary cortisol was significantly lower in EW group compared to the control group, the
inferences that can be made from the results regarding our primary outcome are limited due to
the absence of baseline and Day 7 measures. Furthermore, although the use of salivary measures
provides a non-invasive approach, it also comes with methodological and practical problems. For
example, even a subclinical oral infection can affect levels of salivary biomarkers, especially
CRP161,230. We tried to eliminate this limitation by educating participants with specific details
about oral hygiene prior to collecting saliva, see Appendix K. Also, measures of cancer
participants’ health behaviors, e.g. food habits, exercise, that could be potential moderators of
PNI outcome measures, were not obtained in this study.
The second area of limitations in this study is related to the sample characteristics of this
study. We chose a very specific and narrow cancer population for this study, which was CS that
were disease-free and in the re-entry phase of survivorship (2-12 months post-radiation). These
restrictive sampling criteria for this study limit the generalizability of the findings to wider
clinical populations. Also, due to lower than expected recruitment rates, the sample size for this
study was small. A larger sample size would have also possibly increased the diversity of our
sample with regards to variables such as age, gender, race, type of cancer. Furthermore, due to
the technology component of the EW intervention we may have excluded participants who were
unable to use computers and the internet and would have benefited from EW using a paper-andpencil format. However, data regarding access to the internet and computers has shown a
consistent upward trend towards internet usage and device ownership across all segments of the
population, regardless of race, income and age. Also, initiatives such as the “PC PLEDGE 100”
from public-private institutions such as the Federal Communications Commission (FCC)231 has
called for corporations to recycle and divert computers to help low-income families get online.
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Therefore, we expect internet-based interventions such as the one used in this study will soon be
widely available to marginalized and underserved individuals and populations as well.
“Lost in Transition:” Cancer Survivorship and Coping with Cancer
The numbers of cancer survivors in the United States and the world over have been
consistently increasing due to advances in early detection and treatments. Patients with cancer
are now progressively more likely to survive and participate in their normal work and family
lives, with almost 70% of patients with cancer surviving five years beyond their initial cancer
diagnosis. Every year there will be a million new cancer patients that join the existing population
of 13.7 million cancer survivors who are alive today2. These cancer survivors are faced with
several physical as well as psychological and social (psychosocial) problems and limitations
during their transition from after completing treatments to reassuming their roles in work and
family. Health organizations such as the American Cancer Society (ACS), CDC and IOM have
repeatedly advocated that researchers, health practitioners and policy makers in the oncology
setting need to raise awareness of and attend to the unmet psychosocial needs of cancer
survivors1. In this study we attempted to advance the IOM’s recommendations with regards to
taking steps to improve the science and delivery of psychosocial interventions and identifying
ways to link cancer patients and providers with appropriate psychosocial interventions.
What are the psychosocial health needs of cancer survivors? Cancer has a unique
psychosocial impact on patients different than other chronic illnesses and challenges individuals
on their mental, emotional and social levels as well raises spiritual and existential questions in
afflicted individuals. Every phase of the cancer care trajectory, from diagnosis and treatment to
survivorship or palliative care, poses exceptional tribulations with regards to the psychosocial
health of cancer patients. Patients transitioning from completing their treatments to long-term
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follow-up, referred to as cancer survivors in this study, are at high risk for experiencing stress
and were the focus of this study. Cancer survivors are faced with the early, late and long-term
impacts of cancer diagnosis and treatments on their physical and psychosocial well-being
through the rest of their lifespan. Psychosocial health issues in cancer survivors include stress,
angry rumination, depression, loneliness, fear of cancer recurrence as well as sleep related
problems such as insomnia or hypersomnia1.
The incredible complexities of the psychosocial health needs of cancer survivors can
grasped to a certain degree by studying cancer survivors experiences, such as the following quote
of from a cancer survivor who had just finished her last radiation treatment,
After my very last radiation treatment for breast cancer, I lay on a cold steel table
hairless, half-dressed, and astonished by the tears streaming down my face. I thought I
would feel happy about finally reaching the end of treatment, but instead, I was sobbing.
At the time, I wasn't sure what emotions I was feeling. Looking back, I think I cried
because this body had so bravely made it through 18 months of surgery, chemotherapy,
and radiation. Ironically, I also cried because I would not be coming back to that familiar
table where I had been comforted and encouraged. Instead of joyous, I felt lonely,
abandoned, and terrified. This was the rocky beginning of cancer survivorship for
me232(p479).
Other stressors for cancer survivors include follow-up clinical appointments and medical tests
which often have wait times ranging from several days to weeks for laboratory confirmation. In
previous research conducted by the first author, these wait times have been metaphorically
described by cancer survivors as “torture” and being on a “roller coaster”206. Thus, cancer
survivors have several psychosocial health needs with regards to reducing stress and negative
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emotions and managing uncertainty. We urge patient advocates, health researchers and
professionals to recognize that cancer survivors have unique psychosocial health needs during
the survivorship phase. Therefore, we support the ACS and IOM’s recommendations with
regards to defining cancer survivorship as a separate phase of cancer care and taking measures to
address the specific psychosocial needs of cancer survivors1.
How do we address the psychosocial health needs of cancer survivors? An important
first step in addressing the psychosocial health needs of cancer survivors is raising awareness
about psychosocial health needs of cancer survivors amongst oncology care providers. The
medical management of cancer is very complex and demanding for oncology care providers who
primarily consider clinical outcomes such as the cancer cell morphology, possible metastases,
grading and staging the cancer and monitoring the response to specific doses of the cancer
treatments. However, health outcomes that are important to patients may include quality of life
and subjective well-being233. The oncology-care literature indicates that while from the
physicians’ perspective the end goal is the cancer free patient, what the patient is experiencing
during and after treatments seems insignificant and is often ignored by care providers3. Thus,
there is a discrepancy between the health outcomes that oncology care providers are concerned
about and the outcomes valuable to patients. We recommend care providers to consider patientcentered outcomes in addition to clinical outcomes during cancer treatments and most
importantly during cancer survivorship. In the current team-based model of oncology care, we
recommend oncology care providers to include staff trained in dealing with psychosocial issues
such as psychologists or social workers. Also, psychosocial interventions that can bridge the gap
between the world-view of the oncology-care providers and perspective of the cancer survivors
are needed.
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Psychosocial interventions for cancer survivors: Expressive writing. In our literature
review we identified two major categories of psychosocial interventions for cancer patients, a)
cognitive-behavioral and b) complementary medical. We chose expressive writing (EW) as a
psychosocial intervention (from the cognitive-behavioral interventions group) for reducing stress
in cancer survivors transitioning of their final radiation treatment. Several aspects of the
expressive writing intervention are discussed below which make it an appropriate psychosocial
intervention for cancer survivors during survivorship care.
EW: Brief and inexpensive. A very convenient feature of EW is that it requires limited
resources with respect to time and administration. Typically EW interventions require a total of
1.3-2 hours over four days (20-30 min per day) without any need for booster sessions. This short
duration is appealing for cancer survivors who may not have large blocks of time to spare for
stress-management interventions. Moreover, EW can be administered in almost any setting, from
home to classrooms as well as in-patient and out-patient clinical settings. This makes EW very
adaptable to relevant environmental constraints. In this study we administered EW online, so CS
did not spend time travelling to the place of intervention. Also, since EW involves participants
responding to written instructions, EW requires minimal training and input from trained health
professionals making it a low-cost intervention. In this study we did not require any trained
health professionals for administering EW to cancer survivors, although we had a licensed
clinical social worker on our team to address any possible adverse situations. Our literature
review found that one study consisting of only three hours of therapeutic interaction with a single
psychologist116 demonstrated significant changes in immune outcomes. Further research is
needed to investigate other brief and inexpensive psychosocial interventions involving
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expressive disclosure for cancer survivors as well as future studies need to define EW’s
minimum and maximum dose response effect for impacting physical and psychosocial outcomes.
EW: Coping with cancer. Due to rapid advances in cancer prevention, early detection and
management, cancer is now considered to be more of a chronic disease rather than an acute lifethreatening condition234. Thus coping with cancer on a long-term basis is an essential aspect of
living as cancer survivor. After patients with cancer learn to cope with stress of diagnosis and
treatment, as cancer survivors they must now learn to cope with loneliness and fears of cancer
recurrence. Studies of coping strategies in cancer survivors have shown that survivors use
strategies such as a “fighting spirit” attitude, social support, religious faith and spirituality to
cope with cancer during survivorship235. Expressive writing, as a medium, can help patients cope
with cancer through problem-focused coping as well as emotion focused coping. The research
literature suggests that interventions which allow patients to read clinical experiences of other
patients form a basis for making informed decisions about treatments and follow-up care236.
Also, studies show that reading about cancer survivorship stories about individuals who were
diagnosed with cancer and who are now successfully cured and living normal lives can decrease
cancer survivors anxiety and improve coping237,238. Thus EW interventions that can connect
communities of cancer survivors will help provide CS with health information (problem-focused
coping) as well as provide a sense of social support (emotion-focused coping). Previous research
indicates that cancer survivors describe benefits of expressing their emotions during the writing
process, for example, at the conclusion of completing their writing a CS wrote “I realize this
story was disjointed and rambled on, but it felt good to get off my chest” 206(p.85). Results from
this study found that cancer survivors that participated in EW had a significant decrease in their
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fear of cancer recurrence and further research is needed with regards to EW’s coping function in
CS.
EW: Health benefits. The positive health benefits of EW have a growing evidence-base in
the research literature. EW has shown effects on all types of health outcomes, ranging from selfreported symptoms and psychosocial outcomes such as depression to neuroendocrine and
immune outcomes such as CD4+ T cells127,239. Also, beneficial health effects of EW are
consistent across study populations that include healthy individuals as well as diverse clinical
populations such as, HIV+ patients, cancer patients and survivors, and patients with asthma,
autoimmune and cardiovascular disorders127,128. The results from this study adds to the research
evidence for EW’s health benefits specifically for the cancer survivor population. CS are
particularly at risk for experiencing stress during their transition phase which is approximately 218 months after completing all treatments223. We found that expressive writing was successful as
a stress-management intervention during this transition phase and CS who participated in EW
had significantly lower levels of cortisol (regulation of HPA axis response) and reported lower
fear of cancer recurrence (FCR) in the six weeks after completing their EW intervention. Further
efforts from researchers and practitioners are needed to study the health benefits of EW
specifically for CS and deliver EW interventions as part of cancer survivorship care.
EW: Building relationships between care-providers and cancer survivors. Currently the
health care system is failing to understand cancer survivors’ experiences and psychosocial needs
by not including expressive disclosure interventions such as EW in oncology care. Several
institutional and pragmatic limitations prevent oncology care providers from understanding the
psychosocial needs cancer survivors and identifying health outcomes important for cancer
survivors. Expressing emotions and experiences related to cancer is a time-consuming and
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demanding task that care providers may not prioritize in their schedules. Expressive writing is a
very practical tool that can enable oncology researchers and care providers to better understand
the psychosocial needs of cancer survivors. Cancer survivors can write about their stressful
experiences at their own convenience and time, and then present them to their oncology care
providers for their perusal. The oncology care providers can learn valuable information with
regards to the patient experience of survivorship including stressors and issues that concern
cancer survivors and identify specific health outcomes important for cancer survivors during
survivorship. These expressive writing narratives can also provide a lens through which
researchers and oncology-care providers can vicariously experience the world of cancer
survivors. Future research should also measure the benefits of incorporating EW interventions
for the oncology care providers in addition to benefits for cancer survivors.
EW service delivery: Adaptable to technology and the internet. One of the most dramatic
revolutions in modern times with regards to individual lifestyles and societies at large has been
the advent of computers and the internet. In a less than three decades since the internet was first
offered to the public by internet service providers (ISPs), the world has transformed into a global
village allowing for human interaction to occur in cyberspace, which include psychosocial
interventions. Researchers and professionals have been increasingly using the internet to deliver
psychosocial interventions for patients with cancer and have encouraged other researchers to
view the internet as an accessible and increasingly popular medium for reaching diverse cancer
populations149. Patients with cancer have reported that internet-based interventions are
acceptable and feasible. However, in our literature review we found only two studies used
communication technology to deliver their interventions to cancer patients which were through
telephone conversations105,118. An innovative aspect of this study was that we adapted the paper-

155

pencil format of EW to an online format which was delivered using the survey software
Qualtrics.
There are several advantages to using the online format of EW for cancer survivors. After
completion of treatments, CS generally have follow-up appointments that range from three to six
months post-treatment. During this time most CS experience fears and uncertainty and do not
have ready access to their health care team. In this transition phase, internet-based EW
interventions can easily be made accessibly to CS which can help them express their thoughts
and emotions. This will help ease pent-up anxiety and stress in CS as well as reconnect them to
their health-care team. The EW essays will inform the survivorship-care team with regards to
symptoms and concerns of CS. Thus, internet-based EW is a very simple and accessible way for
the health-care team to deliver follow-up care to CS during survivorship. Our internet-based EW
study was successful in reducing stress measured by lowered salivary cortisol and fear of cancer
recurrence in cancer survivors 2-12 months post- radiation. However it is important to note that
our study sample was predominantly well educated and higher income cancer survivors who had
access to a computer and the internet. The ability and willingness to disclose experience in
written format online could be attributed to the higher educational and socio-economic level of
our sample. Future studies should also include oral expressive disclosure prompts to participants
from diverse educational and socio-economic strata through the internet or by phone.
Important areas of concern with regards to internet-based EW interventions are audience
responsiveness to the EW essays and data privacy. Research has shown that patients may alter
the content of the EW essays based on the audience that is going to read their narratives. EW
studies for CS should clearly inform participants as to which personnel will read their essays.
Another are of concern is with regards to data privacy. The conversation with regards to internet
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privacy continues to concern data providers as well as lawmakers and intelligence agencies. The
revelations by whistleblower Edward Snowden with regards to the National Security Agency
(NSA) surveillance240 occurred during the recruitment phase of this study. One potential
participant for this study expressed concerns with regards to data privacy issues and reported a
mistrust with the government and associated agencies. We urge researchers to pursue defining
specific guidelines to ensure confidentiality and privacy of data when adapting psychosocial
interventions to the internet. Thus, several challenges remain for introducing EW into
survivorship care and making psychosocial interventions part of the standard of cancer care.3,241
Psychosocial Interventions in Cancer-Care: Preparing the Health Care System
A comprehensive and well-organized approach towards post-treatment survivorship care
is essential. The IOM has described that introducing psychosocial interventions for CS in the
standard of cancer-care is faced with some major challenges. These challenges include 1)
deficiency of health care professionals that specialize in care for CS, 2) immense diversity in the
in psychosocial interventions and insufficient evidence-based guidelines for designing and
delivering care for CS and 3) inadequate reimbursement for clinical and therapeutic services. In
this section we discuss some steps to address these challenges in the immediate future.
Education and training for health professionals. This study concurs with the IOM’s
concern with regards to the lack of standardization in education and training materials for the
wide variety of health professionals involved in psychosocial health interventions and services
for cancer patients3. Psychosocial health professionals range from oncologists and physicians to
nurses, social workers, psychologists and counselors. It is difficult to estimate the demand for
psychosocial health services due to the lack of available data. Presently, comprehensive cancercare centers have instituted guidelines and standards for health-care professionals to address
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psychosocial issues in CS and providing CS with survivorship care plans242. However, these
standards are ambiguous and do not define the specifics with regards to how these educational
standards will be translated into credit hours, methods, or the delivery of survivorship care242,243.
A first step towards addressing the gap in psychosocial care for CS is to raise awareness about
CS unmet psychosocial needs amongst oncology care providers and primary health providers.
We also recommend comprehensive cancer centers to design specific training modules for health
professionals interested in specializing in psychosocial oncology care and service delivery for
CS. Finally, we suggest that knowledge and skills required for the management of psychosocial
problems of CS during survivorship care be introduced immediately within the current standards
for educational accreditation and licensure by way of additional curricula and continuing medical
education credits.
Defining evidence-based guidelines for intervention studies. An important deficiency
in the psycho-oncology literature is the absence of evidence-based guidelines for developing
psychosocial interventions for diverse cancer populations. Defining guidelines for the
psychosocial management of cancer is more complex and difficult than it is for well-defined
discrete chronic diseases such as asthma, diabetes, or heart disease. For example breast cancer
has a considerably different psychosocial impact on patients than prostate or lung cancer.
Furthermore, the particular psychosocial health care needs may vary for cancer survivors with
regards to specific cancer sites (breast versus bone), stage of survivorship (re-entry versus longterm survivorship) and type of cancer treatments (chemotherapy versus radiation). Provided that
there exist more than a hundred different types of cancer, defining generalized guidelines for
particular psychosocial interventions is problematic since their efficacy can differ based on
cancer site, stage and treatments. In this study we chose a cancer survivors 2-12 months post-
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radiation since they were at risk for post-treatment stress and were an understudied cancer
population. Our literature review uncovered a wide range of psychosocial interventions that
could be beneficial to cancer patients. The results of this study found promising but incomplete
evidence for EW as psychosocial intervention for reducing stress in cancer survivors.
We recommend that future studies of psychosocial interventions in cancer survivors, that
employ PNI outcomes, should consider: a) clearly defining activities and therapies involved in
the intervention; b) specifying duration of the interventions and time estimated for each session,
including time for booster session(s); c) considering the timing of the intervention delivery with
regards to treatment regimens (i.e. chemotherapy/ surgery); d) monitoring adherence to the
intervention protocol; and e) evaluating sustainability of the intervention in routine clinical
practice. We also urge researchers and policy makers to take action on the IOM’s
recommendation for developing “standard outcome measures”3(p15) for evaluating the efficacy of
psychosocial therapies and services for cancer patients. Collaborative interdisciplinary efforts
are needed to use similar approaches with regards to descriptions of the cancer populations,
psychosocial interventions (including components and activities involved), psychometric
instruments for psychosocial functions, and biomarkers for bio-behavioral outcomes (e.g.
neuroendocrine-immune). Such efforts will contribute towards building a convincing empirical
evidence-base for the effectiveness of PNI-based psychosocial therapies for cancer survivors.
Policies for reimbursing psychosocial services. As described above there are a wide
variety of services and health professionals that provide psychosocial services for CS.
Reimbursements for these psychosocial services are difficult due to the regulations that restrict
insurance payments to health professionals. These restrictions make it difficult for psychosocial
health service providers to be in same physical location as clinical and surgical oncology
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professionals. The IOM also states that due to the low quality of health care, simply improving
reimbursement will not improve health care services, and additional initiatives are needed such
as quality measurement and improvement activities3. We urge policy makers to include
provisions for psychosocial health care services and interventions for cancer patients and
survivors. Recent changes in health policies are encouraging for increasing the availability and
reach of psychosocial health services in the cancer survivor population.
The Patient Protection and Affordable Care Act (PPACA) has the potential to deliver one
of the greatest expansions of coverage for psychosocial health services in a generation by
requiring that most health insurance plans on the Health Insurance Marketplaces (HIM) to cover
mental health services244. There are new requirements in the law (in the Mental Health Parity and
Addiction Equity) that provide benefits for mental health services and expand protections for
behavioral health to 62 million Americans. Starting in 2014 most health insurance plans will not
be able to deny coverage because of a pre-existing mental illness. Also, the PPACA aims to
reduce cancer-care disparities by expanding coverage for Medicaid and eliminating previous
barriers to health coverage244. Also, the PPACA mandates that health coverage must now include
preventive mental health services like depression screening for adults. In future steps, we
recommend policy makers outline protections for specific health services, such as survivorship
care for defined patient populations, for example CS. We also support policies that will provide
guidelines for reimbursement with regards to health professionals, service providers and insurers
involved in survivorship care and for delivering comprehensive survivorship care plans for CS.
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Chapter VIII. Conclusion
In this study we found that a simple and inexpensive online expressive writing (EW)
intervention was successful in reducing stress in cancer survivors post-radiation. This study
provides evidence for the potential efficacy of delivering online EW online to cancer survivors
during survivorship care to aid in stress-management. This study supports to the movement
towards integrative models of cancer care which seeks to synthesize evidence-based therapies
that concurrently address the physical as well as psychosocial-spiritual needs of cancer
patients.245,246 We also support the IOM’s appeal for designing a framework to develop and
provide cancer care for the whole patient.
Bio-psychosocial Model of Health: Providing “Cancer Care for the Whole Patient”
Several historic social-cultural factors in the science and research community favor
investments for research and development for therapies impacting “hard” therapeutic outcomes
such as tumor growth as opposed to “soft” psychosocial outcomes such as quality of life247. This
bias towards investing primarily in technology driven inventions is demonstrated is by the
breakthrough innovations in cancer detection and cancer treatments such as targeted
chemotherapy and robotic surgery, as opposed to only marginal advances in the science and
delivery of psychosocial interventions3. However, the turn of the 21st Century has given way to a
considerable transformation in the understanding of disease and health care, particularly in the
oncology setting. In 2001, a National Research Council (NRC) Committee on Health and
Behavior overwhelmingly supported the bio-psychosocial model of health by concluding that
“health and disease are determined by dynamic interactions among biological, psychological,
behavioral, and social factors,”248(p16) and discussed implications of the science of stress and
psychoneuroimmunology for patients with cancer. In less than a decade after that report, in 2008,
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the IOM recommended psychosocial health interventions and services should be a part of the
standard of cancer care and emphasized the unmet psychosocial needs of cancer survivors3.
Furthermore, in the past decade health organizations such as the IOM, NCI and ACS
have made significant efforts to raise awareness with regards to cancer patients psychosocial
needs and have highlighted the need to include patient-centered outcomes in health decisionmaking. The PPACA helped institute the patient-centered outcomes research institute (PCORI)
which aims to conduct research guided by patients, family members and caregivers, and the
wider healthcare community to improve health decision-making, delivery and outcomes249. The
PNI framework and the bio-psychosocial model of health have the potential to provide a bridge
between clinically relevant outcomes and patient-centered outcomes. Furthermore, the biopsychosocial model of health can also serve as a framework for interdisciplinary collaborations
between stakeholders, social scientists, health professionals and policy makers. We will use the
results from this study to inform health practitioners, researchers and policy makers interested in
evaluating the use of psychosocial interventions such as expressive writing in the standard of
cancer care. It is critical that we encourage conversations with regards to including patientcentered outcomes in cancer survivorship research and encourage lawmakers to provide better
protections for patients during survivorship care.
Dissemination Plan
The results from the literature review conducted in preparation for this study have been
published in the peer-reviewed international journal, Integrative Cancer Therapies197. The
diffusion of findings from the results of this study research will be reported to cancer survivors,
health practitioners, policy makers and the scientific community at large. We will present the
findings from this study in the format of seminars and presentations for community oncologists
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and mental-health professionals including the oncology-care staff and researchers at VCU
Massey Cancer Center (MCC). We will also conduct awareness workshops to educate
community health professionals with regards to stress-management interventions for cancer
survivors and encourage researchers at MCC to introduce psychosocial interventions to reduce
stress in their oncology practice. The findings of our study will be reported in a manuscript and
submitted to a peer reviewed medical journal. We will also notify the science media about our
study by contacting popular media outlets (e.g. Psychology Today) and freelance science
journalists and reporters. The protocol for expressive writing will be provided to the science
media, who can provide the writing prompt to readers in their article or give an online link the
study protocol.
Findings from our study will be reported to the office of survivorship at the NCI. We will
inform the American Cancer Society’s cancer survivor network (CSN) with regards to our study
and educate them about the possibility of conducting online expressive writing groups for cancer
survivors during their survivorship care. We will also inform site administrators of online cancer
survivors support groups such as a) Circle of Sharing (https://circleofsharing.cancer.org/default.aspx), b)
I Can Cope (http://www.cancer.org/icancope/) and c) What Next (https://www.whatnext.com/acs/ ), with
regards to the feasibility of delivering online expressive writing interventions for cancer
survivors. Finally, to assist with national dissemination of this study, we will seek to get the
citations for this study onto NCI/CDC best practices page. We will provide the NCI/CDC with
all materials with regards to this intervention’s delivery and protocol, and will contain relevant
information with respect to our expressive writing intervention and other psychosocial
interventions for cancer survivors. This will ensure that cancer survivors worldwide as well as
the general public will have access to the EW intervention and the results from our study.
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Concluding Thoughts
In conclusion, this study demonstrated that expressive writing can help cancer survivors
(CS) regulate their stress and negative emotions. This study provided the first author an
opportunity to interact with individuals who were faced with enormously stressful life events
during their survivorship. Participants stressors ranged from job loss to family relationships and
fears of death. However, what was touching was the CS willingness to help others despite their
own stressors. In one email, a prospective participant wrote, “Let me know if I can help out...I
don't want my experience to go to waste...,” demonstrating that cancer survivors are often
concerned with how their experience can help others. It is critical that the science and research
community to take consistent steps towards raising awareness about psychosocial stress in cancer
survivors and encourage applied public health interventions for helping cancer survivors, family
members and caregivers and communities deal with an increasing complex, globalized and
stressful world. It must be the endeavor of the science and research community to ensure that the
millions of cancer survivors in the world today are able to lead healthy and productive lives.
Although this study lends evidence for using expressive writing as a stress-management
intervention for cancer survivors, it is possible that EW may not be appreciated by all cancer
survivors. This is an important consideration for researchers and practitioners involved in
delivering survivorship care. Personalized approaches for managing psychosocial health are
needed for cancer survivors that will provide CS access to the quality of life they deserve. This
study has given the first author experience in conducting original research that will hopefully
inform patient-centered decision-making in addition to clinical decision-making in oncology
care. Greater commitments are needed from researchers and health practitioners to institute
compassion and empathy in the delivery of survivorship care. This dissertation is a baby step
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towards future research which will aim to create more meaningful and deeper relationships
between cancer survivors and oncology care providers.
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